



Review

# Single- and Two-Electron Reduction of Nitroaromatic Compounds by Flavoenzymes: Mechanisms and Implications for Cytotoxicity

Narimantas Čėnas<sup>1,\*</sup>, Aušra Nemeikaitė-Čėnienė<sup>2</sup> and Lidija Kosychova<sup>1</sup>

<sup>1</sup> Institute of Biochemistry of Vilnius University, Saulėtekio 7, LT-10257 Vilnius, Lithuania; lidija.kosychova@bchi.vu.lt

<sup>2</sup> State Research Institute Center for Innovative Medicine, Santariškių St. 5, LT-08406 Vilnius, Lithuania; ausra.ceniene@imcentras.lt

\* Correspondence: narimantas.cenas@bchi.vu.lt; Tel.: +370-5-223-4392

**Abstract:** Nitroaromatic compounds (ArNO<sub>2</sub>) maintain their importance in relation to industrial processes, environmental pollution, and pharmaceutical application. The manifestation of toxicity/therapeutic action of nitroaromatics may involve their single- or two-electron reduction performed by various flavoenzymes and/or their physiological redox partners, metalloproteins. The pivotal and still incompletely resolved questions in this area are the identification and characterization of the specific enzymes that are involved in the bioreduction of ArNO<sub>2</sub> and the establishment of their contribution to cytotoxic/therapeutic action of nitroaromatics. This review addresses the following topics: (i) the intrinsic redox properties of ArNO<sub>2</sub>, in particular, the energetics of their single- and two-electron reduction in aqueous medium; (ii) the mechanisms and structure-activity relationships of reduction in ArNO<sub>2</sub> by flavoenzymes of different groups, dehydrogenases-electrontransferases (NADPH:cytochrome P-450 reductase, ferredoxin:NADP(H) oxidoreductase and their analogs), mammalian NAD(P)H:quinone oxidoreductase, bacterial nitroreductases, and disulfide reductases of different origin (glutathione, trypanothione, and thioredoxin reductases, lipoamide dehydrogenase), and (iii) the relationships between the enzymatic reactivity of compounds and their activity in mammalian cells, bacteria, and parasites.

**Keywords:** nitroaromatic compounds; flavoenzymes; cytotoxicity; oxidative stress; bioreductive activation



**Citation:** Čėnas, N.; Nemeikaitė-Čėnienė, A.; Kosychova, L. Single- and Two-Electron Reduction of Nitroaromatic Compounds by Flavoenzymes: Mechanisms and Implications for Cytotoxicity. *Int. J. Mol. Sci.* **2021**, *22*, 8534. <https://doi.org/10.3390/ijms22168534>

Academic Editor: Barbara Jachimska

Received: 13 July 2021

Accepted: 4 August 2021

Published: 8 August 2021

**Publisher's Note:** MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



**Copyright:** © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).


## 1. Introduction

Over the decades, nitroaromatic compounds (ArNO<sub>2</sub>) maintain their importance in relation to industrial processes, environmental pollution, and pharmaceutical application. Current estimates have their production, that is, the synthesis of pigments, polymers, pesticides, explosives, or pharmaceuticals, up to 10<sup>8</sup> tons per year ([1–6], and references therein). Because of contamination of groundwater and soil at military and industrial sites by ArNO<sub>2</sub> that exhibit toxic, mutagenic, and cancerogenic activities, there has been a significant increase in research to understand and apply biological processes for their degradation.


On the other hand, the electron-attracting ability and redox activity make the nitro group a versatile and unique group in medicinal chemistry. Nitroaromatic compounds have a long history of use as antibacterial and antiparasitic drugs and their application as radiosensitizers and hypoxia-selective anticancer agents ([6], and references therein) (Figures 1 and 2). The resurgence of interest in their use is caused by the reevaluation of the problems with their mutagenicity and the new potential fields of their application, e.g., the treatment of oxidic tumors, including the development of antibody- or gene-directed therapies employing bacterial nitroreductases [7,8].

Importantly, both the biodegradation of environmental pollutants such as explosives such as 2,4,6-trinitrotoluene (TNT) (4) or 2,4,6-trinitrophenyl-*N*-methylnitramine (tetryl)


(2) (Figure 3) and the manifestation of toxicity/therapeutic action of nitroaromatic drugs (Figures 1 and 2) may involve similar initial steps, single- or two-electron reduction in  $\text{ArNO}_2$  performed by various flavoenzymes and/or their physiological redox partners, metalloproteins. However, in spite of the rapidly increasing amount of information in this area, the pivotal and still incompletely resolved questions are the identification of the specific enzymes that are involved in the bioreduction of nitroaromatics, the characterization of their reaction mechanisms, and the establishment of their contribution to cytotoxic/therapeutic action of  $\text{ArNO}_2$ .



**Figure 1.** Formulas of nitroaromatic antibacterial and antiparasitic agents: chloramphenicol (23), chinifur (24), nifurxime (25), nitrofurantoin (26), nifurtimox (27), benznidazole (34), misonidazole (35), TH-302 (36), megalzol (38), fexinidazole (39), metronidazole (40), nitazoxanide (52), and PA-824 (57). The numbers of compounds correspond to those in Table A1 (Appendix A).



**Figure 2.** Formulas of nitroaromatic anticancer agents: PR-104 (13), CB-1954 (14), SN-3862 (19), nilutamide (15), flutamide (16), and a representative of nitroCBIs, 1-(chloromethyl)-3-(5-(2-(dimethylamino)ethoxy)indol-2-carbonyl)-5-nitro-1,2-dihydro-3H-benzo[e]indole (56). The numbers of compounds correspond to those in Table A1 (Appendix A).



**Figure 3.** Formulas of nitroaromatic explosives: pentryl (1), tetryl (2), 2,4,6-trinitrotoluene (TNT) (4), 4,5,6,7-tetranitrobenzimidazolone (42), 4,6-dinitrobenzofuroxane (47), ANTA (54), and NTO (55). The numbers of compounds correspond to those in Table A1 (Appendix A).

This review, although it is not meant to be exhaustive, addresses the above problems with special emphasis on the characterization of flavoenzymes performing single- and two-electron reduction in nitroaromatics, the mechanisms and structure-activity relationships of reactions, and the relationships between the reactivity of compounds and their activity in biological systems.

## 2. Redox Properties of Nitroaromatic Compounds and Their Reduction Products

The quantitative characterization of intrinsic redox properties of nitroaromatic compounds is instrumental in the analysis of their enzymatic reduction mechanisms. In this part, we attempt to address the energetics of single- and two-electron reduction in ArNO<sub>2</sub> in aqueous medium and some relevant properties of their reduction products. Another important mechanism of their reduction, the formation of Meisenheimer-type hydride adducts [9], is beyond the scope of this review because it is more relevant to the biodegradation of ArNO<sub>2</sub> rather than their cytotoxicity.

ArNO<sub>2</sub> can be reduced by multistep net six-electron transfer into corresponding amines (ArNH<sub>2</sub>) with the formation of anion-radical (ArNO<sub>2</sub><sup>•-</sup>), nitroso (ArNO), and hydroxylamine (ArNHOH) intermediates. In this aspect, the best-characterized is the energetics of first electron transfer, described by a midpoint redox potential of the ArNO<sub>2</sub>/ArNO<sub>2</sub><sup>•-</sup> couple ( $E^1$ , or  $E^1_7$  at pH 7.0). Due to the instability of free radicals in aqueous media, the  $E^1_7$  values of nitroaromatics (Table A1, Appendix A) are usually obtained from anaerobic pulse radiolysis experiments [10–24]. The range of  $E^1_7$  values of ArNO<sub>2</sub> with biomedical interest is from –0.6 V to –0.2 V. Further in the text, all the potentials will be given with respect to NHE. For most important groups of compounds,  $E^1_7$  decreases in the order nitropyridines > nitrofurans ≥ nitrothiophenes > nitrobenzenes > nitroimidazoles (Table A1). For the series of homologous compounds, their  $E^1_7$  values may be roughly correlated with the  $\sigma$  values of their substituents. In addition, the value of  $E^1_7$  decreases if a nitro group loses a coplanarity with the aromatic system due to sterical hindrances. The  $pK_a$  values of ArNO<sub>2</sub><sup>•-</sup> span from 2.0 to 3.0 (nitrobenzenes, nitrofurans) [25,26] to 5.7–6.1 (nitroimidazoles) [27]. In terms of an “outer-sphere” electron transfer mechanism ([28–30], and Appendix B), the electron self-exchange rate constants of ArNO<sub>2</sub> are  $\sim 10^6$  M<sup>-1</sup>s<sup>-1</sup> [25,26].

Alternatively, the values of  $E^1$  of the number of nitroaromatics were determined by cyclic voltammetry. Typically, the electrochemical reduction in ArNO<sub>2</sub> in aqueous media proceeds irreversibly with the formation of ArNHOH. However, this process takes place in two steps, with the pH-independent transfer of the first electron and pH-dependent transfer of three electrons:




At pH 11–12, the redox potential of a second step may become more negative than the potential of ArNO<sub>2</sub>/ArNO<sub>2</sub><sup>•-</sup> couple. In this case, a separate reversible process of single-electron transfer at  $E_m = E^1_7$  is observed in cyclic voltammetry ([31], and references therein).

There is some interest in the prediction of  $E^1_7$  of ArNO<sub>2</sub> from quantum mechanical calculations or the use of substitute descriptors such as the electron affinities of ArNO<sub>2</sub> or the heats of formation ( $\Delta H_f$ ) of ArNO<sub>2</sub><sup>•-</sup>. However, the calculations in vacuo frequently do not provide reliable predicted  $E^1_7$  values due to the large data scattering or may be confined only to a series of homologous compounds [32–35]. Some improvement may be expected upon the introduction of solvent matrix effects into calculations [36]. On the other hand, the  $E^1_7$  values of ArNO<sub>2</sub> may be predicted from linear log (rate constant) vs.  $E^1_7$  relationships in single-electron reduction in nitroaromatics by flavoenzymes dehydrogenases-electrontransferases or their redox partners, FeS proteins [11–13]. The use of the geometric average of rate constants obtained in several enzymatic systems improves the prediction accuracy. The calculated reduction potentials ( $E^1_{7(\text{calc.})}$ , Table A1, Appendix A) deviate from the experimental ones by no more than 40 mV (standard devia-

tion,  $\pm 18$  mV) and thus should be considered as realistic. Importantly, this approach may be applied for groups of structurally diverse  $\text{ArNO}_2$ .

The reoxidation of  $\text{ArNO}_2^- \cdot$  by  $\text{O}_2$  and their dismutation are among the most important factors influencing their cytotoxicity. The oxidation of anion-radicals is accompanied by the formation of superoxide ( $\text{O}_2^-$ ) and subsequently,  $\text{H}_2\text{O}_2$ :




The latter further form cytotoxic hydroxyl radical ( $\text{OH}\cdot$ ) in transition metal-catalyzed Fenton reaction. The rate constants of  $\text{ArNO}_2^-$  oxidation by  $\text{O}_2$  decrease with an increase in their  $E^1_7$ , for example,  $7.7 \times 10^6 \text{ M}^{-1}\text{s}^{-1}$  (nitrobenzene),  $1.4 \times 10^6 \text{ M}^{-1}\text{s}^{-1}$  (*p*-nitroacetophenone),  $2.5 \times 10^5 \text{ M}^{-1}\text{s}^{-1}$  (nitrofurantoin),  $1.5 \times 10^5 \text{ M}^{-1}\text{s}^{-1}$  (nifuroxime) [25,26]. During the single-electron reduction in  $\text{ArNO}_2$  by NAD(P)H-oxidizing flavoenzymes, the reactions (3,4) are responsible for typical redox cycling events, oxidation of significant excess NAD(P)H over  $\text{ArNO}_2$ , the stoichiometric to NAD(P)H consumption of  $\text{O}_2$ , and superoxide dismutase-sensitive reduction in added cytochrome *c*. The dismutation of nitro anion-radicals yields the nitroso compounds:




The dismutation rate constants ( $2k_d$ ) are structure-sensitive. For the radicals of *o*-, *m*-, and *p*-dinitrobenzenes, they are equal to  $2.4 \times 10^6 \text{ M}^{-1}\text{s}^{-1}$ ,  $8.0 \times 10^6 \text{ M}^{-1}\text{s}^{-1}$ , and  $3.3 \times 10^8 \text{ M}^{-1}\text{s}^{-1}$ , respectively, whereas the radicals of nitroimidazoles and nitrofurans are more stable ( $2k_d = 10^4 \div 10^5 \text{ M}^{-1}\text{s}^{-1}$  [25–27]). The competition between the dismutation of  $\text{ArNO}_2^-$  and their reoxidation by  $\text{O}_2$  is responsible for the formation of a fraction of stable reduction products under partial aerobic conditions [37].

Finally,  $\text{ArNO}_2^-$  possessing substituents with potential leaving groups may undergo fragmentation, which competes with their reoxidation by  $\text{O}_2$  (Equation (6)). This approach is used in the development of hypoxia-selective antitumour agents such as TH-302 (36) [20].



The redox properties of  $\text{ArNO}_2$  multielectron reduction products are insufficiently characterized in quantitative terms. In aqueous medium,  $\text{ArNO}_2$  are electrochemically reduced into  $\text{ArNHOH}$  directly, bypassing  $\text{ArNO}$  (Equations (1) and (2)). On the other hand, the use of mixed ethanol-aqueous solution with pH 1.0–4.0 enabled the detection of reduction intermediate dihydroxylamine ( $\text{ArN}(\text{OH})_2$ ), which further undergoes dehydration [38]:




However, the voltammetric characteristics of this reaction could not be extrapolated into aqueous medium with pH 7.0. Following this approach, it was assumed that the rate-limiting step of enzymatic two-electron reduction in  $\text{ArNO}_2$  is a net hydride transfer with the formation of  $\text{ArN}(\text{OH})\text{O}^-$  [39]. The calculated heats of formation ( $\Delta\text{Hf}(\text{ArN}(\text{OH})\text{O}^-)$ ) increase with the electron-accepting potency of substituents and roughly correlate with  $\Delta\text{Hf}(\text{ArNO}_2^-)$  and  $E^1_7$  of nitroaromatics.

In aqueous medium, nitrosobenzene is reversibly electrochemically reduced into phenylhydroxylamine at  $E^0_7 = 0.184 \text{ V}$  [40]. It is suggested that the intermediate free radical  $\text{ArNOH}\cdot$  is unstable, and that the redox potentials of first and second electron transfer are separated by  $-0.5 \text{ V}$ . Because  $\text{ArNO}$  are more powerful oxidants than  $\text{ArNO}_2$ , they can be directly reduced by NAD(P)H, GSH, ascorbate, and other reductants. For example, nitrosobenzene is reduced by NADPH and ascorbate with  $k = 124 \text{ M}^{-1}\text{s}^{-1}$  and  $2.8 \times 10^3 \text{ M}^{-1}\text{s}^{-1}$ , respectively [41,42]. The reactivity of nitrosobenzenes increases with their electron-accepting properties. The reactions of  $\text{ArNO}$  with GSH proceed with

the formation of semimercaptal ( $\text{ArN(OH)-SG}$ ) intermediate, which may rearrange into sulfenamide ( $\text{ArNH-(O)SG}$ ), whose acid hydrolysis will yield  $\text{ArNH}_2$  or further oxidize GSH [43].

$\text{ArNHOH}$  are relatively unstable in aqueous medium. Under aerobic conditions, the products of decomposition of phenylhydroxylamine are nitrosobenzene, nitrobenzene, and nitrophenol [44].  $\text{ArNHOH}$  can also disproportionate yielding  $\text{ArNO}$  and  $\text{ArNH}_2$  [45].

The mechanisms of alkylation of DNA by  $\text{ArNHOH}$ , especially by the reduction products of bifunctional dinitrobenzenes CB-1954 (**14**) and SN-23682 (**19**) and their homologues, were thoroughly analyzed and reported elsewhere [7,46], therefore, will not be addressed in this review. Another type of reaction is the fragmentation of  $\text{ArNHOH}$  with leaving groups containing a drug or chromophore molecule (Scheme 1). Because the  $-\text{NHOH}$  or  $-\text{NH}_2$  groups possess electron-donating properties, the reduction products hydrolyze or react with nucleophiles more easily than the parent nitroaromatics. This approach is used in the design of hypoxia-selective alkylating agents, gene-directed therapy involving nitroreductases, hypoxic tumour imaging, or imaging of nitroreductases in transfected tumors [47–51].



**Scheme 1.** Fragmentation of reduction products of nitrobenzyl carbamates (a), nitrobenzyl sulfonates (b), and nitrobenzyl phosphoramidate mustards (c). Adapted from the work of [47–51].

The energetics of formation of  $\text{ArNH}_2$  from  $\text{ArNHOH}$  in aqueous medium is also incompletely characterized. At metal or carbonaceous electrodes, nitrobenzene is reduced into phenylhydroxylamine with half-wave potentials ( $E_{1/2}$ ) of  $-0.30$ – $-0.45$  V, whereas the latter is reduced into aniline with  $E_{1/2} = -0.55$ – $-0.70$  V at pH 7.0 [52]. However, the overvoltage of this reaction depends on the electrode material [53]. On the other hand, the second electron transfer in this reaction, reduction in aniline radical into aniline, is characterized by  $E^1 = 1.03$  V at pH 6.9 [10]. Thus, in spite of the uncertain value of  $E^0$  of phenylhydroxylamine/aniline redox couple, it is clear that the reduction in phenylhydroxylamine into aniline radical should proceed at very negative potential. This may impose certain barriers toward the enzymatic formation of  $\text{ArNH}_2$  from  $\text{ArNHOH}$ , in particular, single-electron transfer steps.



### 3. Mechanisms of Reduction in Nitroaromatic Compounds by Flavoenzymes

An early study of nonenzymatic reduction in nitroaromatics by reduced FMN under anaerobic conditions demonstrated a linear dependence of  $\log k$  on  $E^{1/7}$  of  $\text{ArNO}_2$  [54]. Its extrapolation to  $\Delta E^{1/7} = 0$  gives  $k \sim 10^7 \text{ M}^{-1}\text{s}^{-1}$ , which agrees with an “outer-sphere” electron transfer model (Appendix B). The products of the reduction in nitroaromatics were hydroxylamines. Since that time, a substantial amount of information accumulated in this area, evidencing the diversity of reaction mechanisms, which will be analyzed in subsequent subsections.

#### 3.1. Single- and Mixed Single- and Two-Electron Reduction in Nitroaromatic Compounds by Flavoenzymes Dehydrogenases-Electrontransferases

Flavoenzymes dehydrogenases-electrontransferases transform two-electron (hydride) transfer into a single-electron one, and, most frequently, possess single-electron transferring redox partner, heme- or FeS-containing protein. Their action is characterized by the formation of neutral (blue) flavin semiquinone,  $\text{FMNH}^\cdot$  or  $\text{FADH}^\cdot$ , as a reaction intermediate. In this section, the properties of flavohemoproteins or heme-reducing flavoenzymes and flavoenzymes FeS reductases are discussed separately. This is related not to the different properties or action mechanisms of their flavin cofactors but to the different roles of the heme or FeS redox centers in the reduction in nitroaromatics.

NADPH: cytochrome P-450 reductase (P-450R) is a 78 kD enzyme associated with the endoplasmic reticulum of a variety of eukaryotic cells. It is responsible for electron transfer from NADPH to the cytochromes P-450 and to other microsomal enzyme systems ([55], and references therein). Rat liver P-450R has a hydrophobic 6 kD N-terminal membrane-binding domain, the FMN-binding domain next to it, the connecting domain, and the FAD- and NADPH-binding domains at the C-terminal side [56]. In catalysis, the transfer of redox equivalents follows the pathway  $\text{NADPH} \rightarrow \text{FAD} \rightarrow \text{FMN} \rightarrow \text{cytochrome P-450}$  (cytochrome *c*). The pyrimidine part of the isoalloxazine ring of FMN is accessible to solvent. The edge-to-edge distance between the isoalloxazine rings of FMN and FAD is 3.5–4.5 Å. The negatively charged FMN-binding domain and hydrophobic membrane-binding domain are involved in the complex formation between P-450R and cytochromes P-450 or cytochrome *c*. The potentiometric and kinetic characteristics of P-450R are presented in Table 1. The large differences between the redox potential values for the first and second electron transfer point to the high stability of flavin semiquinones. A catalytic cycle involving one-, two-, and three-electron-reduced states of reductase with  $\text{FMNH}_2$  acting as the principal donor of electrons to oxidants is proposed [57]. It is suggested that the rates of interflavin electron transfer are higher or similar to the rate of FAD reduction by NADPH [58]. Cytochromes P-450 reoxidize P-450R with low rates, 0.15–1.0  $\text{s}^{-1}$  [59].

**Table 1.** Potentiometric and kinetic characteristics of heme-reducing flavoenzymes and flavohemoproteins.

Enzyme	Redox Potential vs. NHE	Rate Constants of Electron (Hydride) Transfer, pH 7.0
NADPH: cytochrome P-450 reductase (rat liver)	−0.325 V (FAD/FADH $^\cdot$ ), −0.372 V (FADH $^\cdot$ /FADH $_2$ ), −0.068 V (FMN/FMNH $^\cdot$ ), −0.246 V (FMNH $^\cdot$ /FMNH $_2$ ), pH 7.4 [60]	30 $\text{s}^{-1}$ (NADPH to cytochrome <i>c</i> via FAD and FMN, steady-state) [61], $k_{\text{cat}}/K_{\text{m}} = 6.8 \times 10^2$ – $5.9 \times 10^6 \text{ M}^{-1}\text{s}^{-1}$ (ArNO $_2$ , steady-state) [13]
Nitric oxide synthase (rat neurons)	−0.250 V (FAD/FADH $^\cdot$ ), −0.260 V (FADH $^\cdot$ /FADH $_2$ ), −0.120 V (FMN/FMNH $^\cdot$ ), −0.220 V (FMNH $^\cdot$ /FMNH $_2$ ), −0.290 V (Fe $^{3+}$ /Fe $^{2+}$ ), H 7.0 [62]	242 $\text{s}^{-1}$ (NADPH to flavins, fast phase), 46 $\text{s}^{-1}$ (FMNH $_2$ to heme), pH 7.6 [63]; $k_{\text{cat}}/K_{\text{m}} = 1.2 \times 10^2$ – $2.8 \times 10^5 \text{ M}^{-1}\text{s}^{-1}$ , (steady-state, ArNO $_2$ , calmodulin is absent) [64]
Flavohemoglobin (bacteria, fungi)	$\leq -0.150 \text{ V}$ (FAD/FADH $^\cdot$ ), −0.120 V (heme) ( <i>E. coli</i> Fhb, pH 8.0) [65]; −0.190 V (FAD/FADH $^\cdot$ ), −0.170 V (heme) ( <i>S. aureus</i> Fhb, pH 7.6) [66]	130 $\text{s}^{-1}$ (NADH to heme via FAD), $k_{\text{cat}} = 4$ – $25 \text{ s}^{-1}$ , $k_{\text{cat}}/K_{\text{m}} = 6.2 \times 10^2$ – $1.1 \times 10^5 \text{ M}^{-1}\text{s}^{-1}$ (steady-state, ArNO $_2$ , <i>S. aureus</i> Fhb) [67]

P-450R reduces nitroaromatic compounds in a single-electron way and is the enzyme used most frequently to demonstrate their redox cycling reactions. For this reaction, the linear dependence of logarithms of reaction rate or  $k_{\text{cat}}/K_m$  on  $E^1_7$  of  $\text{ArNO}_2$  was observed [68,69]. This is in line with an “outer-sphere” electron transfer model [28]. Moreover,  $\text{ArNO}_2$  are systematically less reactive than quinones with the same  $E^1_7$  values [69–71]. This additionally supports an “outer-sphere” reaction model because the electron self-exchange constants for  $\text{ArNO}_2$  are by two orders of magnitude lower than those for quinones [25,26,29]. Subsequently, the linear  $\log(k_{\text{cat}}/K_m)$  vs.  $E^1_7$  relationships were used for the estimation of unknown  $E^1_7$  values of nitroaromatics [11–13].

The redox partners of P-450R, cytochromes P-450, catalyze the denitration of  $\text{ArNO}_2$  with the formation of corresponding hydroxyl derivatives [72,73] and reverse the accumulation of the amine products of polinitrobenzene reduction, catalyzing the formation of their hydroxylamines [74]. On the other hand, cytochrome P-450 101A1 is able to reduce *m*-nitroacetophenone into a corresponding amine [75]. However, the impact of these reactions on the cytotoxicity of  $\text{ArNO}_2$  has not been studied in detail.


Nitric oxide synthases (NOS) are dimeric flavohemoproteins that catalyze the conversion of *L*-arginine to citrulline and nitric oxide ( $\text{NO}\cdot$ ) at the expense of NADPH. Each monomer of NOS consists of a heme domain with tetrahydrobiopterin bound at its *N*-terminus and a FAD- and FMN-containing reductase domain at its *C*-terminus. The reductase and by domains are linked by a calmodulin (CAM)-binding sequence ([76], and references therein). The reductase domain is highly similar to P-450R. In catalysis, the redox equivalents are transferred in the pathway  $\text{NADPH} \rightarrow \text{FAD} \rightarrow \text{FMN} \rightarrow \text{heme}$  (tetrahydrobiopterin), involving mainly one- and three-electron reduced states of the reductase domain in the turnover ([77,78], and references therein). The potentiometric and kinetic characteristics of neuronal NOS are presented in Table 1. Although these data may vary in various publications, it is accepted that the redox potential of cofactors decreases in the order  $\text{FMN}/\text{FMNH}\cdot \gg \text{FMNH}\cdot/\text{FMNH}_2 \geq \text{FAD}/\text{FADH} \cdot > \text{FADH}\cdot/\text{FADH}_2 \geq \text{heme}$ , and that the flavins are reduced much faster than heme. NOS reduces quinones and  $\text{ArNO}_2$  in a single-electron way via  $\text{FMNH}_2$  [79–81]. The reasons why the heme moiety is not involved in the reduction process are unclear. It may be partly explained by an increase in its redox potential after the binding of ligands. Under anaerobic conditions, nilutamide (15) and CB-1954 (14) are reduced into corresponding hydroxylamines [80,81]. TNT (4) and dinitrobenzenes inhibit the formation of  $\text{NO}\cdot$  by NOS [82,83], most possibly by trapping of  $\text{NO}\cdot$  with the product of their redox cycling,  $\text{O}_2^-$ , resulting in the formation of peroxyxynitrite. An alternative mechanism is the diversion of electron flux from  $\text{FMNH}_2$  to heme. Like in P-450R-catalyzed reactions, the reactivity of  $\text{ArNO}_2$  was characterized by the linear  $\log k_{\text{cat}}/K_m$  vs.  $E^1_7$  relationship with some possible discrimination against the negatively charged compounds [64].  $\text{ArNO}_2$  were less reactive than quinones with the same  $E^1_7$  values.

Flavohemoglobins (FHbs) have been found in a wide variety of bacteria and fungi and play a key role in their resistance to nitrosative stress. They consist of an *N*-terminal heme-binding domain and of *C*-terminal FAD- and NAD(H)-binding modules. During turnover, NADH reduces FAD, which further reduces the  $\text{Fe}^{3+}$  form of hemoglobin ( $\text{HbFe}^{3+}$ ); oxy-hemoglobin ( $\text{HbFe}^{2+}\text{O}_2$ ) is finally formed under aerobic conditions. The reaction of the  $\text{HbFe}^{2+}\text{O}_2$  with  $\text{NO}\cdot$  leads to  $\text{NO}\cdot$  detoxification, i.e., the formation of nitrate instead of the toxic peroxyxynitrite ( $\text{ONOO}^-$ ). The reactions proceed with a high turnover rate, ca.  $100 \text{ s}^{-1}$  [84]. The crystal structures of FHb from various sources show that the pyrimidine ring of the FAD isoalloxazine is partly accessible to solvent, whereas the access to heme may be partly hampered by a bound phospholipid molecule 66 [85]. The potentiometric and kinetic characteristics of FHb are given in Table 1. The steady-state reduction in quinones or  $\text{ArNO}_2$  by *S. aureus* FHb follows a “ping-pong” mechanism with the oxidative half-reaction as a rate-limiting catalysis step [67]. During the turnover in the presence of an oxidant, the reduced FAD is reoxidized by >10 times more rapidly than  $\text{HbFe}^{2+}\text{O}_2$  moiety, i.e., it acts as a preferred electron donor. The reoxidation of heme may be hampered by a bound



phospholipid molecule; moreover, the binding of O<sub>2</sub> may significantly increase the potential of Fe<sup>3+</sup>/Fe<sup>2+</sup>O<sub>2</sub> couple. The log  $k_{\text{cat}}/K_m$  of nitrobenzenes and nitrofurans displays a well-expressed parabolic dependence on their  $E^{17}$ . In contrast to reactions of other electron-transferases, TNT and *p*-nitrobenzaldehyde were reduced with a 35–40% single-electron flux. The mixed character of reduction is possibly determined by the relatively low stability of the FAD semiquinone state of Fhb, 15% at equilibrium [65].

Flavoenzymes FeS reductases either have the FeS proteins as redox partners or perform the intramolecular electron transfer to a FeS redox center. Some of their representatives may transfer electrons in both directions to and from FeS centers. Typically, both FeS reductases and their redox partners participate in the reduction in ArNO<sub>2</sub> and other groups of redox-active xenobiotics (Scheme 2):



**Scheme 2.** A general scheme of reduction in nitroaromatics by FeS reductases and their FeS redox partners.

NADPH:adrenodoxin reductase (ADR) is a monomeric 51 kD FAD-containing enzyme, first isolated from bovine adrenal cortex mitochondria. It reduces 13.3 kD Fe<sub>2</sub>S<sub>2</sub> protein adrenodoxin (ADX), which in turn reduces mitochondrial cytochromes P-450 that participate in the biosynthesis of steroid hormones. The ADR-ADX complex formation is determined by the electrostatic interaction between the positively charged amino acid residues of ADR and negatively charged residues of ADX ([86], and references therein). The potentiometric and kinetic characteristics of ADR and ADX are presented in Table 2.

**Table 2.** Potentiometric and kinetic characteristics of flavoenzymes FeS reductases and FeS proteins.

Enzyme	Redox Potential vs. NHE, pH 7.0	Rate Constants of Electron (Hydride) Transfer, pH 7.0
Bovine adrenal cortex NADPH: adrenodoxin reductase	−0.250–−0.274 V (FAD/FADH <sub>2</sub> ), −0.320 V (FAD/FADH <sup>•−</sup> ), −0.260 V (ADX, free), −0.360 V (ADX, ADR-bound) [86–88]	28 s <sup>−1</sup> (NADPH to FAD), 10 e <sup>−</sup> /s (FADH <sub>2</sub> to ADX <sub>ox</sub> , steady-state) [86–88]
Ferredoxin: NADP(H) oxidoreductase, <i>Anabaena</i> PCC7119 [89–91]	−0.296 V (FAD/FADH <sup>•−</sup> ), −0.280 V (FAD/FADH <sup>•−</sup> ), −0.384 V (Fd), pH 7.5	6200 e <sup>−</sup> /s (Fd <sub>red</sub> to FAD), 250 e <sup>−</sup> /s (Fd <sub>red</sub> to FADH), >600 s <sup>−1</sup> (FADH <sup>•−</sup> to NADP <sup>+</sup> ), pH 8.0; 140 s <sup>−1</sup> (NADPH to FAD), >600 s <sup>−1</sup> (FADH <sup>•−</sup> to Fd <sub>ox</sub> )
Ferredoxin: NADP(H) oxidoreductase, <i>Plasmodium falciparum</i> [92,93]	−0.280 V (FAD/FADH <sup>•−</sup> ), −0.260 V (Fd)	125–148 s <sup>−1</sup> (NADPH to FAD) 13–15 e <sup>−</sup> /s (FADH <sup>•−</sup> to Fd <sub>ox</sub> , steady-state)
Bovine heart mitochondrial NADH:ubiquinone reductase (complex I)	−0.345 V (FMN/FMNH <sub>2</sub> ), −0.382 V (FMN/FMNH <sup>•−</sup> ) [94]; ≤ −0.380 V (N1a), −0.240–−0.270 V (N1b, N3, N4, N5), −0.050–−0.120 V (N2) [95]	3500 e <sup>−</sup> /s (NADH to FMN (ferricyanide), steady-state) [96,97]; 150–380 s <sup>−1</sup> (NADH to ubiquinone, steady-state, proteoliposomes) [98]


NADPH reduces ADR with the final formation of the FADH<sub>2</sub>-NADP<sup>+</sup> charge-transfer complex ( $K_d \sim 10^{-8}$  M). NADP<sup>+</sup> also binds to the oxidized and semiquinone form of ADR but with a lower affinity. NADPH binds to the FAD semiquinone more efficiently than NADP<sup>+</sup> [99].

The steady-state reactions of quinone or ArNO<sub>2</sub> reduction by ADR proceed with  $k_{cat} = 20\text{--}25\text{ s}^{-1}$ , which is close to the maximal rate of enzyme reduction by NADPH [100]. However, NADPH acts as a strong ( $K_i = 5.0\text{--}6.0\text{ }\mu\text{M}$ ) inhibitor with respect to oxidants. Calculated by extrapolation to  $[\text{NADPH}] = 0$ ,  $k_{cat}/K_m$  values for the reduction in nitrofurans by ADR are low,  $1.0 \div 4.0 \times 10^3\text{ M}^{-1}\text{s}^{-1}$  [101]. It was concluded that quinones and ArNO<sub>2</sub> oxidize free enzyme form and its complexes with NADPH and NADP<sup>+</sup>, although with slower rates. Most probably, the rate-limiting step of this reaction is the oxidation of FAD semiquinone. On the other hand, ADX stimulates the reduction in ArNO<sub>2</sub> by ADR, eliminating the inhibition by NADPH and providing a more efficient alternative reduction pathway via reduced ADX [100,101]. The  $k_{cat}/K_m$  values of nitroaromatics are much higher than in the oxidation of ADR. Their logarithms increase with their  $E^1_7$ ; moreover, ArNO<sub>2</sub> are less reactive than quinones with the same  $E^1_7$  values [70,71].

*Mycobacterium tuberculosis* contains ADX-type 50 kD NADPH-ferredoxin reductase FprA [102]. The  $E^0_7$  of FAD is equal to  $-0.235\text{ V}$  [103]. The rate of FAD reduction by NADPH exceeds  $160\text{ s}^{-1}$ ; however, the reaction analysis is complicated by the enzyme reoxidation by NADP<sup>+</sup>. Blue FAD semiquinone is formed during the reduction in the enzyme by NADPH or during its photoreduction in the presence of NADP<sup>+</sup>. The enzyme reduces *M. smegmatis* Fe<sub>7</sub>S<sub>7</sub> ferredoxin with  $k_{cat} = 3.4\text{ s}^{-1}$  [102]. However, the data on the reactions of FprA and its redox partner(s) with ArNO<sub>2</sub> are absent.

Most ferredoxin:NADP(H) oxidoreductases (FNRs) are 35–36 kD monomeric FAD-containing enzymes that transfer electrons from reduced FeS-protein ferredoxin (Fd) to NADP<sup>+</sup>, thus providing NADPH for CO<sub>2</sub> assimilation in plants and cyanobacteria. However, some FNRs act in the opposite direction, reducing Fd at the expense of NADPH, thus supplying reduced Fd for nitrate assimilation (roots) or biosynthesis of isoprenoids (malaria parasite *Plasmodium falciparum*).

In this part, we discuss the mechanisms of ArNO<sub>2</sub> reduction by enzymes that function in opposite directions, FNR from cyanobacterium *Anabaena* PCC7119 and from *P. falciparum* (PfFNR). Their potentiometric and kinetic characteristics are presented in Table 2. The isoalloxazine ring of FAD of both FNRs is partly exposed to solvent [104–106]. Electrostatic interaction between the negatively charged Fd and positively charged FNR and hydrophobic interactions are involved in the formation of the *Anabaena* FNR-Fd complex [89]. An analogous electrostatic complex is formed between PfFNR and PfFd [105]. Both enzymes reduce quinones and ArNO<sub>2</sub> in a single-electron way [107–109]. Reactions follow the “ping-pong” mechanism with the oxidative half-reaction as a partly rate-limiting step,  $100\text{ s}^{-1}$  for *Anabaena* FNR, and up to  $63\text{ s}^{-1}$  for PfFNR. They are characterized by parabolic dependences of  $\log k_{cat}/K_m$  of quinones and nitroaromatics on their  $E^1_7$  value. Again, ArNO<sub>2</sub> comprised a separate series of compounds with lower reactivity. In both enzymes, the rate-limiting step in FADH<sup>−</sup> reoxidation is the oxidation of FADH<sup>•</sup>. Like in reactions of ADR, Fd stimulated the reduction in nonphysiological oxidants by both FNRs, providing an alternative reduction pathway with lower  $k_{cat}$  and higher  $k_{cat}/K_m$  of oxidants. In another study, several low-potential nitroimidazoles were found to oxidize reduced *Anabaena* Fd with  $k = 630 \div 3500\text{ M}^{-1}\text{s}^{-1}$  [110], which was much faster than the reduction in their analogs by FNR alone [102]. PfFd also stimulated the reduction in quinones and nitroaromatics by PfFNR, providing the faster pathway of their reduction with  $k_{cat}$  equal to the rate of PfFNR-PfFd electron transfer. Like spinach FNR, both *Anabaena* FNR and PfFNR catalyze the reductive denitration of tetryl (2) into *N*-methylpicramide (3) accompanied by redox cycling of free radical intermediate [111] (Scheme 3):



**Scheme 3.** Reductive denitration of tetryl (2) into *N*-methylpicramide (3).

The above data indicate that although *PfFNR* possesses low homology, 20–30%, with plant FNRs and functions in the opposite direction, its nitroreductase reaction mechanism and absence of substrate specificity are the same as of *Anabaena* FNR. However, because Fds possess higher nitroreduction rates, an important but insufficiently studied problem is their possible nitroaromatic substrate specificity.

NADH:ubiquinone reductase (CoQR, complex I) is localized in the inner mitochondrial membrane. It is a large (1 MD) enzyme of 45 subunits, catalyzing NADH oxidation by ubiquinone and performing transmembrane proton translocation. The data of numerous studies of bovine mitochondrial complex I [94,98,112–114] may be summarized as follows: (i) FMN and 8 FeS clusters N1-6, separated by 7.6–14 Å distances, are localized in the hydrophilic arm of L-shaped complex I that extends into the mitochondrial matrix. FMN is located in 51 kD subunit; (ii) the hydrophobic domain of the complex, localized in the inner mitochondrial membrane, pumps 4 protons from the matrix to intermembrane mitochondrial space per molecule of NADH oxidized; and (iii) the sequence of transfer of redox equivalents is NADH → FMN → N3(N1a) → N1b → N4 → N5 → N6a → N6b → N2 → bound ubiquinone. The reduction in ubiquinone is inhibited by tightly binding rotenone and piericidin. The potentiometric and kinetic characteristics of bovine complex I are presented in Table 3.

The mechanism of reduction in soluble quinones, nitroaromatics, and other artificial electron acceptors by CoQR is still a matter of debate. In this context, the reference reaction is its reduction in ferricyanide, where ferricyanide presumably directly oxidizes reduced FMN [96,97]. This reaction proceeds according to a “ping-pong” mechanism with double competitive substrate inhibition, which shows that both substrates compete for the same binding site in reduced and oxidized enzyme form. The use of 4-S-<sup>2</sup>H- NADH decreases  $k_{cat}$  of reaction and  $k_{cat}/K_m$  of NADH by two times, which shows that the rate-limiting step of the process is the reduction in FMN by NADH. The reduction in soluble quinones and nitroaromatics by complex I is insensitive to rotenone and is characterized by a common parabolic dependence of  $\log k_{cat}/K_m$  on  $E^1_7$  of oxidants. For the most active oxidants,  $k_{cat}$  of reaction reaches  $100 \text{ s}^{-1}$ . Importantly,  $\text{ArNO}_2$  are reduced in a mixed single- and two-electron way with a single-electron flux of 45–70%. The studies of the complex I inhibition by NADH,  $\text{NAD}^+$ , redox inactive ADP-ribose, and slowly reacting quinones enabled us to conclude that quinones and nitroaromatics bind close to the ferricyanide binding site [115–117]. In contrast to ferricyanide, they may oxidize both free enzyme form and its complexes with NADH ( $K_d = 3.0 \text{ }\mu\text{M}$ ) and  $\text{NAD}^+$  ( $K_d = 30\text{--}60 \text{ }\mu\text{M}$ ), although with slower rates. Because the above  $K_d$  differ from NADH and  $\text{NAD}^+$  inhibition constants toward ferricyanide, it is possible that ferricyanide and quinones or  $\text{ArNO}_2$  oxidize different redox states of the enzyme. The possible involvement of FeS centers in nitroreduction warrants further studies.

Among the similar redox systems that may contribute to cytotoxic/therapeutic action of  $\text{ArNO}_2$ , *Trichomonas vaginalis* contain a partly characterized Fd-dependent system. *T. vaginalis* ferredoxin ( $E^1_7 = -0.347 \text{ V}$ ) plays a central role in hydrogenosomal electron transport, reversibly transferring electrons from pyruvate:ferredoxin oxidoreductase (PFOR)

to hydrogenase or to the NADH dehydrogenase module that contains FMN in 51 kD subunit, and  $\text{Fe}_2\text{S}_2$  cluster in 24 kD subunit (FOR) [118–120]. Hypothetically, FOR can reduce nitroaromatics; however, the data on its nitroreductase reactions are absent. On the other hand, using the hydrogenosomal extracts of *T. vaginalis*, PFOR catalyzed pyruvate-dependent reduction in a series of  $\text{ArNO}_2$  ( $E^{17} = -0.564 \text{ V} \text{--} -0.243 \text{ V}$ ) under anaerobic conditions [121]. At fixed compound concentration, a linear log (reduction rate) vs.  $E^{17}$  relationship is observed. *T. vaginalis* Fd stimulated the reduction in  $\text{ArNO}_2$ ; however, the reaction rate almost did not depend on  $E^{17}$ . Furthermore, it has been shown that *T. vaginalis* Fd reduces low-potential metronidazole (40) and other nitroimidazoles with an unexpectedly high rate,  $k = 4.2 \times 10^5 \div 1.0 \times 10^6 \text{ M}^{-1}\text{s}^{-1}$  [110]. On the other hand, metronidazole and another low-potential compound, chloramphenicol (23), are also rapidly reduced by another NADH oxidizing 26 kD FMN and FeS-containing protein, with  $k_{\text{cat}} = 56 \text{ s}^{-1}$  and  $k_{\text{cat}}/K_{\text{m}} = 2.0 \times 10^6 \text{ M}^{-1}\text{s}^{-1}$ , and  $k_{\text{cat}} = 130 \text{ s}^{-1}$  and  $k_{\text{cat}}/K_{\text{m}} = 1.7 \times 10^6 \text{ M}^{-1}\text{s}^{-1}$ , respectively [122]. The functions of this protein are unknown.

Microaerophilic bacterium *Helicobacter pylori* contains a similar partly characterized system, consisting of PFOR and flavodoxin:quinone oxidoreductase (FqrB) [123]. The electrons between these flavoenzymes are reversibly transferred by a low-potential electron carrier flavoprotein flavodoxin. Importantly, the reduction in  $\text{NADP}^+$  by FqrB was inhibited by nitrothiazole nitazoxanide (52) and a number of nitrochromanes, nitrobenzenes, and nitrobenzoxadiazoles, which were binding to flavodoxin [124]. The system consisting of PFOR, ferredoxin: $\text{NAD}^+$  reductase, and ferredoxin, the latter participating in  $\text{ArNO}_2$  reduction, is also present in *Giardia* spp. [125]. However, the catalytic properties of its components are insufficiently characterized.

Mammalian xanthine oxidase (XOD) attracted some attention as a model system for the single-electron reduction in  $\text{ArNO}_2$ . The reactions with nitroimidazoles [126] and nitroacridines [127] were characterized by the absence of structure specificity, i.e., an increase in log (reaction rate) with  $E^{17}$  of oxidants. However, one may note that XOD is a product of proteolysis of native  $\text{NAD}^+$ -reducing xanthine dehydrogenase (XDH) under a variety of pathophysiological conditions ([128], and references therein). While XDH prevails intracellularly, XOD is prevalent in body fluids such as milk and plasma, where it may be secreted or released from dead cells. XDH is a  $2 \times 145 \text{ kD}$  dimer, with each subunit containing molybdopterin cofactor, FAD, and two  $\text{Fe}_2\text{S}_2$  clusters. During the catalysis, electrons are transferred from the purine substrate to molybdopterin, then to FAD via FeS clusters, and ultimately to the final electron acceptor,  $\text{NAD}^+$  (XDH) or  $\text{O}_2$  (XOD). The rate-limiting catalysis step is the reductive half-reaction [129]. Partly purified XDH under aerobic conditions reduces nitrofurazone into several products, including its amino metabolite [130]. The fractions of XDH and XOD in the cytosol under anaerobiosis reduced 1- and 2-nitropyrenes and 4-nitrobiphenyl into their amino metabolites [131]. However, the studies of nitroreductase reactions of XDH did not receive further attention.

Summing up, the single-electron reduction in  $\text{ArNO}_2$  by P-450, NOS, and FNR may be attributed to the high stability of their flavin semiquinone state. Evidently, the reaction follows an “outer-sphere” electron transfer mechanism. The distances of electron transfer ( $R_{\text{p}}$ ) calculated according to this model (Appendix B, Equation (A3)), are equal to 4.2 (P-450R), 3.9 (nNOS), 4.4 (*Anabaena* FNR), 4.9–5.6 (*Pf*FNR) [109], and 2.1–3.7 Å (bovine ADX) [71,101]. These orientational values are consistent with the partial exposure of their redox centers to solvent. In all these cases, however, the principal factor determining the reactivity of  $\text{ArNO}_2$  is their  $E^{17}$ . This leaves relatively little space for the improvement of the enzymatic reactivity of compounds. The reasons for the mixed single- and two-electron way of  $\text{ArNO}_2$  reduction by CoQR and Fhb are unclear. Because of the limited amount of data, the factors determining nitroaromatic oxidant specificity for the single-electron transferring flavoenzymes of *M. tuberculosis*, *T. vaginalis*, *H. pylori*, and *Giardia* spp. are unclear. On the other hand, the application of Equation (A3) in the analysis of reactions of *T. vaginalis* Fd [110] gives  $R_{\text{p}} \leq 1.5 \text{ \AA}$ , which points to strong electronic coupling and deviation from an “outer-sphere” electron transfer model. This is in accordance with the

possible binding of ArNO<sub>2</sub> at the unique cavity near the FeS cluster of *T. vaginalis* Fd ([110], and references therein) and points to the possible substrate structure specificity.

### 3.2. Two-Electron Reduction in Nitroaromatic Compounds by NAD(P)H:Quinone Oxidoreductase (NQO1) and Bacterial Nitroreductases

Mammalian NAD(P)H:quinone oxidoreductase (NQO1, DT-diaphorase) is a dimeric 2 × 30 kD enzyme containing one molecule of FAD per subunit. It catalyzes two-electron reduction in quinones and ArNO<sub>2</sub> at the expense of NADH or NADPH. The physiological functions of NQO1 are incompletely understood. It is supposed that it maintains vitamins K1, K2, and K3 in a reduced state and participates in the stabilization of transcription factor p53 ([132], and references therein). The activity of NQO1 is frequently elevated in various tumors ([133], and references therein). For this reason, there exists a continuing interest in the development of NQO1-directed bioreductive drugs. The studies of rat, mice, and human NQO1 revealed that the bound nicotinamide ring of NADP(H) displaces Phe178', interacts with Tyr126' and Tyr128', and is stacked with FAD isoalloxazine ring at a distance of 3.4 Å. Duroquinone, other quinones, and dicoumarol, competitive to NAD(P)H, occupy the nicotinamide binding site [134–137]. In contrast, another inhibitor, cibacron blue, binds at the adenosine binding site and almost does not interact with the nicotinamide binding site. The potentiometric and kinetic characteristics of NQO1 are given in Table 3. Under redox equilibrium, NQO1 contains 8% red (anionic) semiquinone. During the reoxidation of reduced NQO1 by quinones and single-electron acceptor ferricyanide, the transient semiquinone formation was not observed. It means that the rate-limiting step of this process is the oxidation of two-electron reduced FAD [138].

The mechanism of reduction in quinones by NQO1 is understood better than the reduction in ArNO<sub>2</sub>. The reactions follow the “ping-pong” mechanism and are frequently characterized by quinone substrate inhibition due to the formation of dead-end complexes with the oxidized enzyme. The reactivity (log  $k_{\text{cat}}/K_m$ ) of rat NQO1 with the number of quinones of different structures increased with their  $E^{1/2}$  and decreased with their van der Waals volume (VdWvol) [139]. Their optimal VdWvol was estimated to be  $\leq 200 \text{ \AA}^3$ . The entropies of activation ( $\Delta S^\ddagger$ ) calculated according to  $k_{\text{cat}}/K_m$  of reduction in rapidly reacting quinones were equal to  $-84 \div -76 \text{ J mol}^{-1} \text{ K}^{-1}$ , whereas the reduction in “slow” quinones was characterized by  $\Delta S^\ddagger = -36 \div -11 \text{ J mol}^{-1} \text{ K}^{-1}$ . This demonstrates more efficient electronic coupling of “fast” oxidants in the transition state [140].

**Table 3.** Potentiometric and kinetic characteristics of mammalian NAD(P)H:quinone oxidoreductase and bacterial nitroreductases.

Enzyme	Redox Potential vs. NHE, pH 7.0	Rate Constants of Electron (Hydride) Transfer, pH 7.0
Rat liver NAD(P)H:quinone oxidoreductase	−0.159 V (FAD/FADH <sup>−</sup> ), −0.201 V (FAD/FAD <sup>•−</sup> ) [138]	>1000 s <sup>−1</sup> (NADPH to FAD) [138]; $k_{\text{cat}} = 0.1\text{--}2300 \text{ s}^{-1}$ , $k_{\text{cat}}/K_m = 3 \times 10^2\text{--}5.4 \times 10^8 \text{ M}^{-1}\text{s}^{-1}$ (quinones, steady-state) [139]; $k_{\text{cat}} = 0.04\text{--}75 \text{ s}^{-1}$ , $k_{\text{cat}}/K_m = 5.0 \times 10^1\text{--}5.7 \times 10^5 \text{ M}^{-1}\text{s}^{-1}$ (ArNO <sub>2</sub> , steady-state) [141]
<i>E. coli</i> NfsB		>1000 s <sup>−1</sup> (NADH to FMN) [142]; $k_{\text{cat}} = 225 \text{ s}^{-1}$ , $k_{\text{cat}}/K_m = 1.5 \times 10^5 \text{ M}^{-1}\text{s}^{-1}$ (nitrofurazone), $k_{\text{cat}}/K_m = 650 \text{ M}^{-1}\text{s}^{-1}$ (nitrobenzene, steady-state) [143]; $k_{\text{cat}} = 140 \text{ s}^{-1}$ , $k_{\text{cat}}/K_m = 7.0 \times 10^3 \text{ M}^{-1}\text{s}^{-1}$ (CB-1954, steady-state) [144]; $k_{\text{cat}} = 60 \text{ s}^{-1}$ , $k_{\text{cat}}/K_m = 1.3 \times 10^4 \text{ M}^{-1}\text{s}^{-1}$ (PR-104A, steady-state) [145]
<i>E. cloacae</i> NR-B	−0.190 V (FMN/FMNH <sup>−</sup> ) [146]	>1000 s <sup>−1</sup> (NADH to ArNO <sub>2</sub> , steady-state) [39]; 700 s <sup>−1</sup> (NADH to FMN), 1.9 s <sup>−1</sup> (FMNH <sup>−</sup> to <i>p</i> -nitrobenzoic acid, 4 °C) [147]
<i>E. coli</i> NfsA	−0.215 V (FMN/FMNH <sup>−</sup> ) [148]	>400 s <sup>−1</sup> (NADPH to FMN), $k_{\text{cat}} = 14\text{--}180 \text{ s}^{-1}$ , $k_{\text{cat}}/K_m = 10^4\text{--}7.9 \times 10^6 \text{ M}^{-1}\text{s}^{-1}$ (ArNO <sub>2</sub> , steady-state) [149]
<i>M. smegmatis</i> MsPnBA	−0.190 V (FMN/FMNH <sup>−</sup> ) [150]	$k_{\text{cat}} = 3.4\text{--}19.2 \text{ s}^{-1}$ , $k_{\text{cat}}/K_m = 1.2 \times 10^3\text{--}1.6 \times 10^5 \text{ M}^{-1}\text{s}^{-1}$ (ArNO <sub>2</sub> , steady-state) [150]
Peroxioredoxin-nitroreductase hybrid enzyme, <i>Thermotoga maritima</i>	−0.185 V (FMN/FMNH <sup>−</sup> , pH 8.0) [151]	146 s <sup>−1</sup> (NADH to FMN), $k_{\text{cat}} \leq 15 \text{ s}^{-1}$ , $k_{\text{cat}}/K_m = 10^1\text{--}5.8 \times 10^5 \text{ M}^{-1}\text{s}^{-1}$ (ArNO <sub>2</sub> , steady-state) [152]



NQO1 reduces ArNO<sub>2</sub> more slowly than quinones (Table 3) [141]. For example, CB-1954 (14) is reduced by rat NQO1 with  $k_{\text{cat}} \leq 0.1 \text{ s}^{-1}$  and  $k_{\text{cat}}/K_{\text{m}} < 10^3 \text{ M}^{-1}\text{s}^{-1}$ . The reactivity of human NQO1 is even lower because of a Tyr104Glu substitution [153]. Next, we will address the kinetic properties of rat NQO1. Its best substrates, tetryl (2) and tetranitrobenzimidazolone (42) are characterized by  $k_{\text{cat}} \geq 70 \text{ s}^{-1}$  and  $k_{\text{cat}}/K_{\text{m}} > 10^5 \text{ M}^{-1}\text{s}^{-1}$ . The  $\Delta S^\ddagger$  of reduction in ArNO<sub>2</sub> is even less negative than those of “slow” quinone substrates, which points to their less efficient electronic coupling. One should note that NQO1 performs the reductive *N*-denitration of tetryl (2) (Scheme 3) in a mixed single- and two-electron way [154]. This supports the possibility of a multistep ( $e^-$ ,  $\text{H}^+$ ,  $e^-$ ) hydride transfer in the reduction in other nitroaromatics with an initial single-electron transfer.

The reactivity of a series of nitrobenzimidazoles toward rat NQO1 increases with their  $E_{7(\text{calc.})}^{17}$  [155]. However, for a larger set of compounds, the dependence of  $\log k_{\text{cat}}/K_{\text{m}}$  on  $E_{7}^{17}$  is almost absent. The reactivity of ArNO<sub>2</sub> increases with the stability of their complexes with the oxidized form of NQO1 [141,155]. However, the criteria for efficient complex formation are poorly understood. Another factor enhancing the reactivity of ArNO<sub>2</sub> is an increased torsion angle of the nitro group. This, in particular, explains why NQO1 reduces the 4-nitro group of CB-1954 (13). The combined studies of the effects of dicoumarol and cibacron blue and interdependent quinone and ArNO<sub>2</sub> inhibition enabled us to conclude that nitroaromatics and bulky quinones bind partly outside the nicotinamide/dicoumarol binding pocket and may partly occupy adenosine/cibacron blue binding pocket [139,141].

Bacterial type I oxygen-insensitive nitroreductases (NRs) catalyze NAD(P)H-dependent multistep reduction in ArNO<sub>2</sub> with the formation of nitroso, hydroxylamine and amino products. Among several groups of type I NRs, two major ones are distinguished according to their similarity with *E. coli* nitroreductases A or B [156]. The physiological functions and physiological electron acceptors for bacterial type I NRs are not clearly characterized. It is suggested that they participate in the antioxidant defense of microorganisms as part of the soxRS regulon, whose genes are upregulated in response to oxidative stress [157]. Oxygen-insensitive NRs play a considerable role in the bioreductive degradation of polynitroaromatic explosives such as 2,4,6-trinitrotoluene (TNT) (4) [3]. They also are potential candidates for gene-directed enzyme-prodrug cancer therapy (GDEPT) using nitroaromatic compounds. This approach is based on the much higher rates of two-electron reduction in ArNO<sub>2</sub> by bacterial NRs than by human NQO1 [7,8,15]. In this case, genes encoding NRs are inserted into the tumor cells using either a virus or a plasmid. Further, we will address the properties of NRs with well-characterized catalysis mechanisms and/or well-established biomedical importance.

Most type I reductases are  $2 \times 24 \div 27$  kD dimers, containing one FMN per subunit. They may reduce a wide spectrum of oxidants, including nitroaromatics, quinones, riboflavin derivatives, and inorganic complexes [142,158,159]. Typically, they are inhibited by micromolar or lower concentrations of dicoumarol, which binds at the dihydronicotinamide binding site of NAD(P)H, and acts as a competitive inhibitor toward NAD(P)H. Their reactions proceed according to the “ping-pong” mechanism. The potentiometric and kinetic characteristics of NRs are given in Table 3.

The best-characterized members of group B NRs are *E. coli* nitroreductase B (NfsB) and *Enterobacter cloacae* nitroreductase (*E. cloacae* NR). The X-ray studies of NfsB show that the FMN isoalloxazine ring is localized in the intersubunit domain, its *re*-plane is solvent-accessible [143,160,161]. The nicotinamide ring of bound NAD(P) is stacked between isoalloxazine and Phe124'. Nitroaromatic compounds bind close to the nicotinamide binding domain of NfsB; however, there exist several potential binding sites of CB-1954 (14), with the participation of Lys14, Lys74, Ser12, or Phe124, Asn71, and Gly166 [150]. On the other hand, nitrofurazone interacts with Glu165 and Phe70 and binds in nonproductive conformation because its nitrofuran group does not stack over the isoalloxazine ring of FMN [143]. This may point to the flexibility of the active center of NfsB during catalysis and to its ability to accommodate the oxidants of different sizes and shapes. This is particularly indicated by the ability of NfsB to reduce either the 2- or 4-nitro group of CB-1954 and only




the 2-nitro group of SN-23682 (19) [162]. The kinetic parameters of NfsB (Table 3) show that it reduces CB-1954 much more rapidly than does NQO1. As the maximal rates of reduction in nitroaromatics are lower than the rate of reduction in FMN (Table 3), the oxidative half-reaction is the rate-limiting step of catalysis of NfsB. The early studies [158,159] point to the possible absence of substrate specificity and the increase in their reactivity with reduction potential. According to the studies of a series of derivatives of CB-1954 and SN-23682, their  $k_{\text{cat}}/K_m$  varied in the range of  $4.8 \times 10^2$ – $6.3 \times 10^4 \text{ M}^{-1}\text{s}^{-1}$  [162]. This data scattering points to a definite effect of the size and position of substituents on the reactivity of compounds, which, however, is difficult to characterize. On the other hand, the reactivity of compounds starts to decrease at their  $\text{VdWvol} \geq 400 \text{ \AA}^3$ .

*E. cloacae* NR possesses 88% homology with NfsB [163]. The potentiometric and kinetic characteristics of the enzyme are given in Table 4. The semiquinone state of FMN of *E. cloacae* NR is extremely unstable, ca. 0.01% at equilibrium [146]. This possibly determines the two-electron character of reduction in  $\text{ArNO}_2$ . The oxidative half-reaction is the rate-limiting step of the catalytic cycle. Using 4- $R$ - $^2\text{H}$ -NADH, kinetic isotope effects are observed in both reductive and oxidative half-reactions [147]. It shows that the H atom, transferred from dihydronicotinamide to N-5 position of isoalloxazine, is subsequently transferred to oxidant during two-electron reduction if the exchange of proton at N-5 position with the solvent is sufficiently slow. In contrast with single-electron transferring flavoenzymes and NQO1, *E. cloacae* NR reduced  $\text{ArNO}_2$  faster than quinones with the same  $E^{17}$  value [39,164]. The reactivity of nitroaromatics increased with their  $E^{17}$  or correlated with their  $\Delta\text{Hf}(\text{ArN}(\text{OH})\text{O}^-)$  or  $\Delta\text{Hf}(\text{ArNO}_2^-)$ , thus showing little structure specificity. The  $k_{\text{cat}}/K_m$  of the most efficient oxidants, derivatives of tetryl (2), reached  $10^7 \text{ M}^{-1}\text{s}^{-1}$ . TNT (4) oxidized 4 NADH equivalents in two steps, apparently being reduced to dihydroxylamino derivative, whereas tetryl oxidized 6 NADH equivalents. Importantly, *E. cloacae* NR did not catalyze reductive *N*-denitration of tetryl (Scheme 3) and reduced it into currently unidentified products.


*Salmonella typhimurium* NR is a  $2 \times 24 \text{ kD}$  dimer containing FMN and possessing 89% identity with *E. cloacae* NR [165]. It reduces nitrobenzene derivatives with  $k_{\text{cat}} = 5.8$ – $290 \text{ s}^{-1}$  and  $k_{\text{cat}}/K_m = 1.7 \times 10^3$ – $3.7 \times 10^5 \text{ M}^{-1}\text{s}^{-1}$  [150]. The reactivity of nitrobenzenes increases with the  $\sigma$  value of their substituents.

*E. coli* NfsA, an FMN-dependent NADPH-specific enzyme, is the best-characterized member of group A nitroreductases [166]. The kinetic and potentiometric characteristics of the enzyme are given in Table 3. NfsA follows the “ping-pong” mechanism with the rate-limiting oxidative half-reaction [149]. The reactivity of  $\text{ArNO}_2$  is systematically higher than the reactivity of quinones possessing the same  $E^{17}$ . NfsA reduced tetryl (2) to the same unidentified products as did *E. cloacae* NR. The second step of a net four-electron reduction in  $\text{ArNO}_2$ , the formation of  $\text{ArNHOH}$  from  $\text{ArNO}$  intermediate, is most likely the direct nonenzymatic reduction in  $\text{ArNO}$  by NADPH (Scheme 4, pathway (b)) [41]:



**Scheme 4.** A general scheme of reduction in nitroaromatics by oxygen-insensitive nitroreductases involving an enzymatic (pathway (a)) and nonenzymatic (pathway (b)) reduction in nitroso intermediate.

Like in NfsA, nitrofurantoin binds at the active center of NfsA in nonproductive orientation (Figure 4), its nitrofuran ring interacts with Arg15 and Lys167, and its imidazole group binding over the isoalloxazine ring interacts with Arg225 [142]. This shows that the catalysis of NfsA, NfsB, and *E. cloacae* NR may share some common features. However, there may exist certain differences in their action. The computer modeling study suggests that the binding CB-1954 to NfsA involves Ser40 (Ser41 in NfsB) and Ile129' (Phe124' in NfsB); however, it may also involve Phe42 that is absent in NfsB [167]. In contrast to *E. cloacae* NR and NfsB, dicoumarol does not quench the fluorescence of FMN, which points to its relatively weak interaction with isoalloxazine [149].



**Figure 4.** The orientation of nitrofurantoin (pink) and FMN (gray) in the complex of nitrofurantoin with oxidized *E. coli* NfsA. The structure is taken from the Protein Data Bank, accession code 7NB9 [142].

In NfsA-catalyzed reactions,  $\log k_{\text{cat}}/K_m$  of a series of nitrobenzenes including CB-1954 and nitrofurans correlated well with their  $E^1_7$  [149]. The  $k_{\text{cat}}/K_m$  of the most efficient oxidant, tetryl, reaches  $7.9 \times 10^6 \text{ M}^{-1}\text{s}^{-1}$ . The reduction rate constants of several 2-nitroimidazoles ( $E^1_7 \sim -0.390 \text{ V}$ ), dinitrobenzene PR-104 (13), and metronidazole (40) obtained in other studies [15,168,169] are also close to this correlation. Thus, the data available so far demonstrate that the reactivity is determined mainly by the reduction potential of  $\text{ArNO}_2$  and not by their structural peculiarities.

*Mycobacterium smegmatis* enzyme MsPnBA is classified as group A nitroreductase [150]. The kinetic and potentiometric characteristics of the enzyme are presented in Table 3. This nitroreductase reduces antitubercular benzothiazinones into their amines and confers *M. smegmatis* resistance to these drugs [170]. Like in NfsA-catalyzed reactions, the reactivity of a series of examined nitrobenzenes increases with the  $\sigma$  value of their substituents [150]. Other less-characterized NfsA-like nitroreductases from *Neisseria meningitidis* and *Bartonella henselae* reduce CB-1954 and metronidazole with similar rates to those of NfsA [169].

A relatively well-characterized oxygen-insensitive NR is the peroxiredoxin- nitroreductase (Prx-NR) hybrid enzyme of *Thermotoga maritima*, which consists of a Prx domain at the N-terminus, and an FMN-containing NR domain at the C-terminus. These domains function independently without the exchange of redox equivalents [151]. The NR domain of Prx-NR (residues 142–321) possesses a 20–24% homology with *E. coli* NfsB and *E. cloacae* NR, and 18% homology with NfsA [152], and does not contain the residues analogous to Phe124', Phe70, Ser40, Lys14 and Lys74 of group B NRs. The rate-limiting step of Prx-NR catalysis is the oxidative half-reaction. Importantly, the substrate specificity of Prx-NR differs from that of *E. cloacae* NR and NfsA. Although the  $\log k_{\text{cat}}/K_m$  of  $\text{ArNO}_2$  increased with their  $E^1_7$ , nitroaromatics were less reactive than quinones with the same  $E^1_7$  values [152]. Because this phenomenon is characteristic of single-electron reduction (see Section 3.1), it is possible that  $\text{ArNO}_2$  are reduced in a multistep ( $e^-$ ,  $\text{H}^+$ ,  $e^-$ ) way with a rate-limiting first electron transfer.

*Helicobacter pylori* contains nitroreductase RdxA, an FMN-containing  $2 \times 26 \text{ kD}$  dimer that shows no more than 29% sequence identity with other homologous structures of NRs [171,172]. RdxA exhibits high NADPH oxidase activity,  $2.8 \text{ s}^{-1}$ . The maximal reduction rate of nitrofurazone and CB-1954 was similar to RdxA oxidase activity. They were reduced with  $k_{\text{at}}/K_m$  of  $1.4 \times 10^6 \text{ M}^{-1}\text{s}^{-1}$  and  $3.0 \times 10^5 \text{ M}^{-1}\text{s}^{-1}$ , respectively. Metronidazole was reduced with a much lower rate,  $k_{\text{cat}} = 0.22 \div 0.62 \text{ s}^{-1}$  and  $k_{\text{at}}/K_m = 2.0 \times 10^3 \text{ M}^{-1}\text{s}^{-1}$ . Nitrothiazole nitazoxanide (52) was reduced by RdxA with a rate similar to that of metron-

idazole [173]. Another *H. pylori* nitroreductase, FrxA, is even more scarcely characterized. In this case, the reactivity of ArNO<sub>2</sub> increases in the order metronidazole < nitrofurans < nitazoxanide [173]. The factors determining substrate specificity of both NRs are unclear.

Nitroreductase-type enzymes (NTR) were found in parasites *Trypanosoma cruzi* and *T. brucei* [174–176]. They represent 2 × 30 kD dimers containing one FMN per monomer. *T. cruzi* NTR is NADPH-specific, whereas the *T. brucei* enzyme oxidizes both NADH and NADPH. They are inhibited by dicoumarol with  $K_i = 258$  nM and  $K_i = 14$  nM, respectively. These enzymes reduce nitrofurans, nitroimidazoles, and nitrobenzenes with  $k_{cat} = 0.2 \div 1.2$  s<sup>-1</sup>, and  $k_{cat}/K_m$  ranging from  $7.3 \times 10^2$  to  $2.5 \times 10^5$  M<sup>-1</sup>s<sup>-1</sup>. The final product of reduction in nifurtimox under aerobic conditions is unsaturated open-chain nitrile, whose antitrypanosomal activity was close to that of nifurtimox. Benznidazole is metabolized into hydroxylamine products, which further undergoes secondary reactions. The factors determining enzyme-substrate specificity are unclear. It is evident that the activity of compounds does not correlate with their  $E^{1,7}$ .

*Leishmania* spp. possess several types of NTR. An FMN-dependent mitochondrial 34.7 kD NADH and NADPH-oxidizing nitroreductase (NTR1) from *Leishmania major* reduces benznidazole, nifurtimox, CB-1954, and related compound without pronounced substrate specificity, with  $k_{cat} = 0.01 \div 0.07$  s<sup>-1</sup> and  $k_{cat}/K_m = 2.5 \times 10^3 \div 1.0 \times 10^4$  M<sup>-1</sup>s<sup>-1</sup> [177]. This enzyme participates in the bioactivation of a novel antitrypanosomal and leishmanicidal agent fexinidazole (39); however, the kinetics data are not presented [178]. Because fexinidazole is a representative of 5-nitroimidazoles, one may expect its  $E^{1,7}$  in the range of  $-0.490 \div 0.430$  V (Table 1). Another FMN-dependent cytosolic 39.6 kD enzyme (NTR2) was identified in *L. donovani* [179]. It is specific toward bicyclic low-potential nitroimidazooxazines such as R-PA-824 (57) and its analogs, whose turnovers are equal to  $2.0 \div 10.1$  s<sup>-1</sup> at 100 μM compound concentration, whereas the more powerful monocyclic oxidants nifurtimox and fexinidazole are reduced much slower, with rates of 0.12 and <0.01 s<sup>-1</sup>, respectively [179].

There exist limited data on the formation of amines as the final product of reduction in ArNO<sub>2</sub> by type I NRs, although this problem is relevant both to biomedicine and ecotoxicology. NfrA from *Bacillus LMA* exhibits 40% homology with NfsB and reduces 3,5-dinitro-trifluoromethylbenzene to diamine product with  $k_{cat} = 18$  s<sup>-1</sup> [180]. Nitrofurazone is reduced to its amine derivative at a lower rate. *S. typhimurium* NR quantitatively reduces nitrobenzene into aniline [165]. It is unclear whether the tendency for amine formation is determined by the properties of ArNO<sub>2</sub> or nitroreductase or by both factors. It has been suggested that the possibility of amine formation increases with the reduction potential of ArNO<sub>2</sub> and the size of their aromatic system [150]. A recent study shows that *Haemophilus influenza* NR-B reduces chloroamphenicol (23) into a corresponding amine with  $k_{cat} = 10.2$  s<sup>-1</sup> and  $k_{at}/K_m = 2.0 \times 10^4$  M<sup>-1</sup>s<sup>-1</sup> [181]. This NR possesses unusual and undisclosed substrate specificity because it reduces more powerful oxidant metronidazole (40) (Table 1) with a lower rate,  $k_{cat} = 0.34$  s<sup>-1</sup> and  $k_{at}/K_m = 4.6 \times 10^3$  M<sup>-1</sup>s<sup>-1</sup> with the formation of its hydroxylamine metabolite.

There also exist several potentially important but insufficiently characterized flavin-independent enzymes with nitroreductase activity. In spite of the presence of nitroreductase MspnBA in *M. smegmatis* [170], this enzyme is absent in *M. tuberculosis*. In this case, the antitubercular drug S-PA-824 (57) is reduced by deazaflavin F-420 (7,8-didemethyl-8-hydroxy-5-deazariboflavin)-dependent nitroreductase [182]. This reaction with  $k_{cat} = 0.1$  s<sup>-1</sup> leads to the formation of NO·. Under aerobic conditions, human aldo-keto reductase 1C3 catalyzes NADPH-dependent reduction in PR-104A (13) into its hydroxylamino metabolite with  $k_{cat} = 0.013$  s<sup>-1</sup> [183].

Summing up, the two-electron reduction in ArNO<sub>2</sub> by NQO1 and bacterial oxygen-insensitive NRs may be attributed to the low stability of their flavin semiquinone state. However, the relative stability of FAD<sup>-</sup> of NQO1, 8% under equilibrium [138], may enable this enzyme to perform the reductive denitration of tetryl (2) (Scheme 3) in a mixed single- and two-electron way [143]. This reaction is not characteristic for *E. cloacae* NR-B and *E. coli* NfsA [39,149], evidently due to the much lower stability of their FMN semiquinone [146].

The crystallographic studies of NRs from *E. coli* [142,143,160,161] point to the flexibility of their active sites and to their ability to accommodate the substrates of various sizes. The kinetic studies of several A- and B-type NRs demonstrate that the reactivity of ArNO<sub>2</sub> is strongly influenced by their reduction potential [39,149,150]. However, this leaves some space for the improvement of the activity of compounds. Another unresolved problem is the factors determining substrate specificity of nitroreductases from *H. pylori*, *H. influenzae*, *Leishmania*, and *Trypanosoma* spp.

### 3.3. Single- and Two-Electron Reduction in Nitroaromatic Compounds by Flavoenzymes Disulfide Reductases

Flavoenzymes disulfide reductases contain FAD and redox-active disulfide group, which participate in the transfer of redox equivalents in a sequence NAD(P)H → FAD → catalytic disulfide → low-*M<sub>r</sub>* or protein disulfide substrate. In most cases, they perform antioxidant functions. These reactions proceed via obligatory two-electron (hydride) transfer without the formation of free radical intermediates ([184,185], and references therein). Although being slow, the nitroreductase reactions of disulfide reductases received significant attention because of the combined action of ArNO<sub>2</sub>, redox cycling, and inhibition of physiological reactions of disulfide reductases. It is important to note that these compounds are reduced by flavin but not by reduced disulfide cofactor due to unfavorable energetics of single-electron oxidation of dithiols [186].

Glutathione reductase (GR) and trypanothione reductase (TR), the 2 × 55 kD homodimers, contain one FAD and catalytic disulfide per subunit. GR catalyzes the reduction in glutathione disulfide (GSSG), and TR catalyzes the reduction in trypanothione (TS<sub>2</sub>), a glutathione-spermidine conjugate. The structure and reaction mechanism of both enzymes are similar [187–189]. GR performs antioxidant functions in various organisms. TR is found exclusively in trypanosomes and leishmanias, the causative parasites of several tropical diseases, including African sleeping sickness and Chagas disease. These parasites do not contain GSSG/GSH, and their antioxidant defense relies mainly on TR-catalyzed regeneration of T(SH)<sub>2</sub>. The presence of amino acids with different charge in the disulfide substrate-binding domain of HGR and *T. congolense* TR [187,190] enable the discrimination between the negatively charged GSSG and positively charged TS<sub>2</sub>.

GR and TR are reduced by NADPH to two-electron reduced form (EH<sub>2</sub>), which is the FAD-thiolate charge-transfer complex with the main electron density being localized on thiolate. Next, EH<sub>2</sub> is reoxidized by disulfide. These reactions follow a “ping-pong” mechanism with reductive half-reaction as a rate-limiting step. The *k<sub>cat</sub>* values of human erythrocyte GR (HGR), *P. falciparum* GR (*PfGR*), and TRs span between 120 and 240 s<sup>-1</sup> [185,191–195]. More precisely, their mechanism should be classified as “hybrid ping-pong” because during turnover, GSSG reoxidizes not free EH<sub>2</sub> form, but its tight complex with repeatedly bound NADPH (*K<sub>d</sub>* = 2.1 μM, yeast GR [196]). In this case, GSSG oxidizes free EH<sub>2</sub> and its complexes with NADPH and NADP<sup>+</sup> with sufficiently close rates. The redox potentials of HGR, *PfGR* and *T. congolense* TR are equal to −0.227 (pH 8.2 [193]), −0.206 (pH 6.9 [197]), and −0.275 V (pH 7.5 [198]), respectively. Under artificial conditions, GR may be further reduced into the four-electron reduced state (EH<sub>4</sub>); however, this form is not formed during the enzyme turnover. This is attributed to the tight binding of NADPH, which stabilizes the EH<sub>2</sub> form.

ArNO<sub>2</sub> are reduced by GR and TR in a single-electron way. The most efficient oxidant of HGR and *PfGR* is tetryl (2) (*k<sub>cat</sub>* ≥ 5 s<sup>-1</sup>, *k<sub>cat</sub>*/*K<sub>m</sub>* = 2.0 ÷ 7.5 × 10<sup>3</sup> M<sup>-1</sup>s<sup>-1</sup> [195]). The low reaction rates complicate the substrate specificity studies. However, the introduction of basic substituents into nitrofurans molecule enhances their reactivity toward TR (*k<sub>cat</sub>* = 2.5 ÷ 3.0 s<sup>-1</sup>, *k<sub>cat</sub>*/*K<sub>m</sub>* = 3.3 ÷ 9.2 × 10<sup>4</sup> M<sup>-1</sup>s<sup>-1</sup> [199,200]). A specific feature of quinone and nitroreductase reactions of GR and TR is the activation by the reaction product NADP<sup>+</sup> [192,201]. Although the main electron density in the FAD-thiolate charge-transfer complex is localized on thiolate, its minor part remains on FAD. The binding of NADP<sup>+</sup> to EH<sub>2</sub> with a concomitant displacement of NADPH increases the electron density on FAD, which may accelerate the reduction in xenobiotics. The order of reactivity of various redox



forms of GR and TR with quinones and presumably with ArNO<sub>2</sub> is EH<sub>2</sub> < EH<sub>2</sub>-NADPH < EH<sub>2</sub>-NADP<sup>+</sup> < EH<sub>4</sub> [192,202]. However, the site(s) of their reduction are not characterized.

An important aspect of the interaction of ArNO<sub>2</sub> with GR and TR is the inhibition of the reduction in their physiological disulfide oxidants [17,195,199–203]. In these cases, compounds act as non- or uncompetitive inhibitors with respect to NADPH and disulfide substrate and bind at the intersubunit domain of GR or TR close to the binding sites of GSSG or TS<sub>2</sub>. The amino acid residues of this domain of HGR, PfGR, and TR are strikingly different [189,204]. Currently, significant efforts are devoted to the studies of efficient and specific inhibitors targeting this domain, with an aim to develop new antimalarial or trypanocidal drugs [194,205]. The efficiency of ArNO<sub>2</sub> or other redox-active compounds is evaluated by the ratio  $(k_{\text{cat}}/K_{\text{m}})/K_{\text{i}}$ , which combines their ability to serve as redox cycling agents and inhibit GSSG/TS<sub>2</sub> reduction [194]. For most active compounds, this ratio is above 10<sup>11</sup> M<sup>-2</sup>s<sup>-1</sup> (naphthoquinones) and above 10<sup>10</sup> M<sup>-2</sup>s<sup>-1</sup> (nitrofurans) [194,199,200].

Lipoamide dehydrogenase (LipDH, NADH:lipoamide oxidoreductase) is structurally similar to GR and TR, although it does not perform antioxidant functions. Mammalian LipDH catalyzes the NAD<sup>+</sup>-dependent oxidation of covalently bound dihydrolipoate of the pyruvate dehydrogenase or  $\alpha$ -ketoglutarate dehydrogenase complexes [184]. Pig heart enzyme catalyzes the rapid transfer of two redox equivalents in both directions, from dihydrolipoamide to NAD<sup>+</sup> and from NADH to lipoamide (LipS<sub>2</sub>NH<sub>2</sub>). In the latter case, the rate-limiting step of the process is the oxidative half-reaction [184,206]. Like GR or TR, LipDH shuttles between E<sub>ox</sub> and EH<sub>2</sub> states.

Pig heart and *T. cruzi* LipDH reduce nitroaromatic compounds with  $k_{\text{cat}} = 0.1 \div 2.0 \text{ s}^{-1}$  [203,207] that makes 0.02–0.5% of LipS<sub>2</sub>NH<sub>2</sub> reduction rate. Some information on the reaction mechanism may be obtained from the studies of quinone reduction, which takes place with 20% (pig heart LipDH [206]), or even with 80% of maximal disulfide oxidant reduction rate (*M. tuberculosis* LipDH [208]). It was concluded that the EH<sub>4</sub> fraction of LipDH, which is formed in the absence of NAD<sup>+</sup>, is mostly responsible for quinone reduction. Because *M. tuberculosis* LipDH efficiently reduces quinones,  $k_{\text{cat}} = 165\text{--}190 \text{ s}^{-1}$  [208], one may also expect its significant nitroreductase activity, which, however, was not investigated.

NAD(P)H-thioredoxin reductases (TrxRs) are important antioxidant enzymes in both prokaryotic and eukaryotic organisms [209]. There exist two groups of TrxRs: high-*M<sub>r</sub>* (2 × 54–58 kD) enzymes contain FAD, catalytic disulfide, and a third cofactor, selenylsulfide (mammalians), or additional disulfide (*P. falciparum*) in their active center. Low-*M<sub>r</sub>* enzymes (2 × 35 kD) from plants, bacteria, and archaea contain FAD and catalytic disulfide. The physiological substrates of TrxRs are 10–12 kD disulfide proteins thioredoxins (Trxs), and sometimes disulfide or monothiol-containing glutaredoxins (Grxs). Apart from the antioxidant action, they perform other numerous physiological functions [210,211]. It is important to note that human TrxR is overexpressed in numerous cancers [212].

First, let us discuss the properties of mammalian (rat, human) TrxR. The catalytic cycle of the enzyme is similar to GR, except for the participation of selenylsulfide, which is located at the C-end of the protein [213,214]. The rate-limiting catalysis step, 30 ÷ 40 s<sup>-1</sup>, is the two-electron transfer between dithiolate and selenylsulfide, which is responsible for the reduction in Trx and other numerous substrates of mammalian TrxR. During catalysis, the enzyme cycles between EH<sub>2</sub> and EH<sub>4</sub> redox states ( $E^0_7 = -0.294 \text{ V}$  [215]). Mammalian TrxR may directly reduce 5,5'-dithiobis(2-nitrobenzoic acid) (DTNB), with the maximal rate being equal to that of Trx reduction. Other less efficient oxidants are cystine, lipoate, alloxan, dehydroascorbate, vitamin E, coenzyme Q10, and vitamin K, lipid peroxides, and H<sub>2</sub>O<sub>2</sub>.

Rat TrxR reduces ArNO<sub>2</sub> either in a two-electron way (*p*-dinitrobenzene) or in a single-electron way (tetryl) [216]. During the reaction, TrxR cycles between four- and two-electron reduced states. The reactivity of ArNO<sub>2</sub>,  $k_{\text{cat}} = \leq 0.1\text{--}2.8 \text{ s}^{-1}$ , and  $k_{\text{cat}}/K_{\text{m}} = < 10^2\text{--}1.4 \times 10^4 \text{ M}^{-1}\text{s}^{-1}$  [216,217], is comparable with that of quinones, which follow poorly expressed linear log  $k_{\text{cat}}/K_{\text{m}}$  vs.  $E^1_7$  relationship [215]. The reduction in nitroaromatics that may

alkylate -SH/-Se<sup>-</sup> groups (1-chloro-2,4-dinitrobenzene, tetryl (2), dinitrobenzo-furoxane (48), 2-phenylsulfonylnitropyridines) is accompanied by a rapid covalent modification of the enzyme with a loss of DTNB and Trx reductase activity and to an increase in NADPH oxidase activity [216,218,219]. The most important feature of TrxR is that in addition to reduced FAD, the reduced selenylsulfide may participate in the reduction in fully substituted quinones such as phenanthrene quinone or toxoflavin [215,220], and, presumably, nitroaromatics. This was demonstrated by the selective suppression of these reactions by Au-thioglucose, which specifically reacts with selenol. The participation of selenocysteine but not cysteine in these reactions may be explained by the relative ease of its single-electron oxidation since  $E_7(\text{Sec}\cdot/\text{Sec}^-)$  is equal to 0.43 V, whereas  $E_7(\text{Cys}\cdot/\text{CysH})$  is equal to 0.92 V [186]. Dinitrobenzenes and nitrofurans acted as weak noncompetitive inhibitors with respect to DTNB ( $K_i = 17\text{--}400\ \mu\text{M}$ ), whereas tetryl and dinitrobenzofuroxane (48) acted as competitive inhibitors with  $K_i$  values of 12.5 and 5.0  $\mu\text{M}$ , respectively [216]. This points to the existence of several binding sites of ArNO<sub>2</sub>.

Another representative of high- $M_r$  enzymes, *P. falciparum* TrxR, contains FAD and two catalytic disulfides, Cys88, Cys93, and Cys535, Cys540 in the active center [221]. The enzyme reduces its physiological oxidant, *Pf*Trx1, and quinones with relatively high and similar rates, 51.7 and 31–67 s<sup>-1</sup>, respectively [222]. This is >10 times faster than the reduction in quinones by *Pf*GR or HGR. However, the nitroreductase reactions of *Pf*TrxR have not been examined.

Low- $M_r$  TrxRs from *E. coli* and other species contain one FAD and one redox-active disulfide per subunit. In contrast with GR and TR, their FAD and disulfide redox groups function separately. The  $E_7^0$  values of FAD/FADH<sub>2</sub> and S<sub>2</sub>/(SH)<sub>2</sub> redox couples are equal to  $-0.243 \div -0.260$  and  $-0.254 \div -0.271$  V, respectively [223]. In *E. coli* TrxR, NADP(H) binds at the vicinity of catalytic disulfide and at 17 Å distance from the isoalloxazine ring of FAD. In order to reduce FAD, the disulfide/NADP(H)-binding domain should undergo substantial rotation, which in turn exposes the catalytic disulfide into solution and makes it accessible to Trx [224]. This makes the formation of charge-transfer complex formation impossible [225,226]. The catalysis rate-limiting step, 25 ÷ 30 s<sup>-1</sup>, is either the conformational transition or Trx reduction. In catalysis, TrxR cycles between two- and four-electron reduced forms, FADH<sub>2</sub>/S<sub>2</sub> and FADH<sub>2</sub>/(SH)<sub>2</sub>. Interestingly, in spite of an obligatory two-electron character of physiological reactions of *E. coli* TrxR, it forms neutral (blue) FAD semiquinone during irradiation under anaerobic conditions [227].

The reactions of ArNO<sub>2</sub> and other prooxidant xenobiotics with *E. coli* TrxR were not studied. However, they were examined with structurally similar TrxRs from *Arabidopsis thaliana* ( $E_7^0(\text{FAD}/\text{FADH}_2) = -0.244$  V) [228–230] and *Thermotoga maritima* ( $E_7^0(\text{FAD}/\text{FADH}_2) = -0.230$  V) [151,231–233]. The latter enzyme preferentially oxidizes NADH, and its physiological oxidant is a 25.2 kD Grx-1. Although its crystal structure is unavailable, this enzyme possesses two catalytic cysteines Cys147 and Cys150, a vicinal NAD(P)H bonding motif, FAD bonding motif, and interdomain motif Gly251, Pro254, which possibly participates in domain rotation [231]. Both enzymes reduced ArNO<sub>2</sub> with 70–90% single-electron flux [230,232] and catalyzed *N*-denitration of tetryl with the formation of *N*-methylpicramide (Scheme 3). This reaction was characterized by  $k_{\text{cat}} = 1.5\ \text{s}^{-1}$  and  $k_{\text{cat}}/K_m = 2.7 \times 10^4\ \text{M}^{-1}\text{s}^{-1}$  (*A. thaliana* TrxR), and  $k_{\text{cat}} = 6.3\ \text{s}^{-1}$  and  $k_{\text{cat}}/K_m = 6.6 \times 10^4\ \text{M}^{-1}\text{s}^{-1}$  (*T. maritima* TrxR). In both cases, the log  $k_{\text{cat}}/K_m$  of reduction in ArNO<sub>2</sub> increased with  $E_7^1$ . The reactivity of nitroaromatics was by one order of magnitude lower than that of quinones with the same  $E_7^1$  values. On the analogy with quinone reduction by *T. maritima* TrxR, the rate-limiting reaction step in nitroreductase reactions of low- $M_r$  TrxRs may be the oxidation of FAD semiquinone [233]. It is important to note that the single-electron character of ArNO<sub>2</sub> reduction and reactivity of *A. thaliana* and *T. maritima* TrxRs are similar to the properties of low- $M_r$  TrxRs from *T. vaginalis* and *Giardia lamblia* [234,235]. Thus, they may be considered as the model enzymes for the studies of this pathway of ArNO<sub>2</sub> activation in parasites.

The structure and functions of *Salmonella typhimurium* alkyl hydroperoxide reductase AhpF share some similarities both with high- $M_r$  and low- $M_r$  TrxRs ([236], and references



therein). Its 58 kD monomer contains FAD and two redox-active disulfide centers, Cys345-Cys348 and Cys129-Cys132. C-terminal FAD-binding domain of AhpF possesses 34% identity with the analogous domain of *E. coli* TrxR. Through putative large interdomain movements, electrons are transferred in a sequence  $\text{NADH} \rightarrow \text{FAD} \rightarrow \text{Cys345-Cys348} \rightarrow \text{Cys129-Cys132}$ . The latter center, located in N-terminus, transfers electrons to the catalytic disulfide of another hydroperoxide reductase, AhpC. In contrast to *E. coli* TrxR, reduced AhpF may form 540 nm absorbing charge-transfer complex under high ionic strength of the solution. AhpF from *E. coli* reduces nitrofurans in a single-electron way [237]. Although the kinetic parameters of these reactions are not reported, AhpH is partly responsible for the sensitivity of *E. coli* to nitrofurans.

Summing up, the low nitroreductase activity of disulfide reductases may be attributed to the low electron density on FAD in FAD-thiolate charge-transfer complexes. This diminishes their role in redox cycling or other modes of activation of  $\text{ArNO}_2$  in the cell. However, low- $M_r$  TrxRs where FAD and catalytic disulfide function separately may more significantly contribute to the redox cycling of  $\text{ArNO}_2$ . The frequently observed single-electron reduction in nitroaromatics is not inconsistent with the redox properties of FAD of disulfide reductases. Apart from the formation of  $\text{FADH}\cdot$  of low- $M_r$  TrxR of *E. coli* under the artificial conditions [227], the complex of reduced GR with  $\text{NADP}^+$  also gradually converts into a product, characterized as the complex of  $\text{NADP}^+$  with  $\text{FAD}^{\cdot-}$  ([184], and references therein). Another relevant problem is the exploitation of the bioreductive potential of a reduced selenylsulfide moiety of mammalian TrxR in nitroreductase reactions.

#### 4. Role of Enzymatic Reduction in Nitroaromatic Compounds in Their Cytotoxicity/Therapeutic Action

##### 4.1. Role of Bioreductive Processes in Mammalian Cell Cytotoxicity of Nitroaromatics

Redox cycling is an intrinsic property of  $\text{ArNO}_2$ ; therefore, the oxidative stress will obligatorily take place during their action under aerobic conditions. In our opinion, the deviation from the limits predicted by the redox cycling activity could be instrumental in the characterization of additional mechanisms of cytotoxicity or therapeutic action of nitroaromatics. It is commonly accepted that if the main cytotoxicity factor is the rate of enzymatic formation of  $\text{ArNO}_2^{\cdot-}$  and their redox cycling, their cytotoxicity may be described by a following quantitative structure-activity relationship (QSAR):

$$\log cL_{50} = a + b E^1_7 + c \log P (\log D), \quad (8)$$

where  $cL_{50}$  is compound concentration causing 50% cell death or analogous quantitative parameter,  $\log P$  is octanol/water partition coefficient, and  $\log D$  is octanol/water distribution coefficient at pH 7.0 [13,155,238–241] (Table 4). These dependences mirror the  $\log$  (rate constant) vs.  $E^1_7$  relationships in single-electron reduction in  $\text{ArNO}_2$  by P-450R, NOS, or other single-electron transferring flavoenzymes (see Section 3.1). An additional diagnostic test is antioxidant protection against cytotoxicity. However, this approach may not be applied in the assessment of the mechanisms of action of  $\text{ArNO}_2$  that possess alkylating, bioreductively alkylating, or leaving groups (see below), or may directly interact with DNA, e.g., the positively charged nitracrine (49) derivatives [242]. Nevertheless, this approach, in particular, the use of  $E^1_{7(\text{calc})}$  obtained from enzymatic single-electron reduction reactions (Table A1, Appendix A), enabled to demonstrate that the main cytotoxicity mechanism of explosives pentryl (1), tetryl (2), TNT (4), tetranitrobenzimidazolone (42), dinitrobenzofuroxane (48), ANTA (54), NTO (55), and nitroaromatic antiandrogens nilutamide (15) and flutamide (16) could be oxidative stress [13,71,155,241,243–246]. On the other hand, although nifurtimox (27) induces oxidative stress in neuroblastoma cells and is synergistic with the GSH synthesis inhibitor buthionine sulfoximine, it is unclear whether this is the main mechanism of its anticancer action [247,248].

**Table 4.** Structure-activity relationships in mammalian cell cytotoxicity of nitroaromatics with possible relevance to bioreductive activation.

Compounds and Cells	Structure-Activity Relationships
<b>Aerobic Conditions</b>	
Nitroimidazoles, nitrofurans, nitrobenzenes, Chinese hamster V79–379A cells [238,239]; nitrobenzenes, nitrofurans, nitrobenzimidazoles, bovine leukemia virus-transformed lamb kidney fibroblast FLK cells [144,240,243]; nitrobenzenes, nitrofurans, nitrothiophenes, murine hepatoma MH22a cells, human colon carcinoma HCT116 cells [13,71]	$\Delta \log cL_{50} / \Delta E^{17} = -8 \div -11 V^{-1}$ , $\Delta \log cL_{50} / \Delta \log P(D) = 0 \div -0.3$ ; CB-1954 ( <b>14</b> ), SN-23682 ( <b>19</b> ) and their derivatives follow the same correlation [240]
Nitrobenzenes, FLK cells [245], primary mice splenocytes [241]	$\Delta \log cL_{50} / \Delta E^{17} = -7.5 \div 8.5 V^{-1}$ , increased cytotoxicity of amino and hydroxylamino metabolites of TNT ( <b>4</b> )
Derivatives of nitracrine ( <b>49</b> ), CHO-AA8 cells [242]	The absence of a relationship between $E^{17}$ and cytotoxicity
4-(Alkylamino)-5-nitroquinolines, Chinese hamster ovary CHO-AA8 cells [249]	Cytotoxicity roughly increases with the rate of drug-stimulated $O_2$ consumption
<i>N,N</i> -bis(2-chloroethyl)- <i>N</i> -methyl- <i>N</i> -(2-nitrobenzyl) ammonium chloride and its derivatives, CHO-AA8 cells [250]	Alkylating bioreductively activated leaving group does not affect the cytotoxicity, the relationship between $E^{17}$ and cytotoxicity is absent
Derivatives of NitroCBI ( <b>54</b> ), Skov3 and HT29 cells [23]	The relationship between $E^{17}$ and cytotoxicity is absent
Nitrofurans, nitrothiophenes, nitropyrroles and nitropyrazoles with alkyl- <i>N</i> -aziridine or alkyloxirane side chains, V79–379A cells [251–253]	Alkylating side chains increase the cytotoxicity, the relationship between $E^{17}$ and cytotoxicity is absent
<b>Hypoxic Conditions</b>	
Nitroimidazoles, nitrofurans, V79–379A cells [254]	$\Delta \log cL_{50} / \Delta E^{17} = -10 V^{-1}$
4-(Alkylamino)-5-nitroquinolines, CHO-AA8 cells [249]	Cytotoxicity and hypoxic selectivity roughly increase with the rate of drug-stimulated $O_2$ consumption
Nitrofurans and nitrothiophenes with alkyl- <i>N</i> -aziridine or alkyloxirane side chains, V79–379A cells [251–253]	Alkylating side chains do not increase hypoxic selectivity
<i>N,N</i> -bis(2-chloroethyl)- <i>N</i> -methyl- <i>N</i> -(2-nitrobenzyl) ammonium chloride and its derivatives, CHO-AA8 cells [250]	Alkylating leaving groups increase cytotoxicity, no relationship between $E^{17}$ and cytotoxicity or hypoxic selectivity
Nitrochloromethylbenzindolines (nitroCBIs, <b>56</b> ), Skov3 and HT29 cells [23]	Hypoxic toxicity does not correlate with $E^{17}$ , hypoxic selectivity roughly increases with $E^{17}$

In this context, one may note that because of the similarity of  $\log$  (rate constant) vs.  $E^{17}$  relationships in the reduction in  $ArNO_2$  by flavoenzymes dehydrogenases-electron-transferases, it is difficult to assess their individual contribution. Some information may be obtained from the hypoxic cytotoxicity studies (see below), assuming that the extent of formation of reduced  $ArNO_2$  metabolites is proportional to the rate of their single-electron enzymatic reduction. In this case, the main enzyme responsible for redox cycling of  $ArNO_2$  should be NADPH:cytochrome P-450 reductase (P-450R) [255,256]. The roles of other P-450R-type enzymes such as inducible NO synthase, human novel oxidoreductase NR1 [257], and methionine synthase reductase [258] depend on the cell type. Although the nitroreductase reactions of the latter two enzymes are uncharacterized, one may expect the similarity of their  $\log$  (rate constant) vs.  $E^{17}$  relationships with those of P-450R and NOS. On the other hand, the contribution of mitochondrial NADH:ubiquinone dehydrogenase and, possibly, other flavoenzymes of mitochondrial respiratory chain to the cytotoxicity of  $ArNO_2$  was recently demonstrated [259]. The comparison of reactivities of P-450R and NOS with those of disulfide reductases (Tables 1 and 2 and Section 3.3) clearly rules out the latter enzymes as the important sources of free radicals of  $ArNO_2$ . The inhibitors of cytochromes P-450 protect against the cytotoxicity of nitrobenzenes, nitrofurans, and

nitrothiophenes [71,205] in several cell lines; however, the roles of cytochromes P-450 in ArNO<sub>2</sub> cytotoxicity remain unclear so far.

The presence of directly alkylating alkyl-*N*-aziridine or alkylloxirane groups in ArNO<sub>2</sub> molecules evidently increases their cytotoxicity and abrogates the log (cytotoxicity) vs.  $E^{17}$  relationships (Table 4). It is important to distinguish the contribution of redox cycling and alkylation in their action, in particular, the role of putative alkylation targets. It is suggested that 2-phenylsulfonylnitropyridines, which possess micromolar cL<sub>50</sub> levels against the NCI cancer cell lines, exert their action through thioredoxin reductase inactivation [219]. However, because of the high  $E^{17}$  value of nitropyridine moiety (Table A1), the redox cycling reactions with flavoenzymes electrontransferases may significantly contribute to their cytotoxicity. The influence of bioreductively activated alkylating groups such as aziridine of nitrogen mustard or bioreductively activated leaving tetraalkylammonium group in the aerobic cytotoxicity of ArNO<sub>2</sub> remains equivocal (Table 4). In these cases, an increase in cytotoxicity of ArNO<sub>2</sub> may be attributed to the formation of a fraction of stable reduction products in cell compartments with reduced O<sub>2</sub> tension such as nucleus and mitochondria. In cell lines with 100–200 U/mg NQO1 (determined according to quinone reduction rate), dicoumarol partly protects against the cytotoxicity of ArNO<sub>2</sub>. However, the cytotoxicity of CB-1954, SN-23682, and their derivatives is close to the limits predicted by their  $E^{17}$  [240], and dicoumarol similarly protects against the cytotoxicity of ArNO<sub>2</sub> that do not contain aziridine or nitrogen mustard groups [71,243].

ArNO<sub>2</sub> are considered to be the hypoxia-selective toxins or therapeutic agents because their hydroxylamine reduction products formed under hypoxia may alkylate DNA and other nucleophiles. Frequently, their -NHOH or -NH<sub>2</sub> metabolites demonstrate even higher cytotoxicity than the parent ArNO<sub>2</sub> ([23,260,261], and references therein). Additionally, the electron-donating character of these groups increases the reactivity of alkylating aziridine or nitrogen mustard groups and accelerates the dissociation of leaving groups. In certain cases, the hypoxic selectivity, i.e., the ratio of cL<sub>50</sub> under oxic and hypoxic conditions, may exceed 1000. It was established that NADPH:cytochrome P-450 reductase (P-450R) plays a major role in the formation of reduced metabolites of ArNO<sub>2</sub> under hypoxia [255,256]. One may expect the correlation of hypoxic toxicity with  $E^{17}$  analogously with the rate of ArNO<sub>2</sub> reduction. However, this type of correlation is frequently absent (Table 4). Evidently, this reflects the superposition of two opposite factors, the ease of reduction increasing with  $E^{17}$  of the parent compound and the alkylating reactivity, decreasing with electron-accepting potency of substituents. The studies of CB-1954, SN-23682, and their reduction product have shown that the cytotoxicity is determined mainly by the alkylating reactivity of reduction products, their stability, and interconversion rate [260].

Nitroreductase-transfected cancer cells are the objects of gene-directed enzyme-prodrug therapy (GDEPT). Most typically, NRs, initially *E. coli* NfsB, activated the alkylating compounds such as CB-1954 and SN-23682 or released a drug molecule bound to ArNO<sub>2</sub> after its reduction (Scheme 1) [7]. Further, we will address the reductive activation of alkylating ArNO<sub>2</sub>, because in the other case, the cytotoxic outcome mostly depends on the properties of the released drug. Early studies have shown that in the presence of exogenous NfsB and NADH in the cell growth medium, the cytotoxicity of CB-1954, SN-23682, and their derivatives roughly correlated with the rate of their enzymatic reduction [162]. The sensitivity to CB-1954 was shown to correlate closely with the level of nitroreductase expression in the cell ([7], and references therein). CB-1954 demonstrated a substantial bystander effect, i.e., killing of non-transfected cells, shown to be mediated via the cell-permeable hydroxylamine metabolite. Among ArNO<sub>2</sub> that do not possess bioreductively activated alkylating groups, nitrofurazone, but not misonidazole (35) or nitracrine (50) showed significant activity in NfsB-transfected cell lines. This may be attributed to its better activity as an enzyme substrate.

However, the further use of NfsB in GDEPT was complicated by the relatively low tolerance of patients to large concentrations of CB-1954, required for its efficient NfsB-catalyzed conversion in the cell ([8,15], and references therein). This has spurred a search

for alternative nitroreductase enzymes that are more effective at converting CB-1954 at its low concentrations and for alternative nitroaromatic compounds. The large-scale screening of various NRs pointed to the versatility of NfsA-group nitroreductases, which in general possess higher  $k_{cat}/K_m$  values of CB-1954 than NfsBs. It is suggested that not a higher  $k_{cat}$  but a much higher affinity (i.e., much lower  $K_m$ ) for a given substrate is a defining characteristic of the efficiency of the process [262]. However, the nitroreductase gene expression was unpredictable in transfected HCT-116 cells, and there was little correlation between the CB-1954 sensitivity of those cell lines and the  $k_{cat}/K_m$  of the purified nitroreductases. Possibly, the long-term stable expression of some nitroreductases is not tolerated in human cell lines. Another potential drawback of the NfsA enzymes is their preference for NADPH, as NADPH is usually present at lower concentrations than NADH in mammalian cells. Currently, efforts are undertaken for the construction of selective mutants of NRs and the improvement of their expression [263,264]. Further studies are performed with new compounds such as PR-104A (13), TH-302 (36), and nitroCBI (56).

Nitroaromatic compounds induce both necrotic and apoptotic mammalian cell death. Thus, finally, one has to address the expression of cell signaling proteins during the apoptotic action of  $ArNO_2$ . The current studies are confined to the changes of expression and phosphorylation of the 'classical' signaling proteins such as tumor suppressor p53, cell cycle inhibitor p21, proapoptotic protein Bax, antiapoptotic protein Bcl-2, protooncogene protein N-Myc, various caspases (cysteine-dependent aspartate-directed proteases, which are the executioners of the apoptotic cell death), mitogen-activated kinases JNK, p38 and ERK, and other kinases (Table 5). In certain cases, the upregulation of p21, p53, Bax/Bcl-2 ratio, and caspase expression was attenuated by antioxidants [265–267]. This shows that  $ArNO_2^-$  initiated oxidative stress contributes to these events.

#### 4.2. Role of Bioreductive Processes in Antibacterial and Antiparasitic Action of Nitroaromatics

The current progress in the design and development of nitroaromatic antibacterial and antiparasitic agents was recently presented in several comprehensive reviews [6,268]. In this subsection, we will address the cases with evidence and, preferentially, quantitative demonstration of the contribution of reductive processes to the action of  $ArNO_2$ .

**Table 5.** Expression of cell signaling proteins during the apoptotic action of nitroaromatic compounds.

Cell. Signaling Protein	Effect	Compound, Cells
p53	Upregulation	Furazolidone, human hepatocytes LO2 [265]; phenylnitrobenzene B16, human cervical carcinoma HeLa [269]
	Upregulation, downregulation of mutant p53	Nitrofurantoin NSC59984, colorectal cancer [270]
	Activation of phosphorylation	1-Nitropyrene, human hepatoma HepG2 [271]
p21	Upregulation	Indolin-2-one-substituted nitrobenzene HO1-02, esophageal cancer [271]; 1,3-dinitrobenzene, rat Sertoli cells [272]
	Downregulation	Furazolidone, HepG2 [267]
Transcription factor STAT-3	Inhibition of phosphorylation	Nifuroxazide, human myeloma [273]
Bax/Bcl-2 ratio	Upregulation	Phenylnitrobenzene B16, HeLa [269]; 1,3-dinitrobenzene, rat Sertoli cells [272]; furazolidone, HepG2 [267]; N-pentyl-furantoin, human promyelocytic leukemia HL-60 [274]; 2-(2-(5-nitrofurantoin-2-yl)-vinyl)-quinoline derivative, non-small cell lung cancer H1299 [275]; nifuroxazide, human breast cancer MCF-6 [276]

Table 5. Cont.

Cell. Signaling Protein	Effect	Compound, Cells
N-Myc	Downregulation	Nifurtimox, neuroblastoma cells [247]
Caspases	Upregulation	Tetryl, HeLa [216]; HO1-02, esophageal cancer [266]; furazolidone, HepG2 [267]; nifuroxazide, MCF-6 [276]; CB-1954, NR-transfected ovarian carcinoma SKOV3 [277]; TNT, HepG2 [278]
JNK	Activation of phosphorylation	1,3-dinitrobenzene, rat Sertoli cells [272]
p38		2-(2-(5-Nitrofuran-2-yl)-vinyl)-quinoline derivative H1299 [275]
ERK	Inhibition of phosphorylation	Nifurtimox, neuroblastoma cells [248]; 5-nitroimidazole DYT-40, human glioma U251 and U87
	Activation of phosphorylation	1,3-dinitrobenzene, rat Sertoli cells [272]
AKT kinase	Inhibition of phosphorylation	2-(2-(5-Nitrofuran-2-yl)-vinyl)-quinoline derivative, H1299 [275]; 5-nitroimidazole DYT-40, U251 and U87 [279]; nifurtimox, human neuroblastoma [280]

Nitroreductase-deficient mutants of *E. coli* were resistant to all types of nitroaromatic compounds [281,282]. This points to the principal role of NRs in their bioactivation. Reflecting the correlation between the reactivity of NfsA and NfsB and  $E^1_7$  of nitroaromatics, the rates of  $\text{ArNO}_2$  aerobic reduction by *E. coli* increased with their electron-accepting potency [283]. However, the activity of  $\text{ArNO}_2$  against *E. coli* and other aerobic bacteria poorly correlated with their electron affinity [284]. This may point to the role(s) of their other insufficiently studied targets such as AhpF [237] or to a parallel activity dependence on the alkylating potency of reduction products, which decreases with the electron-donating potency of substituents [285]. In particular, the activity of a large series of nitroaromatics against anaerobic *Bacteroides fragilis* decreased with their  $E^1_7$  [284]. On the other hand, there was a reasonable correlation between the  $k_{\text{cat}}/K_m$  of 20 purified NRs with CB-1954 as substrate and their ability to induce CB-1954-mediated DNA damage in *E. coli* host cells [15].

Metronidazole and other 5-nitroimidazoles exert a high antitrichomonal activity under both aerobic and anaerobic conditions; in most experiments, however, inhibitory concentrations are higher in aerobiosis than in anaerobiosis [286]. Trichomonad flagellates and anaerobic bacteria become resistant to metronidazole after a loss of PFOR and NADH:ferredoxin reductase (FOR) functions [120,286]. The unexpectedly high rate of reaction of nitroimidazoles by ferredoxin that initiates redox cycling [110] possibly explains the high sensitivity of *T. vaginalis* to metronidazole. Because the rate of reduction  $\text{ArNO}_2$  by ferredoxin is apparently insensitive to their  $E^1_7$  [121], it points to the perspectives of application of low-potential compounds that are nontoxic to mammalian cells. However, the further steps are complicated by the uncharacterized nitroreductase reactions of FOR and a parallel involvement of 26 kD FMN and FeS-containing protein with uncharacterized functions [122], which, under anaerobiosis, reduces metronidazole to amino metabolite and contributes to its detoxification. Because of low nitroreductase activity, the role of TrxR in the activation of  $\text{ArNO}_2$  in *T. vaginalis* remains a matter of debate [234,235].

The current studies of *Helicobacter pylori* most frequently address the mechanisms of its resistance to metronidazole [287]. The sensitivity to metronidazole correlated with NADH- and NADPH-dependent nitroreductase activity in the cytosolic fraction of clinical isolates [288]. In turn, resistance to metronidazole results from loss-of-function mutations in genes encoding nitroreductases RdxA and FrxA ([268], and references therein). However, the individual roles of the above NRs in the action of other nitroaromatic compounds remain poorly understood so far. Moreover, another potential candidate for the efficient



reduction in ArNO<sub>2</sub> is the complex of PFOR, FqrB, and flavodoxin [124]. Nitroaromatic compounds that bind to flavodoxin at micromolar concentrations exhibit activity against *H. pylori* at similar concentrations. Importantly, these compounds were active against metronidazole-resistant isolates, which may point to a different mechanism of their action [289]. Further studies in this direction warrant detailed examination of nitroreductase activity of FqrB and, especially, flavodoxin.

Giardiasis is treated primarily with metronidazole, but other ArNO<sub>2</sub>, including benznidazole, nitazoxanide, and nitrofurans, are also effective [125]. *Giardia* spp. possess numerous potential sources of their activation, such as PFOR, ferredoxin, thioredoxin reductase, and several nitroreductases ([125,290,291], and references therein). However, their individual contributions to the action of particular drugs remain a matter of debate.

The recent review [6] did not reveal the relationships between the antitubercular activity of nitroaromatics and their redox properties. The activity of a series of derivatives of PA-824 (57) against *M. tuberculosis* did not depend on their  $E^1_7$  value in the range of  $-0.570$ – $-0.338$  V [24] or their reduction potentials in acetonitrile [292]. On the other hand, 6,8-dinitro-1,3-benzothiazin-4-ones were more active than their 6-trifluoromethyl-8-nitro analogs [293]. Although the downregulation of F-420-dependent nitroreductase confers the resistance of *M. tuberculosis* to PA-824 and other nitroaromatics [294], the studies of several series of PA-824 derivatives did not demonstrate the relationship between their enzymatic reactivity and antibacterial activity [182,295]. In our opinion, the further development of antitubercular nitroaromatics could be extended by studies of their interaction with *M. tuberculosis* flavoenzymes, e.g., FprA [102] or LipDH [208].

Nifurtimox (27) and benznidazole (34) were the only nitroaromatic compounds to be recently considered for antitrypanosomal drug development ([296], and references therein). Because of its genotoxicity, megalzol (38) was not further developed. The mechanisms of antitrypanosomal action of nifurtimox and other nitrofurans are a matter of debate. The early studies suggested that the main mechanism of action is their single-electron reduction and redox cycling of free radicals, the potential candidates being trypanothione reductase, lipoamide dehydrogenase, and, possibly, P-450R-type enzymes [199,203,297]. However, redox cycling was only observed at high nifurtimox concentrations, which were by two orders of magnitude higher than its micromolar concentrations required for antiproliferative activity [297]. On the other hand, the two-electron transferring trypanosomal NTRs may play a leading role in the bioactivation of nifurtimox and, possibly, other nitrofurans and nitroimidazoles [174–176]. Their upregulation or downregulation increased the sensitivity or resistance of parasites, respectively, toward nifurtimox, benznidazole, and fexinidazole. However, because of limited kinetic data on NTR reactions, including the new groups of ArNO<sub>2</sub> such as 3-nitrotriazoles and nitroquinolin-2(1*H*)-ones [298–302], it is difficult to demonstrate the relationship between their trypanocidal activity and reactivity toward NTR. Moreover, in certain cases, the upregulation or downregulation of NTR causes limited effects on parasite sensitivity. In this context, parallel studies of other flavoenzyme targets of nitroaromatics may be suggested. For example, the nitroreductase activity of trypanothione reductase (TR) is similar to that of NTRs [199,200], although the reaction proceeds in a single-electron way. Moreover, nitrofurans act as TR inhibitors [199,200]. There did not exist a relationship between the trypanocidal activity and TR inhibition potency of a series of nitrofurans, which were weak enzyme inhibitors ( $K_i = 61$ – $1180$   $\mu$ M) [303]. However, the trypanocidal activity of chinifur (24) and its derivatives which were more efficient TR inhibitors ( $K_i = 2.3$ – $110$   $\mu$ M), increased with their TR inhibition potency [304].

NR1 of *Leishmania* spp. participates in the activation of the new antiparasitic agent fexinidazole (38) and nifurtimox (27), because its upregulation increases the parasite sensitivity to these drugs. On the other hand, the knockout of NR2 caused the parasite complete resistance *R*-PA-824 (57) and only marginal resistance to nifurtimox [179,296]. This is in line with their relative efficiency as NR2 substrates.

The action of ArNO<sub>2</sub> against the malaria parasite *P. falciparum* received relatively little attention, although a number of nitrofurans, nitrobenzenes, nitroimidazoles, and 4-



nitrobenzothiadiazole were shown to possess in vitro antiplasmodial activity at micromolar or lower concentrations [17,195,305,306]. The antiplasmodial activity of a series of nitrobenzenes and nitrofurans increases with their  $E^1_7$ ,  $\log D$ , and their efficiency of inhibition of *P. falciparum* glutathione reductase (PfGR) [195]. The relationship between the activity of ArNO<sub>2</sub> and the inhibition of erythrocyte GR is uncertain. Given the data available, *P. falciparum* ferredoxin:NADP<sup>+</sup> oxidoreductase (PfFNR), and, possibly, ferredoxin may act as the most efficient reductants of ArNO<sub>2</sub> in plasmodia. *P. falciparum* thioredoxin reductase may be next to it according to quinone reductase activity [221]. Because *P. falciparum*, during its intraerythrocyte stage, adopts microaerophilic metabolism and relies mainly on anaerobic processes [307], an increase in the activity of ArNO<sub>2</sub> with  $E^1_7$  may equally well reflect the rates of formation of free radicals or DNA-damaging hydroxylamines under the action of PfFNR. On the other hand, the series of tetrazole-containing nitroimidazooxazines and quinoline-based nitroimidazoles exhibited antiplasmodial activity at micromolar concentrations [306], which is beyond the limits expected from their redox potentials (Table A1). This may be attributed to additional modes of their action arising from the hybrid structure of these compounds.

## 5. Conclusions

This review is not meant to be exhaustive in addressing the numerous and complex ways of interaction of nitroaromatic compounds with flavoenzymes and their cytotoxic/therapeutic consequences. However, one may conclude that with some minor exceptions, the single-electron reduction potential of nitroaromatics is the principal factor determining the rate of their single-electron reduction by flavoenzymes dehydrogenases-electrontransferases and their FeS redox partners. This leaves relatively little space for the improvement of the enzymatic reactivity of compounds. On the other hand, although the studies of several two-electron transferring bacterial nitroreductases point to an important role of redox potential in the reactivity of nitroaromatics, the factors determining substrate specificity of nitroreductases from *H. pylori*, *H. influenza*, *Leishmania*, and *Trypanosoma* spp. remain unclear. This leaves more space for the improvement of the activity of compounds.

Low nitroreductase activity of flavoenzymes disulfide reductases diminishes their role in redox cycling or other modes of activation of nitroaromatics in the cell. However, low- $M_r$  TrxRs where FAD and catalytic disulfide function separately may more significantly contribute to the redox cycling of nitroaromatics. Another relevant problem is the exploitation of the bioreductive potential of a reduced selenylsulfide moiety of mammalian TrxR. In our opinion, this review may highlight the potential relevance of a number of flavoenzymes and/or their metalloprotein redox partners whose nitroreductase reactions were studied less comprehensively. Because of the definite perspectives of nitroaromatic compounds in the treatment of oxic tumors, the potential but insufficiently characterized targets of their action are the mitochondrial respiratory chain, in particular, its complex I and cytochromes P-450. Concerning the flavoenzymes of bacteria and parasites, more thorough studies of nitroreductase reactions of FprA and LipDH of *M. tuberculosis*, flavodoxin of *H. pylori*, TrxR, and Fd of *P. falciparum*, and PFOR/Fd/FOR systems of *Trichomonas* and *Giardia* spp. may foster the development of new groups of nitroaromatic agents or the repurposing of existing ones.

**Author Contributions:** L.K., N.Č. and A.N.-Č. wrote the drafts for Sections 2–4, respectively, and N.Č. wrote the final version of this manuscript. All authors have read and agreed to the published version of the manuscript.

**Funding:** This research was funded by the European Social Fund (Measure No. 09.33-LMT-K-712, grant No. DOTSUT-34/09.3.3.-LMT-K712-01-0058/LSS-600000-58).

**Acknowledgments:** We thank Benjaminas Valiauga for technical assistance and Mindaugas Lesanavičius for checking the stylistics of the manuscript.

**Conflicts of Interest:** The authors declare no conflict of interest.

## Appendix A

**Table A1.** Single-electron reduction midpoint potentials of nitroaromatic compounds determined by pulse radiolysis ( $E^1_7$ ) or calculated according to the data of enzymatic single-electron reduction ( $E^1_{7(\text{calc.})}$ ).

No.	Compound	$E^1_7$ (V) <sup>a</sup>	$E^1_{7(\text{calc.})}$ (V) <sup>b</sup>
<b>Nitrobenzenes</b>			
1	2,4,6-Trinitrophenyl- <i>N</i> -nitramino-ethylnitrate (pentryl)	-	-0.175
2	2,4,6-Trinitrophenyl- <i>N</i> -methylnitramine (tetryl)	-	-0.191
3	<i>N</i> -Methylpicramide	-	-0.247
4	2,4,6-Trinitrotoluene (TNT)	-0.253 <sup>c</sup>	-0.279
5	1,4-Dinitrobenzene	-0.257	-0.240
6	1,2-Dinitrobenzene	-0.287	-0.311
7	3,5-Dinitrobenzamide	-	-0.311
8	4-Nitrobenzaldehyde	-0.325	-0.342
9	3,5-Dinitrobenzoic acid	-0.344	-0.336
10	1,3-Dinitrobenzene	-0.348	-0.332
11	2-Hydroxylamino-4,6-dinitrotoluene	-	-0.351
12	4-Nitroacetophenone	-0.355	-0.356
13	2-((2-Bromoethyl)(2,4-dinitro-6-((2-(phosphonooxy)ethyl)carbamoyl)phenyl)amino)ethyl methanesulfonate (PR-104A)	-0.366 <sup>d</sup>	
14	5-(Aziridin-1-yl)-2,4-dinitrobenzamide (CB-1954)	-0.385	-0.352
15	5,5-Dimethyl-3-(4-nitro-3-(trifluoromethyl)phenyl)imidazoline-2,4-dione (nilutamide)	-	-0.399
16	2-Methyl- <i>N</i> -(4-nitro-3-(trifluoromethyl)phenyl)propanamide (flutamide)	-	-0.408
17	2-Amino-4,6-dinitrotoluene	-0.417 <sup>c</sup>	-0.423
18	4-Nitrobenzoic acid	-0.425	-0.423
19	5-(Bis(2,2'-chloroethyl)amino)-2,4-dinitrobenzamide (SN-23682)	-0.425	-0.398
20	4-Hydroxylamino-2,6-dinitrotoluene	-	-0.429
21	4-Amino-2,6-dinitrotoluene	-0.449 <sup>c</sup>	-0.453
22	Nitrobenzene	-0.485	-0.489
23	<i>D</i> -(-)-threo-2-dichloroacetamido-1-(4-nitrophenyl)-1,3-propandiol (chloramphenicol)	-0.546 <sup>e</sup>	
<b>Nitrofurans and nitrothiophenes</b>			
24	2-(5'-Nitrofurylvinyl)-quinoline-4-carboxydiethylamino-1-methyl-but-1-ylamide (chinifur, quinifuryl)	-0.225 <sup>f</sup>	-0.221
25	5-Nitro-2-furaldoxime (nifuroxime)	-0.255	-0.279
26	<i>N</i> -(5-nitro-2-furfurylindene)-1-aminohydantoin (nitrofurantoin)	-0.265	-0.263
27	4-(5-Nitrofurfurylidenamino)-3-methyltiomorpholine-1,1-dioxide (nifurtimox)	-0.260 <sup>g</sup>	-0.285
28	2-Nitrothiophene-5-aldehyde	-0.260 <sup>h</sup>	
29	2-Nitrothiophene-5-aldoxime	-0.280 <sup>h</sup>	
30	2-Nitrothiophene-5-carboxymorpholide	-0.305 <sup>h</sup>	

Table A1. Cont.

No.	Compound	$E^1_7$ (V) <sup>a</sup>	$E^1_{7(\text{calc.})}$ (V) <sup>b</sup>
31	2-Nitrofurán	−0.330	
32	2-Nitrothiophene	−0.390	
<b>Nitroimidazoles</b>			
33	1-Methyl-2-nitroimidazole-5-carboxamide	−0.321	
34	<i>N</i> -Benzyl-2-(2-nitro-1 <i>H</i> -imidazol-1-yl)acetamide (benznidazole)	−0.380	
35	1-Methoxy-3-(2-nitroimidazol-1-yl)propan-2-ol (misonidazole)	−0.389	
36	1-(Methyl-2-nitro-1 <i>H</i> -imidazole-5-yl)-methyl- <i>N,N'</i> -bis(2-bromoethyl)phosphorodiamidate (TH-302, evofosfamide)	−0.407 <sup>i</sup>	
37	2-Nitroimidazole	−0.418	
38	1-Methyl-2-(5-amino-1,3,4-thiadazole)-5-nitroimidazole (megazol)	−0.438 <sup>g</sup>	
39	1-Methyl-2-((4-(methylthio)phenoxy)methyl)-5-nitro-1 <i>H</i> -imidazole (fexinidazole)		−0.458
40	2-Methyl-5-nitroimidazole-1-ethanol (metronidazole)	−0.486	
41	4-Nitroimidazole	≤ −0.527	
<b>Nitrobenzimidazoles</b>			
42	4,5,6,7-Tetranitrobenzimidazolone	-	−0.197
43	4,5,6-Trinitrobenzimidazolone	-	−0.224
44	5,6-Dinitrobenzimidazolone	-	−0.273
45	2-Nitrobenzimidazole	−0.300	-
46	5-Nitrobenzimidazolone	-	−0.355
<b>Miscellaneous</b>			
47	4-Nitropyridine	−0.190	
48	4,6-Dinitrobenzofuroxane	-	−0.258
49	5-Nitro-4-(3'-dimethylaminopropylamino)-quinoline (nitraquine)	−0.286 <sup>j</sup>	
50	1-Nitro-9-(3'-dimethylaminopropylamino)-acridine (nitracrine)	−0.303 <sup>j</sup>	−0.285
51	1- <i>N</i> -alkyl-3-nitro-1,2,4-triazines	−0.310–−0.330 <sup>k</sup>	
52	2-((5-Nitrothiazol-2-yl)carbamoyl)phenyl acetate (nitazoxanide)		−0.380
53	5-Nitrothiazole	−0.400	
54	5-Amino-3-nitro-1,2,4-triazole (ANTA)	-	−0.466
55	3-Nitro-1,2,4-triazolone (NTO)	-	−0.472
56	1-(Chloromethyl)-3-(5-(2-(dimethylamino)-ethoxy)indol-2-carbonyl)-5-nitro-1,2-dihydro-3 <i>H</i> -benzo[ <i>e</i> ]-indole (representative of nitroCBIs)	−0.512 <sup>l</sup>	
57	2-Nitro-6((4-(trifluoromethoxy)benzyl)oxy)-6,7-dihydro-5 <i>H</i> -imidazo [2,1- <i>b</i> ][1,3]oxazine (PA-824)	−0.534 <sup>m</sup>	

<sup>a</sup> Taken from Ref. [10] unless specified otherwise, <sup>b</sup> taken from Refs. [11–13], <sup>c</sup> taken from Ref. [14], <sup>d</sup> taken from Ref. [15], <sup>e</sup> taken from Ref. [16], <sup>f</sup> taken from Ref. [17], <sup>g</sup> taken from Ref. [18], <sup>h</sup> taken from Ref. [19], <sup>i</sup> taken from Ref. [20], <sup>j</sup> taken from Ref. [21], <sup>k</sup> taken from Ref. [22], <sup>l</sup> taken from Ref. [23], <sup>m</sup> taken from Ref. [24].

## Appendix B

The single-electron reduction in nitroaromatics is frequently treated according to an “outer-sphere” electron transfer model, which describes an electron transfer with weak electronic coupling between the reactants ([28], and references therein). In the simplest form, the rate constants of single-electron transfer between reagents ( $k_{12}$ ) depend on the electron self-exchange rate constants of reagents ( $k_{11}$  and  $k_{22}$ ) and equilibrium constant of reaction ( $K$ ) ( $\log K = \Delta E^1$  (V)/0.059, where  $\Delta E^1$  is the difference in the standard single-electron transfer potentials of reactants):

$$k_{12} = (k_{11} \times k_{22} \times K \times f)^{1/2} \quad (\text{A1})$$

and

$$\log f = (\log K)^2 / 4 \log (k_{11} \times k_{22} / Z^2), \quad (\text{A2})$$

where  $Z$  is a frequency factor ( $10^{11} \text{ M}^{-1} \text{ s}^{-1}$ ). According to Equations (A1) and (A2), in the reaction of electron donor with a series of homologous electron acceptors ( $k_{22} = \text{constant}$ ),  $k_{12}$  will exhibit parabolic (square) dependence on  $\Delta E^1$  with a slope  $\Delta \log k / \Delta \Delta E^1 = 8.45 \text{ V}^{-1}$  at  $\Delta E^1 = \pm 0.15 \text{ V}$ . At  $\Delta E^1 = 0$ ,  $k_{12} = (k_{11} \times k_{22})^{1/2}$ . For  $\text{ArNO}_2$ , the self-exchange constants are around  $10^6 \text{ M}^{-1} \text{ s}^{-1}$  [25,26]. For quinones and free flavins, they are around  $10^8 \text{ M}^{-1} \text{ s}^{-1}$  ([29], and references therein). In the reactions of redox proteins, the protein  $k_{11}$  values may be used to evaluate the orientational distances of electron transfer ( $R_p$ ) [30]:

$$R_p (\text{\AA}) = 6.3 - 0.35 \ln k_{11}. \quad (\text{A3})$$

## References

- Spain, J.C. Biodegradation of nitroaromatic compounds. *Annu. Rev. Microbiol.* **1995**, *49*, 523–555. [CrossRef]
- Purohit, V.; Basu, A.K. Mutagenicity of nitroaromatic compounds. *Chem. Res. Toxicol.* **2000**, *13*, 674–692. [CrossRef] [PubMed]
- Roldan, M.D.; Perez-Reinado, E.; Castillo, F.; Moreno-Vivian, E. Reduction of polynitroaromatic compounds: The bacterial nitroreductases. *FEMS Microbiol. Rev.* **2008**, *32*, 474–500. [CrossRef]
- Kovacic, P.; Somanathan, R. Nitroaromatic compounds: Environmental toxicity, carcinogenicity, mutagenicity, therapy and mechanism. *J. Appl. Toxicol.* **2014**, *34*, 810–824. [CrossRef] [PubMed]
- Singh, D.; Mishra, K.; Ramanathan, G. Bioremediation of nitroaromatic compounds. In *Wastewater Treatment Engineering*; Samer, M., Ed.; IntechOpen: London, UK, 2015; pp. 51–83.
- Nepali, K.; Lee, H.-J.; Liou, J.-P. Nitro-group-containing drugs. *J. Med. Chem.* **2019**, *62*, 2851–2893. [CrossRef] [PubMed]
- Denny, W.A. Nitroreductase-based GDEPT. *Curr. Pharm. Des.* **2002**, *8*, 1349–1361. [CrossRef] [PubMed]
- Williams, E.M.; Little, R.F.; Mowday, A.M.; Rich, M.H.; Chan-Hyans, J.V.E.; Copp, J.N.; Smail, J.B.; Patterson, A.V.; Ackerley, D.F. Nitroreductase gene-directed enzyme prodrug therapy: Insights and advances toward clinical utility. *Biochem. J.* **2015**, *471*, 131–153. [CrossRef]
- Williams, R.E.; Rathbone, D.A.; Scrutton, N.S.; Bruce, N.C. Biotransformation of explosives by the old yellow enzyme family of flavoenzymes. *Appl. Environ. Microbiol.* **2004**, *70*, 3566–3574. [CrossRef]
- Wardman, P. Reduction potentials of one-electron couples involving free radicals in aqueous solutions. *J. Phys. Chem. Ref. Data* **1989**, *18*, 1637–1755. [CrossRef]
- Šarlauskas, J.; Nivinskas, H.; Anusevičius, Ž.; Misevičienė, L.; Marozienė, A.; Čėnas, N. Estimation of single-electron reduction potentials ( $E^1_7$ ) of nitroaromatic compounds according to the kinetics of their single-electron reduction by flavoenzymes. *Chemija* **2006**, *17*, 31–37.
- Šarlauskas, J.; Lesanavičius, M.; Aliverti, A.; Čėnas, N. Reduction of nitroaromatic explosives by *Plasmodium falciparum* ferredoxin: NADP<sup>+</sup> reductase: Estimation of their single-electron reduction potentials. In Proceedings of the Abstracts of the 21st Seminar on New Trends in Research of Energetic Materials, Pardubice, Czech Republic, 18–20 April 2018; Pachman, J., Šeššovský, J., Eds.; University of Pardubice: Pardubice, Czech Republic, 2018; p. 135.
- Nemeikaitė-Čėnienė, A.; Marozienė, A.; Misevičienė, L.; Tamulienė, J.; Yantsevich, A.V.; Čėnas, N.K. Flavoenzyme-catalyzed single-electron reduction of nitroaromatic antiandrogens: Implications for their cytotoxicity. *Free Radic. Res.* **2021**, *55*, 246–254. [CrossRef]
- Riefler, R.G.; Smets, B.F. Enzymatic reduction of 2,4,6-trinitrotoluene and related nitroarenes: Kinetics linked to one-electron redox potentials. *Environ. Sci. Technol.* **2000**, *34*, 3900–3906. [CrossRef]
- Prosser, G.A.; Copp, J.N.; Mowday, A.M.; Guise, C.P.; Syddall, S.P.; Williams, E.M.; Horvat, C.N.; Swe, P.M.; Ashoorzadeh, A.; Denny, W.A.; et al. Creation and screening of a multi-family bacterial oxidoreductase library to discover novel nitroreductases that efficiently activate the bioreductive prodrugs CB1954 and PR-104A. *Biochem. Pharmacol.* **2013**, *85*, 1091–1103. [CrossRef]

16. Kapoor, S.; Varshney, L. Redox reactions of chloramphenicol and some aryl peroxy radicals in aqueous solution: A pulse radiolytic study. *J. Phys. Chem. A* **1997**, *101*, 7778–7782. [[CrossRef](#)]
17. Grellier, P.; Šarlauskas, J.; Anusevičius, Ž.; Marozienė, A.; Houee-Levin, C.; Schrevel, J.; Čėnas, N. Antiplasmodial activity of nitroaromatic and quinoidal compounds: Redox potential vs. inhibition of erythrocyte glutathione reductase. *Arch. Biochem. Biophys.* **2001**, *393*, 199–206. [[CrossRef](#)]
18. Viode, C.; de Albuquerque, C.; Chauviere, G.; Houee-Levin, C.; Perie, J. Comparative study by pulse radiolysis of the radical anion derived from compounds used in Chaga's disease therapy. *New J. Chem.* **1997**, *21*, 1331–1338.
19. Breccia, A.; Busi, F.; Gattavechia, E.; Tamba, M. Reactivity of nitro-thiophene derivatives with electron and oxygen radicals studied by pulse radiolysis and polarographic techniques. *Radiat. Environ. Biophys.* **1990**, *29*, 153–160. [[CrossRef](#)] [[PubMed](#)]
20. Meng, F.; Evans, J.W.; Bhupatti, D.; Banica, M.; Lan, L.; Lorente, G.; Duan, J.-X.; Cai, X.; Mowday, A.M.; Guise, C.P.; et al. Molecular and cellular pharmacology of the hypoxia-activated prodrug TH-302. *Mol. Cancer Ther.* **2012**, *11*, 740–751. [[CrossRef](#)]
21. Wilson, W.R.; Siim, B.G.; Denny, W.A.; van Zijl, P.L.; Taylor, M.L.; Chambers, D.M.; Roberts, P.B. 5-Nitro-4- (*N,N*-dimethylaminopropylamino)quinoline (5-nitraq), a new DNA-affinic hypoxic cell radiosensitizer and bioreductive agent: Comparison with nitracrine. *Radiat. Res.* **1992**, *131*, 257–265. [[CrossRef](#)]
22. Fielden, E.M.; Adams, G.E.; Cole, S.; Naylor, M.A.; O'Neill, P.; Stephens, M.A.; Stratford, I.J. Assessment of a range of novel nitro-aromatic radiosensitizers and bioreductive drugs. *Int. J. Radiat. Oncol. Biol. Phys.* **1992**, *22*, 707–711. [[CrossRef](#)]
23. Tercel, M.; Atwell, G.J.; Yang, S.; Stevenson, R.J.; Botting, K.J.; Boyd, M.; Smith, E.; Anderson, R.F.; Denny, W.A.; Wilson, W.R.; et al. Hypoxia-activated prodrugs: Substituent effects on the properties of nitro sec-1,2,9,9a-tetrahydrocyclopropa[*c*]benz[*e*]indol-4-one (nitroCBI) prodrugs of DNA minor groove alkylating agents. *J. Med. Chem.* **2009**, *52*, 7258–7272. [[CrossRef](#)] [[PubMed](#)]
24. Thompson, A.M.; Blaser, A.; Anderson, R.F.; Shinde, S.; Franzblau, S.G.; Ma, Z.; Denny, W.A.; Palmer, B.D. Synthesis, reduction potentials, and antitubercular activity of ring A/B analogues of the bioreductive drug (6*S*)-2-nitro-6-[[4-trifluoromethoxy]benzyl]oxy]-6,7-dihydro-5*H*-imidazo[2,1-*b*][1,3]oxazine (PA-824). *J. Med. Chem.* **2009**, *52*, 637–645. [[CrossRef](#)] [[PubMed](#)]
25. Neta, P.; Simic, M.G.; Hoffman, M.Z. Pulse-radiolysis and electron spin resonance studies of nitroaromatic radical anions. Optical absorption spectra, kinetics, and one-electron reduction potentials. *J. Phys. Chem.* **1976**, *80*, 2018–2023. [[CrossRef](#)]
26. Meotner, M.; Neta, P. Kinetics of electron transfer from nitroaromatic radical anions in aqueous solutions. Effects of temperature and steric configuration. *J. Phys. Chem.* **1986**, *90*, 4648–4650. [[CrossRef](#)]
27. Guissany, A.; Henry, A.; Lougmani, N.; Hickel, B. Kinetic studies of four types of nitroheterocyclic radicals by pulse radiolysis: Correlation of pharmaceutical properties to decay rates. *Free Radic. Biol. Med.* **1990**, *8*, 173–189. [[CrossRef](#)]
28. Marcus, R.; Sutin, N. Electron transfers in chemistry and biology. *Biochim. Biophys. Acta* **1985**, *811*, 265–322. [[CrossRef](#)]
29. Grampp, G.; Jaenicke, W. ESR-spectroscopic investigation of the parallel electron and proton exchange between quinones and their radicals: Part I. Measurements at 298 K. *J. Electroanal. Chem.* **1987**, *229*, 297–303. [[CrossRef](#)]
30. Mauk, A.G.; Scott, R.A.; Gray, H.B. Distances of electron transfer to and from metalloprotein redox sites in reactions with inorganic complexes. *J. Am. Chem. Soc.* **1980**, *102*, 4360–4363. [[CrossRef](#)]
31. La-Scalea, M.A.; Menezes, C.M.S.; Juliao, M.S.S.; Chung, M.C.; Serrano, S.H.P.; Ferreira, E.I. Voltammetric behavior of nitrofuranone and its hydroxymethyl prodrug with potential anti-chagas activity. *J. Braz. Chem. Soc.* **2005**, *16*, 774–782. [[CrossRef](#)]
32. Gal, M.; Kolivoška, W.; Ambrova, M.; Hiveš, J.; Sokolova, R. Correlation of the first reduction potential of selected radiosensitizers determined by cyclic voltammetry with theoretical calculations. *Collect. Czechoslov. Chem. Commun.* **2011**, *76*, 937–946. [[CrossRef](#)]
33. Phillips, K.L.; Sandler, S.I.; Chiu, P.C. A method to calculate the one-electron reduction potentials for nitroaromatic compounds based on gas-phase quantum mechanics. *J. Comput. Chem.* **2011**, *32*, 226–239. [[CrossRef](#)]
34. Fareghi-Alamdari, R.; Zandi, F.; Keshavarz, M.H. A new model for prediction of one electron reduction potential of nitroaryl compounds. *Z. Anorg. Allg. Chem.* **2015**, *641*, 2641–2648. [[CrossRef](#)]
35. Salter-Blanc, A.J.; Bylaska, E.J.; Johnston, H.J.; Tratnyek, P.G. Predicting reduction rates of energetic nitroaromatic compounds using calculated one-electron reduction potentials. *Environ. Sci. Technol.* **2015**, *49*, 3778–3786. [[CrossRef](#)] [[PubMed](#)]
36. Gooch, A.; Sizochenko, N.; Sviatenko, L.; Gorb, L.; Leszczynski, J. A quantum chemical based toxicity study of estimated reduction potential and hydrophobicity in series of nitroaromatic compounds. *SAR QSAR Environ. Res.* **2017**, *28*, 133–150. [[CrossRef](#)]
37. Holtzman, J.; Crankshaw, D.; Peterson, F.; Polnaszek, C. The kinetics of the aerobic reduction of nitrofurantoin by NADPH-cytochrome P-450 *c* reductase. *Mol. Pharmacol.* **1981**, *20*, 669–673. [[PubMed](#)]
38. Darchen, A.; Moinet, C. Mecanisme e.c.e. de reduction du *para*-dinitrobenzene en *para*-nitrophenylhydroxylamine. *J. Electroanal. Chem.* **1977**, *78*, 81–88. [[CrossRef](#)]
39. Nivinskas, H.; Koder, R.L.; Anusevičius, Ž.; Šarlauskas, J.; Miller, A.F.; Čėnas, N. Quantitative structure-activity relationships in two-electron reduction of nitroaromatic compounds by *Enterobacter cloacae* NAD(P)H: Nitroreductase. *Arch. Biochem. Biophys.* **2001**, *385*, 170–178. [[CrossRef](#)]
40. Laviro, E.; Vallat, A.; Meuner-Prest, R. The reduction mechanisms of aromatic nitrocompounds in aqueous medium. Part V. The reduction of nitrosobenzene between pH 0.4 and 13. *J. Electroanal. Chem.* **1994**, *379*, 427–435. [[CrossRef](#)]
41. Valiauga, B.; Misevičienė, L.; Rich, M.H.; Ackerley, D.F.; Šarlauskas, J.; Čėnas, N. Mechanism of two-/four-electron reduction of nitroaromatics by oxygen-insensitive nitroreductases: The role of a non-enzymatic reduction step. *Molecules* **2018**, *23*, 1672. [[CrossRef](#)]



42. Uršič, S.; Vrčik, V.; Ljubas, D.; Vinkovič, I. Interaction of L-ascorbate with substituted nitrosobenzenes. Role of the ascorbate 2-OH group in antioxidant reactions. *New J. Chem.* **1998**, *22*, 221–223. [[CrossRef](#)]
43. Leung, K.H.; Yao, M.; Stearns, R.; Chiu, S.K. Mechanisms of bioactivation and covalent binding of 2,4,6-trinitrotoluene. *Chem. Biol. Interact.* **1995**, *97*, 37–51. [[CrossRef](#)]
44. Becker, A.R.; Sternson, L.A. Oxidation of phenylhydroxylamine in aqueous solution: A model for study of the carcinogenic effect of primary aromatic amines. *Proc. Natl. Acad. Sci. USA* **1981**, *78*, 2003–2007. [[CrossRef](#)]
45. Corbett, M.D.; Corbett, B.R. Bioorganic chemistry of the arylhydroxylamine and nitrosoarene functional groups. In *Biodegradation of Nitroaromatic Compounds*; Spain, J.C., Ed.; Plenum Press: New York, NY, USA, 1995; pp. 151–181.
46. Helsby, N.A.; Atwell, G.J.; Yang, S.; Palmer, B.D.; Anderson, R.F.; Pullen, S.M.; Ferry, D.M.; Hogg, A.; Wilson, W.R.; Denny, W.A. Aziridinyl-dinitrobenzamides: Synthesis, and structure-activity relationships for activation by *E. coli* nitroreductase. *J. Med. Chem.* **2004**, *47*, 3295–3307. [[CrossRef](#)] [[PubMed](#)]
47. Hay, M.P.; Sykes, B.M.; Denny, W.A.; Wilson, W.R. A 2-nitroimidazole carbamate prodrug of 5-amido-1-(chloromethyl)-3-[(5,6,7-trimethoxyindol-2-yl)carbonyl]-1,2-dihydro-3H-benz[e]indole (amino-*seco*-cbi-tmi) for use with ADEPT and GDEPT. *Bioorg. Med. Chem. Lett.* **1999**, *9*, 2237–2242. [[CrossRef](#)]
48. Sykes, B.M.; Hay, M.P.; Bohinc-Herceg, D.; Helsby, N.A.; O'Connor, C.J.; Denny, W.A. Leaving group effects in reductively triggered fragmentation of 4-nitrobenzyl carbamates. *J. Chem. Soc. Perkin Trans.* **2000**, *1*, 1601–1608. [[CrossRef](#)]
49. Borch, R.F.; Liu, J.; Schmidt, J.P.; Markovits, J.T.; Joswig, C.; Gipp, J.J.; Mulcahy, R.T. Synthesis and evaluation of nitroheterocyclic phosphoramidates as hypoxia-selective alkylating agents. *J. Med. Chem.* **2000**, *43*, 2258–2265. [[CrossRef](#)] [[PubMed](#)]
50. Hu, J.; Van Valckenborg, E.; Xu, D.; Menu, E.; De Raeve, H.; De Bruyne, E.; Xu, S.; Van Camp, B.; Handisides, D.; Hart, C.P.; et al. Synergistic induction of apoptosis in multiple myeloma cells by bortezomib and hypoxia-activated prodrug TH-302, in vivo and in vitro. *Mol. Cancer Ther.* **2013**, *12*, 1763–1773. [[CrossRef](#)]
51. Gruber, T.D.; Krishnamurthy, C.; Grimm, J.B.; Tadross, M.R.; Wysocki, L.M.; Gartner, Z.J.; Lavis, L.D. Cell-specific chemical delivery using a selective nitroreductase-nitroaryl pair. *ACS Chem. Biol.* **2018**, *13*, 2888–2896. [[CrossRef](#)]
52. Cyr, A.; Laviro, E.; Lessard, J. Electrochemical behavior of nitrobenzene and phenylhydroxylamine on copper rotating disk electrodes. *J. Electroanal. Chem.* **1989**, *263*, 69–78. [[CrossRef](#)]
53. Iwase, K.; Fujinani, N.; Hashimoto, K.; Kamiya, K.; Nakanishi, S. Cooperative electrocatalytic reduction of nitrobenzene to aniline in aqueous solution by copper modified covalent triazine network. *Chem. Lett.* **2018**, *47*, 304–307. [[CrossRef](#)]
54. Clarke, E.D.; Wardman, P.; Goulding, K.H. Anaerobic reduction of nitroimidazoles by reduced flavin mononucleotide and by xanthine oxidase. *Biochem. Pharmacol.* **1980**, *29*, 2684–2687. [[CrossRef](#)]
55. Porter, T.D.; Kasper, C.B. Coding nucleotide sequence of rat NADPH-cytochrome P-450 reductase cDNA and identification of flavin-binding domains. *Proc. Natl. Acad. Sci. USA* **1985**, *83*, 973–977. [[CrossRef](#)] [[PubMed](#)]
56. Wang, M.; Roberts, D.L.; Paschke, R.; Shea, T.M.; Masters, B.S.S.; Kim, J.-J.P. Three-dimensional structure of NADPH-cytochrome P450 reductase: Prototype for FMN- and FAD-containing enzymes. *Proc. Natl. Acad. Sci. USA* **1997**, *94*, 8411–8416. [[CrossRef](#)]
57. Oprian, D.D.; Coon, M.J. Oxidation-reduction states of FMN and FAD in NADPH-cytochrome P-450 reductase during the reduction by NADPH. *J. Biol. Chem.* **1982**, *257*, 8935–8944. [[CrossRef](#)]
58. Gutierrez, A.; Paine, M.; Wolf, C.R.; Scrutton, N.S.; Roberts, G.C.K. Relaxation kinetics of cytochrome P450 reductase: Internal electron transfer is limited by conformational change and regulated by coenzyme binding. *Biochemistry* **2002**, *41*, 4626–4637. [[CrossRef](#)] [[PubMed](#)]
59. Guengerich, F.P. Oxidation-reduction properties of rat liver cytochromes P-450 and NADPH-cytochrome P-450 reductase related to catalysis in reconstituted systems. *Biochemistry* **1983**, *22*, 2811–2820. [[CrossRef](#)] [[PubMed](#)]
60. Das, A.; Sligar, S.G. Modulation of the cytochrome P-450 reductase redox potential by the phospholipid bilayer. *Biochemistry* **2009**, *48*, 12104–12112. [[CrossRef](#)] [[PubMed](#)]
61. Hubbard, P.A.; Shen, A.L.; Paschke, R.; Kasper, C.B.; Kim, J.-J.P. NADPH-cytochrome P450 oxidoreductase. Structural basis for hydride and electron transfer. *J. Biol. Chem.* **2001**, *276*, 29163–29170. [[CrossRef](#)]
62. Gao, Y.T.; Smith, S.M.E.; Weinberg, J.B.; Montgomery, H.J.; Newman, E.; Guillemette, J.G.; Ghosh, D.K.; Roman, L.J.; Martasek, P.; Salerno, J.C. Thermodynamics of oxidation-reduction reactions in mammalian nitric-oxide synthase isoforms. *J. Biol. Chem.* **2004**, *279*, 18759–18766. [[CrossRef](#)] [[PubMed](#)]
63. Miller, T.; Martasek, P.; Omura, T.; Masters, B.S.S. Rapid kinetic studies of electron transfer in the three isoforms of nitric oxide synthase. *Biochem. Biophys. Res. Commun.* **1999**, *265*, 184–188. [[CrossRef](#)]
64. Anusevičius, Ž.; Nivinskas, H.; Šarlauskas, J.; Sari, M.A.; Boucher, J.-L.; Čėnas, N. Single-electron reduction of quinone and nitroaromatic xenobiotics by recombinant rat neuronal nitric oxide synthase. *Acta Biochim. Pol.* **2013**, *60*, 207–222. [[CrossRef](#)]
65. Cooper, C.E.; Ioannidis, N.; D'mello, R.; Poole, R.K. Haem, flavin and oxygen interactions in Hmp, a flavohemoglobin from *Escherichia coli*. *Biochem. Soc. Trans.* **1994**, *22*, 709–713. [[CrossRef](#)]
66. Nobre, L.S.; Goncalves, V.L.; Saraiva, L.M. Flavohemoglobin of *Staphylococcus aureus*. *Methods Enzymol.* **2008**, *436*, 203–216.
67. Moussaoui, M.; Misevičienė, L.; Anusevičius, Ž.; Marozienė, A.; Lederer, F.; Baciou, L.; Čėnas, N. Quinones and nitroaromatic compounds as substrates of *Staphylococcus aureus* flavohemoglobin. *Free Radic. Biol. Med.* **2018**, *123*, 107–115. [[CrossRef](#)] [[PubMed](#)]
68. Orna, M.; Mason, R. Correlation of kinetic parameters of nitroreductase enzymes with redox properties of nitroaromatic compounds. *J. Biol. Chem.* **1989**, *264*, 12379–12384. [[CrossRef](#)]

69. Čėnas, N.; Anusevičius, Ž.; Bironaitė, D.; Bachmanova, G.I.; Archakov, A.I.; Öllinger, K. The electron transfer reactions of NADPH-cytochrome P450 reductase with nonphysiological oxidants. *Arch. Biochem. Biophys.* **1994**, *315*, 400–406. [[CrossRef](#)]
70. Nemeikaitė-Čėnienė, A.; Šarlauskas, J.; Jonušienė, V.; Marozienė, A.; Misevičienė, L.; Yantsevich, A.V.; Čėnas, N. Kinetics of flavoenzyme-catalyzed reduction of tirapazamine derivatives: Implications for their prooxidant cytotoxicity. *Int. J. Mol. Sci.* **2019**, *20*, 4602. [[CrossRef](#)] [[PubMed](#)]
71. Nemeikaitė-Čėnienė, A.; Šarlauskas, J.; Jonušienė, V.; Misevičienė, L.; Marozienė, A.; Yantsevich, A.V.; Čėnas, N. QSARs in prooxidant mammalian cell cytotoxicity of nitroaromatic compounds: The roles of compound lipophilicity and cytochrome P-450 and DT-diaphorase-catalyzed reactions. *Chemija* **2020**, *31*, 170–177. [[CrossRef](#)]
72. Li, H.; Lin, D.; Peng, Y.; Zheng, J. Oxidative bioactivation of nitrofurantoin in rat liver microsomes. *Xenobiotica* **2017**, *47*, 103–111. [[CrossRef](#)] [[PubMed](#)]
73. Le Champion, L.; Delaforge, M.; Noel, J.P.; Ouazzani, J. Metabolism of <sup>14</sup>C-labelled 5-nitro-1,2,4-triazol-3-one by rat liver microsomes. Evidence for the participation of cytochromes P450. *Eur. J. Biochem.* **1996**, *248*, 401–406. [[CrossRef](#)] [[PubMed](#)]
74. Guengerich, F.P.; Chun, Y.-J.; Kim, D.; Gillam, E.M.J.; Shimada, T. Cytochrome P450 1B1: A target for inhibition in anticarcinogenesis. *Mutat. Res.* **2003**, *523–524*, 173–182. [[CrossRef](#)]
75. Pochapski, T.C.; Wong, N.; Zhuang, Y.; Fitcher, J.; Pandelia, M.-E.; Teitz, D.R.; Colthart, A.M. NADH reduction of nitroaromatics as a probe for residual ferric form high spin in a cytochrome P450. *Biochim. Biophys. Acta* **2018**, *1866*, 126–133. [[CrossRef](#)] [[PubMed](#)]
76. Daff, S. NO synthase: Structures and mechanism. *Nitric Oxide* **2010**, *23*, 1–11. [[CrossRef](#)]
77. Guan, Z.W.; Kamatani, D.; Kimura, S.; Iyanagi, T. Mechanistic studies on the intramolecular one-electron transfer between the two flavins in the human neuronal nitric oxide synthase and inducible nitric oxide synthase flavin domains. *J. Biol. Chem.* **2003**, *278*, 30859–30868. [[CrossRef](#)] [[PubMed](#)]
78. Haque, M.M.; Tejero, J.; Bayachou, M.; Kenney, T.; Stuehr, D.J. A cross-domain charge interaction governs the activity of NO synthase. *J. Biol. Chem.* **2018**, *293*, 4545–4554. [[CrossRef](#)] [[PubMed](#)]
79. Fu, Y.J.; Yamamoto, K.; Guan, Z.W.; Kimura, T.; Iyanagi, T. Human neuronal nitric oxide synthase can catalyze one-electron reduction of adriamycin: Role of flavin domain. *Arch. Biochem. Biophys.* **2004**, *427*, 180–187. [[CrossRef](#)] [[PubMed](#)]
80. Ask, K.; Dijols, S.; Giroud, C.; Casse, L.; Frapart, Y.M.; Sari, M.A.; Kim, K.S.; Stuehr, D.J.; Mansuy, D.; Camus, P.; et al. Reduction of nilutamide by NO synthases: Implications for the adverse effects of this nitroaromatic antiandrogen drug. *Chem. Res. Toxicol.* **2003**, *16*, 1547–1554. [[CrossRef](#)]
81. Chandor, A.; Dijols, S.; Ramassamy, B.; Frapart, Y.; Mansuy, D.; Stuehr, D.; Helsby, N.; Boucher, J.L. Metabolic activation of the antitumor drug 5-(Aziridin-1-yl)-2,4-dinitrobenzamide (CB1954) by NO synthases. *Chem. Res. Toxicol.* **2008**, *21*, 836–843. [[CrossRef](#)]
82. Miller, R.T. Dinitrobenzene-mediated production of peroxyntirite by neuronal nitric oxide synthase. *Chem. Res. Toxicol.* **2002**, *15*, 927–934. [[CrossRef](#)]
83. Kumagai, Y.; Kikushima, M.; Nakai, Y.; Shimojo, N.; Kanimoto, M. Neuronal nitric oxide synthase (nNOS) catalyzes one-electron reduction of 2,4,6-trinitrotoluene, resulting in decreased nitric oxide production and increased nNOS gene expression: Implications for oxidative stress. *Free Radic. Biol. Med.* **2004**, *37*, 350–357. [[CrossRef](#)]
84. Gardner, A.M.; Martin, L.A.; Gardner, P.R. Steady-state and transient kinetics of *Escherichia coli* nitric oxide dioxygenase (flavo-hemoglobin). The B10 tyrosine hydroxyl is essential for dioxygen binding and catalysis. *J. Biol. Chem.* **2000**, *275*, 12581–12589. [[CrossRef](#)] [[PubMed](#)]
85. Ermler, U.; Siddiqui, R.A.; Cramm, R.; Salzman, A.L. Crystal structure of the flavo-hemoglobin from *Alcaligenes eutrophus* at 1.75 Å resolution. *EMBO J.* **1995**, *14*, 6067–6077. [[CrossRef](#)]
86. Hanukoglu, I. Interfaces in FAD and NADP binding adrenodoxin reductase—A ubiquitous enzyme. *J. Mol. Evol.* **2017**, *85*, 205–218. [[CrossRef](#)]
87. Lambeth, J.D.; Kamin, H. Adrenodoxin reductase and adrenodoxin. Mechanism of reduction of ferricyanide and cytochrome c. *J. Biol. Chem.* **1977**, *252*, 2908–2917. [[CrossRef](#)]
88. Lambeth, J.D.; Seybert, D.W.; Kamin, H. Ionic effects on adrenal steroidogenic electron transport. The role of adrenodoxin as an electron shuttle. *J. Biol. Chem.* **1979**, *254*, 7255–7264. [[CrossRef](#)]
89. Hurley, J.K.; Morales, R.; Martinez-Julvez, M.; Brodie, T.B.; Medina, M.; Gomez-Moreno, C.; Tollin, G. Structure-function relationships in *Anabaena* ferredoxin/ferredoxin:NADP<sup>+</sup> reductase electron transfer: Insight from site-directed mutagenesis, transient absorption spectroscopy and X-ray crystallography. *Biochim. Biophys. Acta* **2002**, *1554*, 5–21. [[CrossRef](#)]
90. Martinez-Julvez, M.; Nogue, I.; Faro, M.; Hurlley, J.K.; Brodie, T.B.; Sanz-Aparicio, J.A.; Stankovich, M.T.; Medina, M.; Tollin, G.; Gomez-Moreno, C. Role of a cluster of hydrophobic residues near the FAD cofactor in *Anabaena* PCC7119 ferredoxin-NADP<sup>+</sup> reductase for optimal complex formation and electron transfer to ferredoxin. *J. Biol. Chem.* **2001**, *276*, 27498–27510. [[CrossRef](#)] [[PubMed](#)]
91. Faro, M.; Gómez-Moreno, C.; Stankovich, M.; Medina, M. Role of critical charged residues in reduction potential modulation of ferredoxin-NADP<sup>+</sup> reductase. *Eur. J. Biochem.* **2002**, *269*, 2656–2661. [[CrossRef](#)]
92. Kimata-Arigo, Y.; Kurisu, G.; Kusunoki, M.; Aoki, S.; Sato, K.; Kobayashi, T.; Kita, K.; Horii, T.; Hase, T. Cloning and characterization of ferredoxin and ferredoxin-NADP<sup>+</sup> reductase from human malaria parasite. *J. Biochem.* **2007**, *141*, 421–428. [[CrossRef](#)]

93. Balconi, E.; Pennati, A.; Crobu, D.; Pandini, V.; Cerutti, R.; Zanetti, G.; Aliverti, A. The ferredoxin-NADP<sup>+</sup> reductase/ ferredoxin electron transfer system of *Plasmodium falciparum*. *FEBS J.* **2009**, *276*, 3825–3836. [[CrossRef](#)]
94. Sled, V.D.; Rudnitsky, N.I.; Hatefi, Y.; Ohnishi, T. Thermodynamic analysis of flavin in mitochondrial NADH:ubiquinone oxidoreductase (complex I). *Biochemistry* **1994**, *33*, 10069–10075. [[CrossRef](#)] [[PubMed](#)]
95. Ingledew, W.J.; Ohnishi, T. An analysis of some thermodynamic properties of iron-sulfur centres in site I of mitochondria. *Biochem. J.* **1980**, *186*, 111–117. [[CrossRef](#)]
96. Dooijewaard, G.; Slater, E.C. Steady-state kinetics of high molecular weight (type-I) NADH dehydrogenase. *Biochim. Biophys. Acta* **1976**, *440*, 1–15. [[CrossRef](#)]
97. Čėnas, N.K. Reactions of complex I of mitochondrial electron-transport chain with artificial electron acceptors. *Ukr. Biokhimičeskii Zhurnal* **1989**, *61*, 23–29. (In Russian)
98. Fedor, J.G.; Jones, A.J.Y.; Di Luca, A.; Kaila, V.R.I.; Hirst, J. Correlating kinetic and structural data on ubiquinone binding and reduction by respiratory complex I. *Proc. Natl. Acad. Sci. USA* **2017**, *114*, 12737–12742. [[CrossRef](#)] [[PubMed](#)]
99. Kobayashi, K.; Miura, S.; Ichikawa, Y.; Tagawa, S. Interactions of NADPH-adrenodoxin reductase with NADP<sup>+</sup> as studied by pulse-radiolysis. *Biochemistry* **1995**, *34*, 12932–12936. [[CrossRef](#)]
100. Čėnas, N.K.; Marcinkevičienė, J.A.; Kulys, J.J.; Usanov, S.A. A negative cooperativity between NADPH and adrenodoxin on binding to NADPH:adrenodoxin reductase. *FEBS Lett.* **1990**, *259*, 338–340. [[CrossRef](#)]
101. Marcinkevičienė, J.; Čėnas, N.; Kulys, J.; Usanov, S.A.; Sukhova, N.M.; Seleznieva, I.S.; Gryazev, V.F. Nitroreductase reactions of the NADPH-adrenodoxin reductase. *Biomed. Biochim. Acta* **1990**, *49*, 167–172.
102. Fischer, F.; Raimondi, D.; Aliverti, A.; Zanetti, G. *Mycobacterium tuberculosis* FprA, a novel bacterial NADPH-ferredoxin reductase. *Eur. J. Biochem.* **2002**, *269*, 3005–3013. [[CrossRef](#)]
103. McLean, K.; Scrutton, N.S.; Munro, A.W. Kinetic, spectroscopic and thermodynamic characterization of the *Mycobacterium tuberculosis* adrenodoxin reductase homologue FprA. *Biochem. J.* **2003**, *372*, 317–327. [[CrossRef](#)] [[PubMed](#)]
104. Serre, L.; Vellieux, F.M.; Medina, M.; Gomez-Moreno, C.; Fontecilla-Camps, J.C.; Frey, M. X-ray structure of the ferredoxin:NADP<sup>+</sup> reductase from the cyanobacterium *Anabaena* PCC7119 at 1.8 Å resolution, and crystallographic studies of NADP<sup>+</sup> binding at 2.25 Å resolution. *J. Mol. Biol.* **1996**, *263*, 20–39. [[CrossRef](#)]
105. Kimata-Arigo, Y.; Yuasa, S.; Saitoh, T.; Fukuyama, H.; Hase, T. *Plasmodium*-specific basic amino acid residues important for the interaction with ferredoxin on the surface of ferredoxin-NADP<sup>+</sup> reductase. *J. Biochem.* **2018**, *164*, 231–237. [[CrossRef](#)] [[PubMed](#)]
106. Milani, M.; Balconi, E.; Aliverti, A.; Mastrangelo, E.; Seeber, F.; Bolognesi, M.; Zanetti, G. Ferredoxin-NADP<sup>+</sup> reductase from *Plasmodium falciparum* undergoes NADP<sup>+</sup>-dependent dimerization and inactivation: Functional and crystallographic analysis. *J. Mol. Biol.* **2007**, *367*, 501–513. [[CrossRef](#)]
107. Anusevičius, Ž.; Martinez Julvez, M.; Genzor, C.G.; Nivinskas, H.; Gomez-Moreno, C.; Čėnas, N. Electron transfer reactions of *Anabaena* PCC 7119 ferredoxin:NADP<sup>+</sup> reductase with nonphysiological oxidants. *Biochim. Biophys. Acta* **1997**, *1320*, 247–255. [[CrossRef](#)]
108. Grellier, P.; Marozienė, A.; Nivinskas, H.; Šarlauskas, J.; Aliverti, A.; Čėnas, N. Antiplasmodial activity of quinones: Roles of aziridinyl substituents and the inhibition of *Plasmodium falciparum* glutathione reductase. *Arch. Biochem. Biophys.* **2010**, *494*, 32–39. [[CrossRef](#)]
109. Lesanavičius, M.; Aliverti, A.; Šarlauskas, J.; Čėnas, N. Reactions of *Plasmodium falciparum* ferredoxin:NADP<sup>+</sup> oxidoreductase with redox cycling xenobiotics: A mechanistic study. *Int. J. Mol. Sci.* **2020**, *21*, 3234. [[CrossRef](#)]
110. Vidakovic, M.; Crossnoe, C.R.; Neidre, C.; Kim, K.; Krause, K.L.; Germanas, J.P. Reactivity of reduced [2Fe-2S] ferredoxin parallels host susceptibility to nitroimidazoles. *Antimicrob. Agents Chemother.* **2003**, *47*, 302–308. [[CrossRef](#)]
111. Shah, M.M.; Spain, J.C. Elimination of nitrite from the explosive 2,4,6-trinitrophenylmethylamine (tetryl) catalyzed by ferredoxin NADP oxidoreductase from spinach. *Biochem. Biophys. Res. Commun.* **1996**, *220*, 563–568. [[CrossRef](#)] [[PubMed](#)]
112. Walker, J.E. The NADH:ubiquinone oxidoreductase (complex I) of respiratory chain. *Quart. Rev. Biophys.* **1992**, *25*, 253–324. [[CrossRef](#)] [[PubMed](#)]
113. Hirst, J. Mitochondrial complex I. *Annu. Rev. Biochem.* **2013**, *82*, 551–557. [[CrossRef](#)]
114. Agip, A.-N.A.; Blaza, J.N.; Fedor, J.G.; Hirst, J. Mammalian respiratory complex I through the lens of cryo-EM. *Annu. Rev. Biophys.* **2019**, *48*, 165–184. [[CrossRef](#)]
115. Bironaitė, D.A.; Čėnas, N.K.; Kulys, J.J. The rotenone-insensitive reduction of quinones and nitrocompounds by mitochondrial NADH:ubiquinone reductase. *Biochim. Biophys. Acta* **1991**, *1060*, 203–209. [[CrossRef](#)]
116. Čėnas, N.K.; Bironaitė, D.A.; Kulys, J.J. On the mechanism of rotenone-insensitive reduction of quinones by mitochondrial NADH-ubiquinone reductase: The high-affinity binding of NAD<sup>+</sup> and NADH to the reduced enzyme form. *FEBS Lett.* **1991**, *284*, 192–194. [[CrossRef](#)]
117. Bironaitė, D.A.; Čėnas, N.K.; Anusevičius, Ž.J.; Medentsev, A.G.; Akimenko, V.K.; Usanov, A.A. Fungal quinone pigments as oxidizers and inhibitors of mitochondrial NADH-ubiquinone reductase. *Arch. Biochem. Biophys.* **1992**, *297*, 253–257. [[CrossRef](#)]
118. Hrdy, I.; Hirt, R.P.; Dolezal, P.; Bardonová, L.; Foster, P.G.; Tachezy, J.; Embley, T.M. *Trichomonas* hydrogenosomes contain the NADH dehydrogenase module of mitochondrial complex I. *Nature* **2004**, *432*, 618–622. [[CrossRef](#)] [[PubMed](#)]
119. Do, P.M.; Angerhofer, A.; Hrdy, I.; Bardonova, L.; Ingram, L.O.; Shanmugam, K.T. Engineering *Escherichia coli* for fermentative dihydrogen production: Potential role of NADH-ferredoxin oxidoreductase from the hydrogenosome of anaerobic protozoa. *Appl. Biochem. Biotechnol.* **2009**, *153*, 21–33. [[CrossRef](#)]



120. Graves, K.J.; Novak, J.; Secor, W.E.; Kissinger, P.J.; Schwebke, J.R.; Muzny, C.A. A systematic review of the literature on mechanisms of 5-nitroimidazole resistance in *Trichomonas vaginalis*. *Parasitology* **2020**, *147*, 1383–1391. [[CrossRef](#)] [[PubMed](#)]
121. Yarlett, N.; Gorrell, T.E.; Marczak, R.; Müller, G. Reduction of nitroimidazole derivatives by hydrogenosomal extracts of *Trichomonas vaginalis*. *Mol. Biochem. Pharmacol.* **1985**, *14*, 29–40. [[CrossRef](#)]
122. Smutná, T.; Pilarová, K.; Tarábek, J.; Tachezy, J.; Hrdý, I. Novel functions of an iron-sulfur flavoprotein from *Trichomonas vaginalis* hydrogenosomes. *Antimicrob. Agents Chemother.* **2014**, *58*, 3224–3232. [[CrossRef](#)] [[PubMed](#)]
123. St. Maurice, M.; Cremades, N.; Croxen, M.A.; Sisson, G.; Sancho, J.; Hoffman, P.S. Flavodoxin:quinone reductase (FqrB): A redox partner of Pyruvate: Ferredoxin oxidoreductase that reversibly couples pyruvate oxidation to NADPH production in *Helicobacter pylori* and *Campylobacter jejuni*. *J. Bacteriol.* **2007**, *189*, 4764–4773. [[CrossRef](#)]
124. Galano, J.J.; Alias, M.; Perez, R.; Velazquez-Campoy, A.; Hoffman, P.S.; Sancho, J. Improved flavodoxin inhibitors with potential therapeutic effects against *Helicobacter pylori* infection. *J. Med. Chem.* **2013**, *56*, 6248–6258. [[CrossRef](#)] [[PubMed](#)]
125. Leitsch, D.; Burgess, A.G.; Dunn, L.A.; Krauer, K.G.; Tan, K.; Duchene, M.; Upcroft, P.; Eckmann, L.; Upcroft, J.A. Pyruvate: Ferredoxin oxidoreductase and thioredoxin reductase are involved in 5-nitroimidazole activation while flavin metabolism is linked to 5-nitroimidazole resistance in *Giardia lamblia*. *J. Antimicrob. Chemother.* **2011**, *66*, 1756–1765. [[CrossRef](#)] [[PubMed](#)]
126. Wardman, P.; Anderson, R.F.; Clarke, E.D.; Jones, N.R.; Milchinton, A.I.; Patel, K.B.; Stratford, I.J.; Watts, M.E. Reduction of nitroimidazoles in model chemical and biological systems. III. Effects of basic substituents in nitroimidazole sidechains. *Int. J. Radiat. Oncol. Biol. Phys.* **1982**, *8*, 777–780. [[CrossRef](#)]
127. O'Connor, C.J.; McLennan, D.J.; Sutton, B.M.; Denny, W.A.; Wilson, W.R. Effect of reduction potential on the rate of reduction of nitroacridines by xanthine oxidase and by dihydro-flavin mononucleotide. *J. Chem. Soc. Perkin Trans.* **1991**, 951–954. [[CrossRef](#)]
128. Batelli, M.G.; Polito, L.; Bortolotti, M.; Bolognesi, A. Xanthine oxidoreductase in drug metabolism: Beyond a role as a detoxifying enzyme. *Curr. Med. Chem.* **2016**, *23*, 4027–4036. [[CrossRef](#)]
129. Harris, C.M.; Massey, V. The oxidative half-reaction of xanthine dehydrogenase with NAD: Reaction kinetics and steady-state mechanism. *J. Biol. Chem.* **1997**, *272*, 28335–28341. [[CrossRef](#)]
130. Kutcher, W.W.; McCalla, D.R. Aerobic reduction of 5-nitro-2-furaldehyde by rat liver xanthine dehydrogenase. *Biochem. Pharmacol.* **1984**, *33*, 799–805. [[CrossRef](#)]
131. Ueda, O.; Sugihara, K.; Ohta, S.; Kitamura, K. Involvement of molybdenum hydroxylases in reductive metabolism of nitro polycyclic aromatic hydrocarbons in mammalian skin. *Drug Metab. Dispos.* **2005**, *33*, 1312–1318. [[CrossRef](#)]
132. Anoz-Carbonell, E.; Timson, D.J.; Pey, A.L.; Medina, M. The catalytic cycle of the antioxidant and cancer associated human NQO1 enzyme: Hydride transfer, conformational dynamics and functional cooperativity. *Antioxidants* **2020**, *9*, 772. [[CrossRef](#)] [[PubMed](#)]
133. Fitzsimmons, A.; Workman, P.; Grever, M.; Paull, K.; Camalier, R.; Lewis, A.D. Reductase enzyme expression across the National Cancer Institute tumor cell line panel—Correlation with sensitivity to mitomycin C and EO9. *J. Natl. Cancer Inst.* **1996**, *88*, 259–269. [[CrossRef](#)]
134. Li, R.; Bianchet, M.A.; Talalay, P.; Amzel, L.M. The three-dimensional structure of NAD(P)H:quinone reductase, a flavoprotein involved in cancer chemoprotection and chemotherapy: Mechanism of the two-electron reduction. *Proc. Natl. Acad. Sci. USA* **1995**, *92*, 8846–8850. [[CrossRef](#)]
135. Faig, M.; Bianchet, M.A.; Talalay, P.; Chen, S.; Winski, S.; Ross, D.; Amzel, L.M. Structures of recombinant human and mouse NAD(P)H: Quinone oxidoreductases: Species comparison and structural changes with substrate binding and release. *Proc. Natl. Acad. Sci. USA* **2000**, *97*, 3177–3182. [[CrossRef](#)]
136. Bianchet, M.A.; Faig, A.; Amzel, L.M. Structure and mechanism of NAD(P)H:quinone acceptor oxidoreductases (NQO). *Meth. Enzymol.* **2004**, *382*, 144–174.
137. Asher, G.; Dym, O.; Tsvetkov, P.; Adler, J.; Shaul, Y. The crystal structure of NAD(P)H quinone oxidoreductase 1 in complex with its potent inhibitor dicoumarol. *Biochemistry* **2006**, *45*, 6372–6378. [[CrossRef](#)]
138. Tedeschi, G.; Chen, S.; Massey, V. DT-diaphorase. Redox potential, steady-state, and rapid reaction studies. *J. Biol. Chem.* **1995**, *270*, 1198–1204. [[CrossRef](#)] [[PubMed](#)]
139. Anusevičius, Ž.; Šarlauskas, J.; Čėnas, N. Two-electron reduction of quinones by rat liver NAD(P)H: Quinone oxidoreductase: Quantitative structure-activity relationships. *Arch. Biochem. Biophys.* **2002**, *404*, 254–262. [[CrossRef](#)]
140. Hubig, S.; Rathore, R.; Kochi, J. Steric control of electron transfer. Changeover from outer-sphere to inner-sphere mechanisms in arene/quinone redox pairs. *J. Am. Chem. Soc.* **1999**, *121*, 617–626. [[CrossRef](#)]
141. Misevičienė, L.; Anusevičius, Ž.; Šarlauskas, J.; Čėnas, N. Reduction of nitroaromatic compounds by NAD(P)H:quinone oxidoreductase (NQO1): The role of electron-accepting potency and structural parameters in the substrate specificity. *Acta Biochim. Pol.* **2006**, *53*, 569–576. [[CrossRef](#)] [[PubMed](#)]
142. Day, M.A.; Jarrom, D.; Christofferson, A.J.; Graziano, A.E.; Anderson, J.L.R.; Searle, P.F.; Hyde, E.I.; White, S.A. The structures of *E. coli* NfsA bound to the antibiotic nitrofurantoin: To 1,4-benzoquinone and FMN. *Biochem. J.* **2021**, *478*, 2601–2617. [[CrossRef](#)]
143. Race, P.R.; Lovering, A.L.; Green, R.M.; Osson, A.; White, S.A.; Searle, P.F.; Wrighton, C.J.; Hyde, E.I. Structural and mechanistic studies of *Escherichia coli* nitroreductase with the antibiotic nitrofurazone: Reversed binding orientations in different redox states of the enzyme. *J. Biol. Chem.* **2005**, *280*, 13256–13264. [[CrossRef](#)]
144. Jarrom, D.; Jaberipour, M.; Guise, C.P.; Daff, S.N.; White, S.A.; Searle, P.F.; Hyde, E.I. Steady-state and stopped-flow kinetic studies of three *Escherichia coli* NfsB mutants with enhanced activity for the prodrug CB1954. *Biochemistry* **2009**, *48*, 7665–7672. [[CrossRef](#)]

145. Prosser, G.A.; Copp, J.N.; Syddall, S.P.; Williams, E.M.; Smaill, J.B.; Wilson, W.R.; Patterson, A.V.; Ackerley, D.F. Discovery and evaluation of *Escherichia coli* nitroreductases that activate the anti-cancer prodrug CB1954. *Biochem. Pharmacol.* **2010**, *79*, 678–687. [[CrossRef](#)]
146. Koder, R.L.; Haynes, C.A.; Rodgers, M.E.; Rodgers, D.W.; Miller, A.F. Flavin thermodynamics explain the oxygen insensitivity of enteric nitroreductases. *Biochemistry* **2002**, *41*, 14197–14205. [[CrossRef](#)]
147. Pitsawong, W.; Hoben, J.P.; Miller, A.F. Understanding the broad substrate repertoire of nitroreductase based on its kinetic mechanism. *J. Biol. Chem.* **2014**, *289*, 15203–15214. [[CrossRef](#)]
148. Valiauga, B. Studies of Reduction Mechanisms of Quinones and Nitroaromatic Compounds by Flavoenzymes Dehydrogenases-Transhydrogenases. Ph.D. Thesis, Vilnius University, Vilnius, Lithuania, 2020.
149. Valiauga, B.; Williams, E.M.; Ackerley, D.F.; Čėnas, N. Reduction of quinones and nitroaromatic compounds by *Escherichia coli* nitroreductase A (NfsA): Characterization of kinetics and substrate specificity. *Arch. Biochem. Biophys.* **2017**, *624*, 14–22. [[CrossRef](#)]
150. Miller, A.F.; Park, J.T.; Ferguson, K.L.; Pitsawong, W.; Bommarius, A.S. Informing efforts to develop nitroreductase for amine production. *Molecules* **2018**, *23*, 211. [[CrossRef](#)]
151. Couturier, J.; Prosper, P.; Winger, A.M.; Hecker, A.; Hirasawa, M.; Knaff, D.B.; Gans, P.; Jacquot, J.-P.; Navazza, A.; Haouz, A.; et al. In the absence of thioredoxins, what are the reductants for peroxiredoxins in *Thermotoga maritima*? *Antioxid. Redox Signal.* **2013**, *18*, 1613–1622. [[CrossRef](#)] [[PubMed](#)]
152. Anusevičius, Ž.; Misevičienė, L.; Šarlauskas, J.; Rouhier, N.; Jacquot, J.-P.; Čėnas, N. Quinone- and nitroreductase reactions of *Thermotoga maritima* peroxiredoxin-nitroreductase hybrid enzyme. *Arch. Biochem. Biophys.* **2012**, *528*, 50–56. [[CrossRef](#)] [[PubMed](#)]
153. Chen, S.; Wu, K.; Zhang, D.; Sherman, M.; Knox, R.; Yang, C.S. Molecular characterization of binding of substrates and inhibitors to DT-diaphorase: Combined approach involving site-directed mutagenesis, inhibitor-binding analysis, and computer modeling. *Mol. Pharmacol.* **1999**, *56*, 272–278. [[CrossRef](#)]
154. Anusevičius, Ž.; Šarlauskas, J.; Nivinskas, H.; Segura-Aguilar, J.; Čėnas, N. DT-diaphorase catalyzes N-denitration and redox cycling of tetra. *FEBS Lett.* **1998**, *436*, 144–148. [[CrossRef](#)]
155. Šarlauskas, J.; Dičkanaitė, E.; Nemeikaitė, A.; Anusevičius, Ž.; Nivinskas, H.; Segura-Aguilar, J.; Čėnas, N. Nitrobenzimidazoles as substrates for DT-diaphorase and redox cycling compounds: Their enzymatic reactions and cytotoxicity. *Arch. Biochem. Biophys.* **1997**, *346*, 219–229. [[CrossRef](#)]
156. Akiva, E.; Copp, J.N.; Tokuriki, N.; Babbitt, P.C. Evolutionary and molecular foundations of multiple contemporary functions of the nitroreductase superfamily. *Proc. Natl. Acad. Sci. USA* **2017**, *114*, E9549–E9558. [[CrossRef](#)]
157. Paterson, E.; Boucher, S.; Lambert, I. Regulation of the nfsA Gene in *Escherichia coli* by SoxS. *J. Bacteriol.* **2002**, *184*, 51–58. [[CrossRef](#)] [[PubMed](#)]
158. Zenno, S.; Koike, H.; Kumar, A.N.; Jayaraman, R.; Tanokura, M.; Saigo, K. Biochemical characterization of NfsA, the *Escherichia coli* major nitroreductase exhibiting a high amino acid sequence homology to Frp, a *Vibrio harveyi* flavin oxidoreductase. *J. Bacteriol.* **1996**, *178*, 4508–4514. [[CrossRef](#)] [[PubMed](#)]
159. Zenno, S.; Kobori, T.; Tanokura, M.; Saigo, K. Conversion of NfsA, the major *Escherichia coli* nitroreductase, to a flavin reductase with an activity similar to that of Frp, a flavin reductase in *Vibrio harveyi*, by a single amino acid substitution. *J. Bacteriol.* **1998**, *180*, 422–425. [[CrossRef](#)] [[PubMed](#)]
160. Parkinson, G.; Skelly, J.; Neidle, S. Crystal structure of FMN-dependent nitroreductase from *Escherichia coli* B: A prodrug-activating enzyme. *J. Med. Chem.* **2000**, *43*, 3624–3631. [[CrossRef](#)]
161. Johansson, E.; Parkinson, G.N.; Denny, W.A.; Neidle, S. Studies on the nitroreductase prodrug-activating system. Crystal structures of complexes with the inhibitor dicoumarol and dinitrobenzamide prodrugs and of the enzyme active form. *J. Med. Chem.* **2003**, *46*, 4009–4020. [[CrossRef](#)]
162. Anlezark, G.M.; Melton, R.G.; Sherwood, R.F.; Wilson, W.R.; Denny, W.A.; Palmer, B.D.; Knox, R.J.; Friedlos, F.; Williams, A. Bioactivation of dinitrobenzamide mustards by an *E. coli* B nitroreductase. *Biochem. Pharmacol.* **1995**, *50*, 609–618. [[CrossRef](#)]
163. Koder, R.L.; Miller, A.F. Steady state kinetic mechanism, stereospecificity, substrate and inhibitor specificity of *Enterobacter cloacae* nitroreductase. *Biochim. Biophys. Acta* **1998**, *1387*, 394–405. [[CrossRef](#)]
164. Nivinskas, H.; Staškevičienė, S.; Šarlauskas, J.; Koder, R.L.; Miller, A.F.; Čėnas, N. Two-electron reduction of quinones by *Enterobacter cloacae* NAD(P)H:nitroreductase: Quantitative structure-activity relationships. *Arch. Biochem. Biophys.* **2002**, *403*, 249–258. [[CrossRef](#)]
165. Yanto, Y.; Hall, M.; Bommarius, A.S. Nitroreductase from *Salmonella typhimurium*: Characterization and catalytic activity. *Org. Biomol. Chem.* **2010**, *8*, 1826–1832. [[CrossRef](#)]
166. Kobori, T.; Sasaki, H.; Lee, W.C.; Zenno, S.; Saigo, K.; Murphy, M.; Tanokura, M. Structure and site-directed mutagenesis of a flavoprotein from *Escherichia coli* that reduces nitrocompounds: Alteration of pyridine nucleotide binding by a single amino acid substitution. *J. Biol. Chem.* **2001**, *276*, 2816–2823. [[CrossRef](#)]
167. Yang, J.; Zhan, J.; Bai, J.; Liu, P.; Xue, Y.; Yang, Q. Residue Phe42 is critical for the catalytic activity of *Escherichia coli* major nitroreductase NfsA. *Biotechnol. Lett.* **2013**, *35*, 1693–1700. [[CrossRef](#)]
168. Williams, E.M. Development of Bacterial Nitroreductase Enzymes for Noninvasive Imaging in Cancer Gene Therapy. Ph.D. Thesis, Victoria University, Wellington, Australia, 2013.



169. Rich, M.H.; Sharrock, A.V.; Hall, K.R.; Ackerley, D.F.; MacKichan, J.K. Evaluation of NfsA-like nitroreductases from *Neisseria meningitidis* and *Bartonella henselae* for enzyme-prodrug therapy, targeted cellular ablation, and dinitrotoluene bioremediation. *Biotechnol. Lett.* **2018**, *40*, 359–367. [[CrossRef](#)] [[PubMed](#)]
170. Manina, G.; Bellinzoni, M.; Pasca, M.R.; Neres, J.; Milano, A.; Ribeiro, A.L.J.L.; Buroni, S.; Skovierova, H.; Dianiskova, P.; Mikusova, K.; et al. Biological and structural characterization of the *Mycobacterium smegmatis* nitroreductase NfnB, and its role in benzothiazinone resistance. *Mol. Microbiol.* **2010**, *77*, 1172–1185. [[CrossRef](#)]
171. Olekhovich, I.N.; Goodwin, A.; Hoffman, P.S. Characterization of the NAD(P)H oxidase and metronidazole reductase activities of the RdxA nitroreductase of *Helicobacter pylori*. *FEBS J.* **2009**, *276*, 3354–3364. [[CrossRef](#)] [[PubMed](#)]
172. Martinez-Júlvez, M.; Rojas, A.L.; Olekhovich, I.; Angarica, V.E.; Hoffman, P.S.; Sancho, J. Structure of RdxA—An oxygen-intensive nitroreductase essential for metronidazole activation in *Helicobacter pylori*. *FEBS J.* **2012**, *279*, 4306–4317. [[CrossRef](#)]
173. Sisson, G.; Goodwin, A.; Raudonikiene, A.; Hughes, N.J.; Mukhopadhyay, A.K.; Berg, D.E.; Hoffman, P.S. Enzymes associated with reductive activation and action of nitazoxanide, nitrofurans, and metronidazole in *Helicobacter pylori*. *Antimicrob. Agents Chemother.* **2002**, *46*, 2116–2123. [[CrossRef](#)]
174. Wilkinson, S.R.; Bot, C.; Kelly, J.M.; Hall, B.S. Trypanocidal activity of nitroaromatic prodrugs: Current treatments and future perspectives. *Curr. Top. Med. Chem.* **2011**, *11*, 2072–2084. [[CrossRef](#)]
175. Hall, B.S.; Bot, C.; Wilkinson, S.R. Nifurtimox activation by trypanosomal type I nitroreductase generates cytotoxic nitrile metabolites. *J. Biol. Chem.* **2011**, *286*, 130088–130095. [[CrossRef](#)] [[PubMed](#)]
176. Hall, B.S.; Meredith, E.L.; Wilkinson, S.R. Targeting the substrate preference of a tupe 1 nitroreductaseto develop antitypanosomal quinone-based prodrugs. *Antimicrob. Agents Chemother.* **2011**, *56*, 5821–5830. [[CrossRef](#)] [[PubMed](#)]
177. Voak, A.A.; Gobalakrishnapillai, V.; Seifert, K.; Balczo, E.; Hu, L.; Hall, B.S.; Wilkinson, S.R. An essential type I nitroreductase from *Leishmania major* can be used to activate leishmanicidal prodrugs. *J. Biol. Chem.* **2013**, *288*, 28466–28476. [[CrossRef](#)]
178. Wyllie, S.; Patterson, S.; Stojanovski, L.; Simeons, F.R.C.; Norval, S.; Kime, R.; Read, K.D.; Fairlamb, A.H. The anti-trypanosome drug fexinidazole shows potential for treating visceral leishmaniasis. *Sci. Transl. Med.* **2012**, *4*, 119re1. [[CrossRef](#)]
179. Wyllie, S.; Roberts, A.J.; Norval, S.; Patterson, S.; Foth, B.J.; Berriman, M.; Read, K.D.; Fairlamb, A.H. Activation of bicyclic nitro-drugs by a novel nitroreductase (NTR2) in *Leishmania*. *PloS Pathog.* **2016**, *12*, e1005971. [[CrossRef](#)] [[PubMed](#)]
180. Chaignon, P.; Cortial, S.; Ventura, A.P.; Lopes, P.; Halgand, F.; Laprevote, O.; Ouazzani, J. Purification and identification of a *Bacillus* nitroreductase: Potential use in 3,5-DNBTF biosensing system. *Enzyme Microb. Technol.* **2006**, *39*, 1499–1506. [[CrossRef](#)]
181. Crofts, T.S.; Sontha, P.; King, A.O.; Wang, B.; Biddu, B.A.; Zanolli, N.; Gaumnitz, J.; Dantas, G. Discovery and characterization of a nitroreductase capable of conferring bacterial resistance to chloramphenicol. *Cell Chem. Biol.* **2019**, *26*, 559–570. [[CrossRef](#)]
182. Gurumurthy, M.; Mukherjee, T.; Dowd, C.; Singh, R.; Niyomrattanakit, P.; Tay, J.A.; Nayar, A.; Lee, Y.S.; Cherian, S.; Boshoff, H.I.; et al. Substrate specificity of the deazaflavin-dependent nitroreductase from *Mycobacterium tuberculosis* responsible for the bioactivation of bicyclic nitroimidazoles. *FEBS J.* **2012**, *279*, 113–125. [[CrossRef](#)]
183. Guise, C.P.; Abbattista, M.R.; Singleton, R.S.; Holford, S.D.; Connolly, J.; Dachs, G.U.; Fox, S.B.; Pollock, R.; Harvey, J.; Guilford, P.; et al. The bioreductive prodrug PR-104A is activated under aerobic conditions by human aldo-keto reductase 1C3. *Cancer Res.* **2010**, *70*, 1573–1584. [[CrossRef](#)]
184. Williams, C.H., Jr. Lipoamide dehydrogenase, glutathione reductase, thioredoxin reductase, and mercuric ion reductase—A family of flavoenzyme transhydrogenases. In *Chemistry and Biochemistry of Flavoenzymes*, 2nd ed.; Miiller, F., Ed.; CRC Press: Boca Raton, FL, USA, 1992; Volume 3, pp. 121–211.
185. Argyrou, A.; Blanchard, J.S. Flavoprotein disulfide reductases: Advances in chemistry and function. *Prog. Nucleic Acid Res. Mol. Biol.* **2004**, *78*, 89–142.
186. Nauser, T.; Dockheer, S.; Kissner, R.; Koppenol, W.H. Catalysis of electron transfer by selenocysteine. *Biochemistry* **2006**, *45*, 6038–6043. [[CrossRef](#)]
187. Karplus, P.; Pai, E.F.; Schulz, G.E. A crystallographic study of the glutathione binding site of glutathione reductase at 0.3-nm resolution. *Eur. J. Biochem.* **1989**, *178*, 693–703. [[CrossRef](#)]
188. Kuriyan, J.; Kong, X.; Krishna, T.; Sweet, R.; Murgolo, N.; Field, H.; Cerami, A.; Henderson, G. X-ray structure of trypanothione reductase from *Crithidia fasciculata* at 2.4-Å resolution. *Proc. Natl. Acad. Sci. USA* **1991**, *88*, 8764–8768. [[CrossRef](#)] [[PubMed](#)]
189. Sarma, G.N.; Savvides, S.N.; Becker, K.; Schirmer, M.; Schirmer, R.H.; Karplus, P.A. Glutathione reductase of the malarial parasite *Plasmodium falciparum*: Crystal structure and inhibitor development. *J. Mol. Biol.* **2003**, *328*, 893–907. [[CrossRef](#)]
190. Sullivan, F.X.; Sobolov, S.B.; Bradley, M.; Walsh, C.T. Mutational analysis of parasite tripanothione reductase: Acquisition of glutathione reductase activity in triple mutant. *Biochemistry* **1991**, *30*, 2761–2767. [[CrossRef](#)] [[PubMed](#)]
191. Krauth-Siegel, R.L.; Ender, S.B.; Henderson, G.B.; Fairamb, A.H.; Schirmer, R.H. Trypanothione reductase from *Trypanosoma cruzi*. Purification and characterization of the crystalline enzyme. *Eur. J. Biochem.* **1987**, *164*, 123–128. [[CrossRef](#)] [[PubMed](#)]
192. Čenas, N.K.; Arscott, D.; Williams, C.H., Jr.; Blanchard, J.S. Mechanism of reduction of quinones by *Trypanosoma congolense* trypanothione reductase. *Biochemistry* **1994**, *33*, 2509–2515. [[CrossRef](#)]
193. Veine, D.; Arscott, L.; Williams, C.H., Jr. Redox potentials for yeast, *Escherichia coli* and human glutathione reductase relative to the NAD<sup>+</sup>/NADH redox couple: Enzyme forms active in catalysis. *Biochemistry* **1998**, *37*, 15575–15582. [[CrossRef](#)]

194. Salmon-Chemin, L.; Buisine, E.; Yardley, V.; Kohler, S.; Debreu, M.A.; Ladry, V.; Sergheraert, C.; Croft, S.L.; Krauth-Siegel, R.L.; Davioud-Charvet, E. 2- And 3-substituted 1,4-naphthoquinone derivatives as subversive substrates of trypanothione reductase and lipoamide dehydrogenase from *Trypanosoma cruzi*: Synthesis and correlation between redox cycling activities and in vitro cytotoxicity. *J. Med. Chem.* **2001**, *44*, 548–565. [[CrossRef](#)] [[PubMed](#)]
195. Marozienė, A.; Lesanavičius, M.; Davioud-Charvet, E.; Aliverti, A.; Grellier, P.; Šarlauskas, J.; Čėnas, N. Antiplasmodial activity of nitroaromatic compounds: Correlation with their reduction potential and inhibitory action on *Plasmodium falciparum* glutathione reductase. *Molecules* **2019**, *24*, 4509. [[CrossRef](#)]
196. Bulger, J.E.; Brandt, K.G. Yeast glutathione reductase. II. Interaction of dinucleotide phosphate. *J. Biol. Chem.* **1971**, *246*, 5578–5587. [[CrossRef](#)]
197. Böhme, C.C.; Arscott, L.D.; Becker, K.; Schirmer, R.H.; Williams, C.H., Jr. Kinetic characterization of glutathione reductase from malarial parasite *Plasmodium falciparum*. Comparison with the human enzyme. *J. Biol. Chem.* **2000**, *275*, 37317–37323. [[CrossRef](#)]
198. Zheng, R.J.; Čėnas, N.; Blanchard, J.S. Catalytic and potentiometric characterization of E201 and E201Q mutants of *Trypanosoma congolense* trypanothione reductase. *Biochemistry* **1995**, *34*, 12697–12703. [[CrossRef](#)]
199. Henderson, G.B.; Ulrich, P.; Fairlamb, A.H.; Rosenberg, I.; Pereira, M.; Sela, M.; Cerami, A. “Subversive” substrates of the enzyme trypanothione disulfide reductase: Alternative approach to chemotherapy of Chagas disease. *Proc. Natl. Acad. Sci. USA* **1988**, *85*, 5374–5378. [[CrossRef](#)] [[PubMed](#)]
200. Čėnas, N.; Bironaitė, D.; Dičkanaitė, E.; Anusevičius, Ž.; Šarlauskas, J.; Blanchard, J.S. Chinifur, a selective inhibitor and subversive substrate for *Trypanosoma congolense* trypanothione reductase. *Biochem. Biophys. Res. Commun.* **1994**, *204*, 224–229. [[CrossRef](#)]
201. Čėnas, N.K.; Bironaitė, D.A.; Kulys, J.J.; Sukhova, N.M. Interaction of nitrofurans with glutathione reductase. *Biochim Biophys. Acta* **1991**, *1073*, 195–199.
202. Bauer, H.; Fritz-Wolf, K.; Winzer, A.; Kühner, S.; Little, S.; Yardley, V.; Vezin, H.; Palfey, B.; Schirmer, R.H.; Davioud-Charvet, E. A fluoro analogue of the menadione derivative 6-[2'-(3'-methyl)-1',4'-naphthoquinolyl]hexanoic acid is a suicide substrate of glutathione reductase. Crystal structure of the alkylated human enzyme. *J. Am. Chem. Soc.* **2006**, *23*, 10784–10794. [[CrossRef](#)]
203. Blumenstiel, K.; Schöneck, R.; Yardley, V.; Croft, S.L.; Krauth-Siegel, R.L. Nitrofurans as common subversive substrates of *Trypanosoma cruzi* lipoamide dehydrogenase and lipoamide dehydrogenase. *Biochem. Pharmacol.* **1999**, *58*, 1791–1799. [[CrossRef](#)]
204. Taylor, M.C.; Kelly, J.M.; Chapman, C.J.; Fairlamb, A.H.; Miles, M.A. The structure, organization, and expression of the *Leishmania donovani* gene encoding trypanothione reductase. *Mol. Biochem. Parasitol.* **1994**, *64*, 293–301. [[CrossRef](#)]
205. Belorgey, D.; Lanfranchi, D.A.; Davioud-Charvet, E. 1,4-Naphthoquinones and other NADPH-dependent glutathione reductase-catalyzed redox cyclers as antimalarial agents. *Curr. Pharm. Des.* **2013**, *19*, 2512–2528. [[CrossRef](#)]
206. Vienožinskis, J.; Butkus, A.; Čėnas, N.; Kulys, J. The mechanism of quinone reductase reaction of pig heart lipoamide dehydrogenase. *Biochem. J.* **1990**, *269*, 101–105. [[CrossRef](#)]
207. Tsai, C.S. Nitroreductase activity of heart lipoamide dehydrogenase. *Biochem. J.* **1987**, *242*, 447–452. [[CrossRef](#)]
208. Argyrou, A.; Sun, G.; Palfey, B.A.; Blanchard, J.S. Catalysis of diaphorase reactions by *Mycobacterium tuberculosis* lipoamide dehydrogenase occurs at the EH<sub>4</sub> level. *Biochemistry* **2003**, *42*, 2218–2228. [[CrossRef](#)]
209. Arner, E.S.; Holmgren, A. Physiological function of thioredoxin and thioredoxin reductase. *Eur. J. Biochem.* **2000**, *267*, 6102–6109. [[CrossRef](#)]
210. Florencio, F.; Yee, B.; Johnson, T.; Buchanan, B.B. An NADP/thioredoxin system in leaves: Purification and characterization of NADP-thioredoxin reductase and thioredoxin h from spinach. *Arch. Biochem. Biophys.* **1988**, *266*, 496–507. [[CrossRef](#)]
211. Meyer, Y.; Buchanan, B.B.; Vignols, F.; Reichheld, J.P. Thioredoxins and glutaredoxins: Unifying elements in redox biology. *Annu. Rev. Genet.* **2009**, *43*, 335–367. [[CrossRef](#)]
212. Lincoln, D.T.; Ali Emadi, E.M.; Tonissen, K.F.; Clarke, F.M. The thioredoxin-thioredoxin reductase system: Over-expression in human cancer. *Anticancer Res.* **2003**, *23*, 2425–2433.
213. Arscott, L.; Gromer, S.; Schirmer, R.; Becker, K.; Williams, C.H., Jr. The mechanism of thioredoxin reductase from human placenta is similar to the mechanisms of lipoamide dehydrogenase and glutathione reductase and is distinct from the mechanism of thioredoxin reductase from *Escherichia coli*. *Proc. Natl. Acad. Sci. USA* **1997**, *94*, 3621–3626. [[CrossRef](#)]
214. Sandalova, T.; Zhong, L.; Lindqvist, Y.; Holmgren, A.; Schneider, G. Three-dimensional structure of a mammalian thioredoxin reductase: Implications of mechanism and evolution of a selenocysteine-dependent enzyme. *Proc. Natl. Acad. Sci. USA* **2001**, *98*, 9533–9538. [[CrossRef](#)]
215. Čėnas, N.; Nivinskas, H.; Anusevičius, Ž.; Šarlauskas, J.; Lederer, F.; Arner, E.S.J. Interactions of quinones with thioredoxin reductase: A challenge to the antioxidant role of the mammalian selenoprotein. *J. Biol. Chem.* **2004**, *279*, 2583–2592. [[CrossRef](#)]
216. Čėnas, N.; Prast, S.; Nivinskas, H.; Šarlauskas, J.; Arner, E.S.J. Interactions of nitroaromatic compounds with the mammalian selenoprotein thioredoxin reductase and the relation to induction of apoptosis in human cancer cells. *J. Biol. Chem.* **2006**, *281*, 5593–5603. [[CrossRef](#)]
217. Millet, R.; Urig, S.; Jacob, J.; Amtmann, E.; Moulinoux, J.P.; Gromer, S.; Becker, K.; Davioud-Charvet, E. Synthesis of 5-nitro-2-furancarbohydrazides and their cis-diamminedichloroplatinum complexes as bitopic and irreversible human thioredoxin reductase inhibitors. *J. Med. Chem.* **2005**, *48*, 7024–7039. [[CrossRef](#)]
218. Nordberg, J.; Arnér, E.S. Reactive oxygen species, antioxidants, and the mammalian thioredoxin system. *Free. Radic. Biol. Med.* **2001**, *31*, 1287–1312. [[CrossRef](#)]

219. Stafford, W.C.; Peng, X.; Olofsson, M.H.; Zhang, X.; Luci, D.K.; Lu, L.; Cheng, Q.; Tresauges, L.; Dexheimer, T.S.; Coussens, N.P.; et al. Irreversible inhibition of cytosolic thioredoxin reductase 1 as a mechanistic basis for anticancer therapy. *Sci. Transl. Med.* **2018**, *10*, eaaf7444. [CrossRef]
220. Gencheva, R.; Cheng, Q.; Arner, E.S.J. Efficient selenocysteine-dependent reduction of toxoflavin by mammalian thioredoxin reductase. *Biochim. Biophys. Acta* **2018**, *1862*, 2511–2517. [CrossRef]
221. Wang, P.F.; Arscott, L.D.; Gilberger, T.W.; Müller, S.; Williams, C.H., Jr. Thioredoxin reductase from *Plasmodium falciparum*: Evidence for interaction between the C-terminal cysteine residues and the active site disulfide-dithiol. *Biochemistry* **1999**, *38*, 3187–3196. [CrossRef] [PubMed]
222. Morin, C.; Besset, T.; Moutet, J.C.; Fayolle, M.; Brückner, M.; Limosin, D.; Becker, K.; Davioud-Charvet, E. The aza-analogues of 1,4-naphthoquinones are potent substrates and inhibitors of plasmodial thioredoxin and glutathione reductase and of human erythrocyte glutathione reductase. *Org. Biomol. Chem.* **2008**, *6*, 2731–2742. [CrossRef]
223. O'Donnell, M.E.; Williams, C.H., Jr. Graphical analysis of interactions between oxidation-reduction sites in two site oxidation-reduction proteins. *Anal. Biochem.* **1984**, *136*, 235–246. [CrossRef]
224. Williams, C.H., Jr. Mechanism and structure of thioredoxin reductase from *Escherichia coli*. *FASEB J.* **1995**, *13*, 1267–1276. [CrossRef]
225. Lennon, B.W.; Williams, C.H., Jr. Reductive half-reaction of thioredoxin reductase from *Escherichia coli*. *Biochemistry* **1997**, *36*, 9464–9477. [CrossRef]
226. Mulrooney, S.; Williams, C.H., Jr. Evidence for two conformational states of thioredoxin reductase from *Escherichia coli*: Use of intrinsic and extrinsic quenchers of flavin fluorescence as probes to observe domain rotation. *Protein Sci.* **1997**, *6*, 2188–2195. [CrossRef]
227. Zanetti, G.; Williams, C.H., Jr.; Massey, V. Influence of photoirradiation on the oxidation-reduction state of thioredoxin reductase. *J. Biol. Chem.* **1968**, *243*, 4013–4019. [CrossRef]
228. Dai, S.; Saarinen, M.; Ramaswami, S.; Meyer, Y.; Jacquot, J.-P.; Eklund, H. Crystal structure of *Arabidopsis thaliana* NADPH dependent thioredoxin reductase at 2.5 Å resolution. *J. Mol. Biol.* **1996**, *264*, 1044–1057. [CrossRef] [PubMed]
229. Bironaitė, D.; Anusevičius, Ž.; Jacquot, J.-P.; Čėnas, N. Interaction of quinones with *Arabidopsis thaliana* thioredoxin reductase. *Biochim. Biophys. Acta* **1998**, *1383*, 82–92. [CrossRef]
230. Miškinienė, V.; Šarlauskas, J.; Jacquot, J.-P.; Čėnas, N. Nitroreductase reactions of *Arabidopsis thaliana* thioredoxin reductase. *Biochim. Biophys. Acta* **1998**, *1366*, 275–283. [CrossRef]
231. Yang, X.; Ma, K. Characterization of a thioredoxin-thioredoxin reductase system from the hyperthermophilic bacterium *Thermotoga maritima*. *J. Bacteriol.* **2010**, *192*, 1370–1376. [CrossRef]
232. Valiauga, B.; Rouhier, N.; Jacquot, J.-P.; Čėnas, N. Quinone- and nitroreductase reactions of *Thermotoga maritima* thioredoxin reductase. *Acta Biochim. Pol.* **2015**, *62*, 303–309. [CrossRef]
233. Valiauga, B.; Rouhier, N.; Jacquot, J.-P.; Čėnas, N. Characterization of redox properties of FAD cofactor of *Thermotoga maritima* thioredoxin reductase. *Chemija* **2020**, *31*, 191–195. [CrossRef]
234. Leitsch, D.; Kolarich, D.; Binder, M.; Stadlmann, J.; Altmann, F.; Duchêne, M. *Trichomonas vaginalis*: Metronidazole and other nitroimidazole drugs are reduced by the flavin enzyme thioredoxin reductase and disrupt the cellular redox system. Implication for nitroimidazole toxicity and resistance. *Mol. Microbiol.* **2009**, *72*, 518–536. [CrossRef]
235. Leitsch, D.; Müller, J.; Müller, N. Evaluation of *Giardia lamblia* thioredoxin reductase as drug activating enzyme and as drug target. *Int. J. Parasitol. Drug Resist.* **2016**, *6*, 148–153. [CrossRef]
236. Jönsson, T.J.; Ellis, H.R.; Poole, L.B. Cysteine reactivity and thiol-disulfide interchange pathways in AhpF and AhpC of the bacterial alkyl hydroperoxide reductase system. *Biochemistry* **2007**, *46*, 5709–5721. [CrossRef]
237. Le, V.V.H.; Davies, I.G.; Moon, C.D.; Wheeler, D.; Biggs, P.J.; Rakonjac, J. Novel 5-nitrofuranyl-activating reductase of *Escherichia coli*. *Antimicrob. Agents Chemother.* **2019**, *63*, e00868-19. [CrossRef] [PubMed]
238. Adams, G.E.; Clarke, E.D.; Jacobs, R.S.; Stratford, I.J.; Wallace, R.G.; Wardman, P.; Watts, M.E. Mammalian cell toxicity of nitro compounds: Dependence upon reduction potential. *Biochem. Biophys. Res. Commun.* **1976**, *72*, 824–829. [CrossRef]
239. Adams, G.E.; Clarke, E.D.; Gray, P.; Jacobs, R.S.; Stratford, I.J.; Wardman, P.; Watts, M.E.; Parrick, J.; Wallace, R.G.; Smithen, C.E. Structure-activity relationships in the development of hypoxic cell radiosensitizers. II. Cytotoxicity and therapeutic ratio. *Int. J. Radiat. Biol.* **1979**, *35*, 151–160.
240. Miškinienė, V.; Sergedienė, E.; Nemeikaitė, A.; Segura-Aguilar, J.; Čėnas, N. Role of redox cycling and activation by DT-diaphorase in cytotoxicity of 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB-1954) and its analogs. *Cancer Lett.* **1999**, *146*, 217–222. [CrossRef]
241. Miliukienė, V.; Čėnas, N. Cytotoxicity of nitroaromatic explosives and their biodegradation products in mice splenocytes: Implications for their immunotoxicity. *Z. Naturforsch. C* **2008**, *63*, 519–525. [CrossRef]
242. Wilson, W.R.; Anderson, R.F.; Denny, W.A. Hypoxia-selective antitumor agents. 1. Relationships between structure, redox properties and hypoxia-selective cytotoxicity for 4-substituted derivatives of nitracrine. *J. Med. Chem.* **1989**, *32*, 23–30. [CrossRef] [PubMed]
243. Čėnas, N.; Nemeikaitė-Čėnienė, A.; Sergedienė, E.; Nivinskas, H.; Anusevičius, Ž.; Šarlauskas, J. Quantitative structure-activity relationships in enzymatic single-electron reduction of nitroaromatic explosives: Implications for their cytotoxicity. *Biochim. Biophys. Acta* **2001**, *1528*, 31–38. [CrossRef]
244. Šarlauskas, J.; Nemeikaitė-Čėnienė, A.; Anusevičius, Ž.; Misevičienė, L.; Marozienė, A.; Markevičius, A.; Čėnas, N. Enzymatic redox properties of novel nitrotriazole explosives: Implications for their toxicity. *Z. Naturforsch. C* **2004**, *59*, 399–404. [CrossRef]



245. Šarlauskas, J.; Nemeikaitė-Čėnienė, A.; Anusevičius, Ž.; Misevičienė, L.; Martines-Julvez, M.M.; Medina, M.; Gomez-Moreno, C.; Čėnas, N. Flavoenzyme-catalyzed redox cycling of hydroxylamino and amino metabolites of 2,4,6-trinitrotoluene for their cytotoxicity. *Arch. Biochem. Biophys.* **2004**, *425*, 184–192. [[CrossRef](#)]
246. Nemeikaitė-Čėnienė, A.; Šarlauskas, J.; Misevičienė, L.; Anusevičius, Ž.; Marozienė, A.; Čėnas, N. Enzymatic redox reactions of explosive 4,6-dinitrobenzofuran (DNBF): Implications for its toxic action. *Acta Biochim. Pol.* **2004**, *51*, 1081–1086.
247. Cabanillas Stanchi, K.M.; Bruchelt, G.; Handgretinger, R.; Holzer, U. Nifurtimox reduces N-Myc expression and aerobic glycolysis in neuroblastoma. *Cancer Biol. Ther.* **2015**, *16*, 1353–1363. [[CrossRef](#)]
248. Du, M.; Zhang, L.; Scorsone, K.A.; Woodfield, S.E.; Zage, P.E. Nifurtimox is effective against tumour cells and is synergistic with buthionine sulfoximine. *Sci. Rep.* **2016**, *6*, 27458. [[CrossRef](#)]
249. Siim, B.G.; Atwell, G.J.; Anderson, R.F.; Wardman, P.; Pullen, S.M.; Wilson, W.R.; Denny, W.A. Hypoxia-selective antitumor agents. 15. Modification of rate of nitroreduction and extent of lysosomal uptake by polysubstitution of 4-(alkylamino)-5-nitroquinoline bioreductive drugs. *J. Med. Chem.* **1997**, *40*, 1381–1390. [[CrossRef](#)]
250. Tercel, M.; Wilson, W.R.; Anderson, R.F.; Denny, W.A. Hypoxia-selective antitumor agents. 12. Nitrobenzyl quaternary salts as bioreductive prodrug of the alkylating agent mechlorethamine. *J. Med. Chem.* **1996**, *39*, 1084–1094. [[CrossRef](#)]
251. Naylor, M.A.; Stephens, M.A.; Cole, S.; Threadgill, M.D.; Stratford, I.J.; O'Neill, P.; Fielden, E.M.; Adams, G.E. Synthesis and evaluation of novel electrophilic nitrofurans carboxamides and carboxylates as radiosensitizers and bioreductively activated cytotoxins. *J. Med. Chem.* **1990**, *33*, 2508–2513. [[CrossRef](#)]
252. Naylor, M.A.; Stephens, M.A.; Stratford, I.J.; Keohane, A.; O'Neill, P.; Threadgill, M.D.; Webb, P.; Fielden, E.M.; Adams, G.E. Aziridinyl nitropyrroles and nitropyrazoles as hypoxia-selective cytotoxins and radiosensitizers. *Anticancer Drug Des.* **1991**, *6*, 151–167.
253. Threadgill, M.D.; Webb, P.; O'Neill, P.; Naylor, M.A.; Stephens, M.A.; Stratford, I.J.; Cole, S.; Adams, G.E.; Fielden, E.M. Synthesis of a series of nitrothiophenes with basic or electrophilic substituents and evaluation as radiosensitizers and as bioreductively activated cytotoxins. *J. Med. Chem.* **1991**, *34*, 2112–2120. [[CrossRef](#)]
254. Adams, G.E.; Ahmed, I.; Clarke, E.D.; O'Neill, P.; Parrick, J.; Stratford, I.J.; Wallace, R.G.; Wardman, P.; Watts, M.E. Structure-activity relationships in the development of hypoxic cell radiosensitizers. *Int. J. Radiat. Biol.* **1980**, *38*, 613–626. [[CrossRef](#)]
255. Wang, J.; Guise, C.P.; Dachs, G.U.; Phung, Y.; Lambie, N.K.; Patterson, A.V.; Wilson, W.R. Identification of one-electron reductases that activate both the hypoxia prodrug SN30000 and diagnostic probe EF5. *Biochem. Pharmacol.* **2014**, *91*, 436–446. [[CrossRef](#)]
256. Hunter, F.W.; Wouters, B.G.; Wilson, W.R. Hypoxia-activated prodrugs: Paths forward in the era of personalized medicine. *Br. J. Cancer* **2016**, *114*, 1071–1077. [[CrossRef](#)]
257. Finn, R.D.; Basran, J.; Roitel, O.; Wolf, C.R.; Munro, A.W.; Paine, M.J.I.; Scrutton, N.S. Determination of the redox potentials and electron transfer properties of the FAD- and FMN-binding domains of the human oxidoreductase NR1. *Eur. J. Biochem.* **2003**, *270*, 1164–1175. [[CrossRef](#)]
258. Wolthers, K.R.; Basran, J.; Munro, A.W.; Scrutton, N.S. Molecular dissection of human methionine synthase-reductase: Determination of the flavin redox potentials in full-length enzyme and isolated flavin-binding domains. *Biochemistry* **2003**, *42*, 3911–3920. [[CrossRef](#)] [[PubMed](#)]
259. Hunter, W.F.; Devaux, J.B.L.; Meng, F.; Hong, C.R.; Khan, A.; Tsai, P.; Ketela, T.W.; Sharma, I.; Kakadia, P.M.; Marastoni, S.; et al. Functional CRISPR and shRNA screens identify involvement of mitochondrial electron transport in the activation of evofosfamide. *Mol. Pharmacol.* **2019**, *95*, 638–651. [[CrossRef](#)] [[PubMed](#)]
260. Helsby, N.A.; Wheeler, S.J.; Pruijn, F.B.; Palmer, B.D.; Yang, S.; Denny, W.A.; Wilson, W.R. Effect of nitroreduction on the alkylating reactivity and cytotoxicity of the 2,4-dinitrobenzamide-5-aziridine CB 1954 and the corresponding nitrogen mustard SN 23862: Distinct mechanisms of bioreductive activation. *Chem. Res. Toxicol.* **2003**, *16*, 469–478. [[CrossRef](#)]
261. Wilson, W.R.; Stribbling, S.M.; Pruijn, F.B.; Syddall, S.P.; Petterson, A.V.; Liyanage, H.D.S.; Smith, E.; Botting, K.J.; Tercel, M. Nitro-chloromethylbenzindolines: Hypoxia-activated prodrugs of potent adenine N<sub>3</sub> DNA minor groove alkylators. *Mol. Cancer Ther.* **2009**, *8*, 2903–2913. [[CrossRef](#)] [[PubMed](#)]
262. Rabbani, G.; Ahmad, E.; Zaidi, N.; Fatima, S.; Khan, R.H. pH-Induced molten globule state of *Rhizopus niveus* lipase is more resistant against thermal and chemical denaturation than its native state. *Cell Biochem. Biophys.* **2012**, *62*, 487–499. [[CrossRef](#)]
263. Copp, J.N.; Mowday, A.M.; Williams, E.M.; Guise, C.P.; Ashoorzadeh, A.; Sharrock, A.V.; Flanagan, J.U.; Smaill, J.B.; Patterson, A.V.; Ackerley, D.F. Engineering a multifunctional nitroreductase for improved activation of prodrugs and PET probes for cancer gene therapy. *Cell Chem. Biol.* **2017**, *24*, 391–403. [[CrossRef](#)]
264. Williams, E.M.; Rich, M.H.; Mowday, A.M.; Ashoorzadeh, A.; Copp, J.N.; Guise, C.P.; Anderson, R.F.; Flanagan, J.H.; Smaill, J.B.; Patterson, A.V.; et al. Engineering *Escherichia coli* NfsB to activate a hypoxia-resistant analogue of the PET probe EF5 to enable non-invasive imaging during enzyme prodrug therapy. *Biochemistry* **2019**, *58*, 3700–3710. [[CrossRef](#)]
265. Dai, C.; Li, D.; Gong, L.; Xiao, X.; Tang, S. Curcumin ameliorates furazolidone-induced DNA damage and apoptosis in human hepatocyte LO2 cells by inhibiting ROS production and mitochondrial pathway. *Molecules* **2016**, *21*, 1061. [[CrossRef](#)] [[PubMed](#)]
266. Zhang, C.; Liu, K.; Yao, K.; Reddy, K.; Fu, Y.; Yang, G.; Zykova, T.A.; Shin, S.H.; Li, H.; Ryu, J.; et al. HOI-O2 induces apoptosis and G2-M arrest in esophageal cancer mediated by ROS. *Cell Death Dis.* **2015**, *6*, e1912. [[CrossRef](#)] [[PubMed](#)]
267. Deng, S.; Tang, S.; Zhang, S.; Zhang, C.; Wang, C.; Zhou, Y.; Dai, C.; Xiao, X. Furazolidone induces apoptosis through activating reactive oxygen species-dependent mitochondrial signaling pathway and suppressing P13K/Akt signaling pathway in HepG2 cells. *Food Chem. Toxicol.* **2015**, *75*, 173–186. [[CrossRef](#)] [[PubMed](#)]

268. Thomas, C.; Gwenin, C.D. The role of nitroreductases in resistance to nitroimidazoles. *Biology* **2021**, *10*, 388. [[CrossRef](#)] [[PubMed](#)]
269. Yi, X.; Zhang, X.; Leong, H.; Shin, Y.M.; Park, D.H.; You, S.; Kim, D.-K. A novel bispidinone analog induces S-phase cell cycle arrest and apoptosis in HeLa human cervical carcinoma cells. *Oncol. Rep.* **2015**, *33*, 1526–1532. [[CrossRef](#)]
270. Zhang, S.; Zhou, L.; Hong, B.; van den Heuvel, P.J.; Prabhu, V.V.; Warfel, N.A.; Kline, C.L.B.; Dicker, D.T.; Kopelovich, L.; El-Deiry, W. Small-molecule NSC59984 restores p53 pathway signaling and antitumor effects against colorectal cancer via p73 activation and degradation of mutant p53. *Cancer Res.* **2015**, *75*, 3842–3852. [[CrossRef](#)]
271. Su, J.-G.J.; Liao, P.-J.; Huang, M.-C.; Chu, M.-C.; Lin, S.-C.; Chang, Y.-J. Aldo-keto reductase 1C2 is essential for 1-nitropyrene's but not for benzo[a]pyrene's induction of p53 phosphorylation and apoptosis. *Toxicology* **2008**, *244*, 257–270. [[CrossRef](#)]
272. Lee, Y.S.; Yoon, H.J.; Oh, J.H.; Park, H.J.; Lee, E.H.; Song, C.W.; Yoon, S. 1,3-Dinitrobenzene induces apoptosis in TM4 mouse Sertoli cells: Involvement of the c-Jun N-terminal kinase (JNK) MAPK pathway. *Toxicol. Lett.* **2009**, *189*, 145–151. [[CrossRef](#)] [[PubMed](#)]
273. Nelson, E.A.; Walker, S.R.; Kepich, A.; Gashin, L.B.; Hideshima, T.; Ikeda, H.; Chauhan, D.; Anderson, K.C.; Frank, D.A. Nifuroxazide inhibits survival of multiple myeloma cells by directly inhibiting STAT3. *Blood* **2008**, *112*, 5095–5102. [[CrossRef](#)]
274. Andrade, J.K.E.; Souza, M.I.F.; Gomes Filho, M.A.; Silva, D.M.F.; Barros, A.L.S.; Rodrigues, M.D.; Silva, P.B.N.; Nascimento, S.C.; Aguiar, J.S.; Brondani, D.J.; et al. N-pentyl-nitrofurantoin induces apoptosis in HL-60 leukemia cell line by upregulating BAX and downregulating BCL-xL gene expression. *Pharmacol. Rep.* **2016**, *68*, 1046–1053. [[CrossRef](#)]
275. Tseng, C.-H.; Tzeng, C.-C.; Chio, C.-C.; Hsu, C.-Y.; Chou, C.-K.; Chen, Y.-L. Discovery of 2-[2-(5-nitrofuran-2-yl)vinyl] quinoline derivatives as a novel type of antimetastatic agents. *Bioorg. Med. Chem.* **2015**, *23*, 141–148. [[CrossRef](#)]
276. Yang, F.; Hu, M.; Lei, Q.; Xia, Y.; Zhu, Y.; Song, X.; Li, Y.; Lie, H.; Liu, C.; Xiong, Y.; et al. Nifuroxazide induces apoptosis and impairs pulmonary metastasis in breast cancer model. *Cell Death Dis.* **2015**, *6*, e1701. [[CrossRef](#)] [[PubMed](#)]
277. Palmer, D.H.; Milner, A.E.; Kerr, D.J.; Young, L.S. Mechanism of cell death induced by the novel enzyme-prodrug combination, nitroreductase/CB1954, and identification of synergism with 5-fluorouracil. *Br. J. Cancer* **2003**, *89*, 944–950. [[CrossRef](#)]
278. Song, L.; Wang, Y.; Wang, J.; Yang, F.; Li, X.; Wu, Y. Trinitrotoluene induces endoplasmic reticulum stress and apoptosis in HePG2 cells. *Med. Sci. Monit.* **2015**, *21*, 3434–3441. [[CrossRef](#)] [[PubMed](#)]
279. Zou, M.; Duan, Y.; Wang, P.; Gao, R.; Chen, X.; Ou, Y.; Liang, M.; Wang, L.; Zhu, H. DYT-40, a novel synthetic 2-styryl-5-nitroimidazole derivative, blocks malignant glioblastoma growth and invasion by inhibiting AEG-1 and NF- $\kappa$ B signaling pathway. *Sci. Rep.* **2016**, *6*, 27331. [[CrossRef](#)]
280. Saulnier Sholler, G.L.; Brand, L.; Straub, J.A.; Dorf, L.; Illeyne, S.; Koto, K.; Kalkunte, S.; Bosenberg, M.; Ashikaga, T.; Nishi, R. Nifurtimox induces apoptosis of neuroblastoma cells in vitro and in vivo. *J. Pediatr. Hematol. Oncol.* **2009**, *31*, 187–193. [[CrossRef](#)]
281. Hof, H.; Ströder, J.; Buisson, J.P.; Royer, R. Effect of different nitroheterocyclic compounds on aerobic, microaerophilic, and anaerobic bacteria. *Antimicrob. Agents Chemother.* **1986**, *30*, 679–683. [[CrossRef](#)]
282. Hof, H.; Chakraborty, T.; Royer, R.; Buisson, J.P. Mode of action of nitro-heterocyclic compounds on *Escherichia coli*. *Drugs Exp. Clin. Res.* **1987**, *13*, 635–639. [[PubMed](#)]
283. Olive, P.L. Correlation between metabolic reduction rates and electron affinity of nitroheterocycles. *Cancer Res.* **1979**, *39*, 4512–4515.
284. Reynolds, A.V. The activity of nitro-compounds against *Bacteroides fragilis* is related to their electron affinity. *J. Antimicrob. Chemother.* **1981**, *8*, 91–99. [[CrossRef](#)]
285. Rabbani, G.; Ahmad, E.; Khan, M.V.; Ashraf, M.T.; Bhat, R.; Khan, R.H. Impact of structural stability of cold adapted *Candida antarctica* lipase B (CaLB): In relation to pH, chemical and thermal denaturation. *RSC Adv.* **2015**, *5*, 20115–20131. [[CrossRef](#)]
286. Müller, M. Reductive activation of nitroimidazoles in anaerobic microorganisms. *Biochem. Pharmacol.* **1986**, *35*, 37–41. [[CrossRef](#)]
287. Olekhnovich, I.N.; Vitko, S.; Valliere, M.; Hoffman, P.S. Response to metronidazole and oxidative stress is mediated through homeostatic regulator HsrA (HP 1043) in *Helicobacter pylori*. *J. Bacteriol.* **2014**, *196*, 729–739. [[CrossRef](#)] [[PubMed](#)]
288. Trend, M.A.; Jorgensen, M.A.; Hazell, S.L.; Mendz, G.L. Oxidases and reductases are involved in metronidazole sensitivity in *Helicobacter pylori*. *Int. J. Biochem. Cell Biol.* **2001**, *33*, 143–153. [[CrossRef](#)]
289. Salillas, S.; Alias, M.; Michel, V.; Mahia, A.; Lucia, A.; Rodriguez, L.; Bueno, J.; Galano-Frutos, J.J.; De Reuse, H.; Velazquez-Campoy, A.; et al. Design, synthesis, and efficacy testing of nitroethylene- and 7-nitrobenzoxadiazol-based flavodoxin inhibitors against *Helicobacter pylori* drug-resistant clinical strains and in *Helicobacter pylori*-infected mice. *J. Med. Chem.* **2019**, *62*, 6102–6115. [[CrossRef](#)]
290. Lopes-Oliveira, L.A.P.; Fantinati, M.; Da-Cruz, A.M. In vitro-induction of metronidazole-resistant *Giardia duodenalis* is not associated with nucleotide alterations in the genes involved in pro-drug activation. *Mem. Inst. Oswaldo Cruz* **2020**, *115*, e200303. [[CrossRef](#)]
291. Müller, J.; Heller, M.; Uldry, A.C.; Braga, S.; Müller, N. Nitroreductase activities in *Giardia lamblia*: ORF 17150 encodes a quinone reductase with nitroreductase activity. *Pathogens* **2021**, *10*, 129. [[CrossRef](#)]
292. Papadopoulou, M.V.; Bloomer, W.D.; Rosenzweig, H.S.; Arena, A.; Arrieta, F.; Rebolledo, J.C.J.; Smith, D.K. Nitrotriazole- and imidazole-based amides and sulfonamides as antitubercular agents. *Antimicrob. Agents Chemother.* **2014**, *58*, 6828–6836. [[CrossRef](#)]
293. Tiwari, R.; Moraski, G.C.; Krchňák, V.; Miller, P.A.; Colon-Martinez, M.; Herrero, E.; Oliver, A.G.; Miller, M.J. Thiolates chemically induce redox activation of BTZ043 and related potent nitroaromatic anti-tuberculosis agents. *J. Am. Chem. Soc.* **2013**, *135*, 3539–3549. [[CrossRef](#)]
294. Hartkoorn, R.C.; Ryabova, O.B.; Chiarelli, L.R.; Riccardi, G.; Makarov, V.; Cole, S.T. Mechanism of action of 5-nitrothiophenes against *Mycobacterium tuberculosis*. *Antimicrob. Agents Chemother.* **2014**, *58*, 2944–2947. [[CrossRef](#)]



295. Cherian, J.; Choi, I.; Nayyar, A.; Manjunatha, U.H.; Mukherjee, T.; Lee, Y.S.; Boshoff, H.I.; Singh, R.; Ha, Y.H.; Goodwin, M.; et al. Structure–activity relationships of antitubercular nitroimidazoles. 3. Exploration of the linker and lipophilic tail of ((S)-2-nitro-6,7-dihydro-5H-imidazo[2,1-b][1,3] oxazin-6-yl)-(4-trifluoromethoxybenzyl)amine (6-amino PA-824). *J. Med. Chem.* **2011**, *54*, 5639–5659. [[CrossRef](#)]
296. Patterson, S.; Fairlamb, A.H. Current and future prospects of nitro-compounds as drugs for trypanosomiasis and leishmaniasis. *Curr. Med. Chem.* **2019**, *26*, 4454–4475. [[CrossRef](#)]
297. Boiani, M.; Piacenza, L.; Hernandez, P.; Boiani, L.; Cerecetto, H.; Gonzalez, M.; Denicola, A. mode of action of nifurtimox and N-oxide-containing heterocycles against *Trypanosoma cruzi*: Is oxidative stress involved? *Biochem. Pharmacol.* **2010**, *79*, 1736–1745. [[CrossRef](#)] [[PubMed](#)]
298. Papadopoulou, M.V.; Trunz, B.B.; Bloomer, W.D.; McKenzie, C.; Wilkinson, S.R.; Prasittichai, C.; Brun, R.; Kaiser, M.; Torrele, E. Novel 3-nitro-1h-1,2,4-triazole-based aliphatic and aromatic amines as anti-chagasic agents. *J. Med. Chem.* **2011**, *54*, 8214–8223. [[CrossRef](#)] [[PubMed](#)]
299. Papadopoulou, M.V.; Bloomer, W.D.; Rosenzweig, H.S.; Chatelain, E.; Kaiser, M.; Wilkinson, S.R.; McKenzie, C.; Ioset, J.R. Novel 3-nitro-1h-1,2,4-triazole-based amides and sulfonamides as potential antitypanosomal agents. *J. Med. Chem.* **2012**, *55*, 5554–5565. [[CrossRef](#)] [[PubMed](#)]
300. Papadopoulou, M.V.; Bloomer, W.D.; Rosenzweig, H.S.; Wilkinson, S.R.; Kaiser, M. Novel nitro(triazole/imidazole)- based heteroarylamides/sulfonamides as potential antitypanosomal agents. *Eur. J. Med. Chem.* **2014**, *87*, 79–88. [[CrossRef](#)] [[PubMed](#)]
301. Papadopoulou, M.V.; Bloomer, W.D.; Rosenzweig, H.S.; Wilkinson, S.R.; Szular, J.; Kaiser, M. Antitypanosomal activity of 5-nitro-2-aminothiazole-based compounds. *Eur. J. Med. Chem.* **2016**, *117*, 179–186. [[CrossRef](#)]
302. Pedron, J.; Boudot, C.; Hutter, S.; Bourgade-Delmas, S.; Stigliani, J.-L.; Sournia-Saquet, A.; Moreau, A.; Boutet-Robinet, E.; Paloque, L.; Mothes, E.; et al. Novel 8-nitroquinolin-2(1H)-ones as NTR-bioactivated antikineto-plasmid molecules: Synthesis, electrochemical and SAR study. *Eur. J. Med. Chem.* **2018**, *155*, 135–152. [[CrossRef](#)]
303. Arias, D.G.; Herrera, F.E.; Garay, A.S.; Rodrigues, D.; Forastieri, P.S.; Luna, L.E.; Bürgi, M.D.; Prieto, C.; Iglesias, A.A.; Cravero, R.M.; et al. Rational design of nitrofurans derivatives. Synthesis and valuation as inhibitors of *Trypanosoma cruzi* trypanothione reductase. *Eur. J. Med. Chem.* **2017**, *125*, 1088–1097. [[CrossRef](#)]
304. Benitez, D.; Comini, M.A.; Anusevičius, Ž.; Šarlauskas, J.; Miliukienė, V.; Miliuvienė, E.; Čėnas, N. 5-Vinylquinoline- substituted nitrofurans as inhibitors of trypanothione reductase and antitypanosomal agents. *Chemija* **2020**, *31*, 111–117. [[CrossRef](#)]
305. Wiesner, J.; Fucik, K.; Kettler, K.; Sakowski, J.; Ortmann, R.; Jamaa, H.; Schlitzer, M. Structure-activity relationships of novel anti-malarial agents. Part 6: N-(4-arylpropionylamino-3-benzoylphenyl)-[5-(4-nitrophenyl)-2-furyl]acrylic acid amides. *Bioorg. Med. Chem. Lett.* **2003**, *13*, 1539–1541. [[CrossRef](#)]
306. Tukulula, M.; Sharma, R.-K.; Meurillon, M.; Mahajan, A.; Naran, K.; Warner, D.; Huang, J.; Mekonen, B.; Chibale, K. Synthesis and antiplasmodial and antimycobacterial evaluation of new nitroimidazole and nitroimidazooxazine derivatives. *ACS Med. Chem. Lett.* **2013**, *4*, 128–131. [[CrossRef](#)]
307. Becker, K.; Tilley, L.; Vennerstrom, J.L.; Roberts, D.; Rogerson, S.; Ginsburg, H. Oxidative stress in malaria parasite-infected erythrocytes. Host-parasite interactions. *Int. J. Parasitol.* **2004**, *34*, 163–189. [[CrossRef](#)] [[PubMed](#)]